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1. Paediatric drug development 
The awareness of the importance of regulations about drug research, i.e. demonstrating 
effectiveness and safety prior to approval of drugs, has grown since the Elixir of 
sulphanilamide poisoning in 1937 and the thalidomide tragedy in 1962 (Hoberman and 
Lewis, 2012). Despite numerous regulations about how to properly perform drug 
development in adults, over the last decades, the paediatric populations largely 
remained neglected during drug development (Kearns, 2003). In 2009, only 25% of the 
marketed drugs used in children were also tested for safety and efficacy in the paediatric 
population (Hoberman and Lewis, 2012). The limited economical profit of drugs adapted 
for children is certainly a major factor in the incentive driven pharma-world, explaining 
the lack of interest in this patient population. Additionally, ethical considerations for 
clinical trials in children remain a restraining factor. The burden of exposing children to a 
well-controlled clinical trial, has to be counterbalanced to the widely exposure of 
children, in less controlled ways of not-studied drugs. Furthermore, paediatric adapted 
methodologies to execute clinical trials and facilities to conduct proper paediatric 
research are often lacking (Brasseur, 2011; Kimland and Odlind, 2012; Roth et al., 2013). 
The lack of clinical trials in children and consequently the lack of drugs labelled for 
children put the clinician into a dilemma: either depriving the child from the assumed 
clinical benefits of a drug, or prescribing the drug off-label, potentially leading to dosage 
errors (Kimland and Odlind, 2012).  
 
The FDA (Food and Drug Administration) and EMA (European Medicines Agency) 
introduced several regulations in order to motivate the industry to perform more 
paediatric drug research. In this respect, the FDA published inter alia, the Paediatric Rule 
(1998), the Best Pharmaceuticals for Children Act (BPCA, voluntary, drugs only) (2002) 
and the Paediatric Research Equity Act (PREA, mandatory, drugs and biologics) (2003), 
whereas EMA launched the Paediatric Regulation (2006) (Hoberman and Lewis, 2012). 
These legislations aim to improve paediatric drug research without performing 
avoidable paediatric clinical trials and without hampering the development of drugs for 
adults (EMA, 2006). In the European Union (EU), the industry is obliged to submit a 




when marketing new medicines or when marketing-authorisation holders want to add 
new indications, pharmaceutical forms, route of administrations for patent protected 
drugs (Figure 1). Although these regulations caused a steady increase in paediatric drug 
trials, still more than 50% of the currently marketed drugs are not adapted for children 
(Kimland and Odlind, 2012; Committee on drugs, 2014). In order to further improve 
paediatric drug development, age-appropriate dosage schemes and formulations have 
to be developed. Therefore, more extensive and innovative research has to be done, 
leading to correctly labelled, safe and effective drugs for children. In this respect, the 
development of new animal models is necessary in order to determine 
pharmacokinetics (PK), pharmacodynamics (PD) and safety of drugs, taking maturation 
and growth into account. 
 
 
Figure 1. Paediatric Investigation Plan (PIP) assessment procedure (adapted from 






2. Paediatric animal models 
The ICH E11 (International Conference on Harmonisation), about the clinical 
investigation of medicinal products in the paediatric population, states that “the need 
for juvenile animal studies should be considered on a case-by-case basis and be based 
on developmental toxicology concerns” (ICHS, 2000). Studies should be performed 
before the initiation of trials in the paediatric subpopulation. The FDA guidance for 
industry about nonclinical safety evaluation of paediatric drug products provides an 
overview of the role and timing of animal studies in nonclinical studies (FDA, 2006). The 
EMA guideline on the need for nonclinical testing in juvenile animals on human 
pharmaceuticals for paediatric indications provides guidance on the need for, role and 
timing of studies in juvenile animals (EMA, 2005). It has been proven that additional 
information can be obtained from paediatric animal models, which cannot be derived 
from standard toxicology studies using adult animals or safety information from adult 
human studies (FDA, 2006). Moreover, juvenile animal models can be used to provide 
additional data, which cannot be adequately, ethically and safely assessed in paediatric 
clinical studies (EMA, 2005). Since organs which undergo postnatal maturation are more 
prone to drug toxicity than mature organs, it is important to characterize the anatomical 
and physiological maturation of the different organ systems in both animals and humans 
and evaluate the potential postnatal developmental ADME and safety of drugs. 
Extrapolation to humans is challenging and should be performed with extra care. 
However the usefulness of juvenile animal models has already been demonstrated 
previously, e.g. negative effect of phenobarbital on the nervous system of the rat which 
has also been reported in children or an increase in susceptibility of verapamil-induced 
cardiovascular complications in infants which was predicted in animal models (Baldrick, 
2004). In 2016, the EMA published a general report on the experience acquired as a 
result of the application of the Paediatric Regulation. Section 3.12 of this report 
described the use of animal studies for safer paediatric research. In 26% of the PIP 
requests (232 PIP) animal studies were included, of which 43% included age categories 






2.1 Species selection 
Selection of an appropriate animal species is pivotal to adequately perform juvenile 
animal studies. The main factors to consider when determining cross-species 
applicability are growth, maturation of the different organ systems, PK/PD properties of 
the drug, expression of the target and feasibility of the animal model for testing the 
drug. To be able to select the most suitable animal species and correct age groups 
different key points should be considered, such as lowest age needed to be included in 
the preclinical trials, duration of treatment, route of administration, PK and metabolism, 
species specific toxicity, etc. (Mulberg et al., 2013). After the thalidomide tragedy, 
preclinical studies in both rodent as non-rodent species are required during the adult 
drug development process. This is not the case in paediatric drug development, where it 
is sufficient to use a single animal species to perform the tests (Leconte et al., 2011; 
Bailey and Marien, 2011). More than 80% of the PIPs which contain juvenile animal 
studies included only one species and about 4% contained studies performed in more 
than one species (EMA, 2016). The first species of choice are rats (76%) based on 
experience and available historical data sets in both the adult and the paediatric 
population (Mulberg et al., 2013). The rat is followed by monkey (10%), dog (8%) and 
mice (6%) (EMA, 2016). The use of rats as primary species is convenient as the rat only 
requires minimal housing facilities and maturation of the rat occurs fast rendering this 
species a good model to study the impact on reproductive and sexual development 
(Mulberg et al., 2013). However, the rat is not always suitable as a juvenile model, for 
instance intravenous (IV) administration in rat pups is technical challenging (due to the 
size of the veins), biochemical differences (i.e. maturation gastrointestinal tract (GIT), 
maturation cytochrome P450 enzymes (CYP450)) are observed rendering the rat less 
feasible as a model for the human infant, maturation of the different organ systems is 
slower in comparison to humans (Downes, 2012). If the rat is not a suitable model, 
alternative species such as the dog, pig and non-human primate can be used (Mulberg et 
al., 2013). As dogs are not always suitable as juvenile animal models (comparing dogs 
and humans, most organs show substantial differences concerning weight and 




more and more considered as unethical, the pig may represent a suitable alternative 
juvenile animal model (Downes, 2012; Gasthuys et al., 2016). 
 
Over the years, pigs (Sus scrofa domestica) became more of interest as alternative 
model due to anatomical, physiological and biochemical resemblances between adult 
pigs and humans (Butler et al., 2009; Bode et al., 2010; Meurens et al., 2012; Helke and 
Swindle, 2013). Therefore the potential use of this animal model could be very broad, 
including PK/PD modelling, xenotransplantation and toxicity testing (Cooper et al., 1991; 
Klymiuk et al., 2010; Swindle et al., 2012; Helke and Swindle, 2013). In literature, the 
commonly used types of swine are domestic and miniature pigs. The most commonly 
used domestic breeds are Yorkshire, Landrace, Duroc and crossbred animals, whereas 
for miniature breeds the Yucatan miniature pig and its micro varieties i.e. Hanford, 
Gottingen, NIH and Sinclair S-1 are more common (Swindle, 2007; McAnulty et al., 
2012). To date, the suitability of growing piglets as a preclinical model for the paediatric 
population still needs to be evaluated. In order to contribute to the development of such 
a porcine model, the maturation processes of several organ systems involved in the 
disposition of drugs and validation of the porcine model in PK/PD and safety studies 
should be performed. The ontogeny of the ADME processes as well as the knowledge 




Table 1. Developmental species comparison in conventional pigs and minipigs with respect to ADME processes.  
ADME  Conventional pig Minipig Reference 
Absorption pH stomach Gastric acid secretion is low at birth but increases 
rapidly during the first week of life, maximal acid 
secretion at 5 to 6 weeks of age (2-4) 
Gastric acid secretion is different among age 
groups, more acidic pH at 4 weeks of age (day 
1: 4.8-5.3, 4 weeks: 3.6-3.8) 
Sangild et al. (1992), Sangild et al. (1995), 
Van Peer et al. (2015) 
 pH intestine No information found about the maturation of 
the pH intestine in growing conventional pigs 
Constant over age (proximal, middle, distal part 
small intestine and colon), decrease in pH 
during the first 28 days of life (caecum)(day 1: 
6.8-7.5, 4 weeks: 6.1-6.4) 
Van Peer et al. (2015) 
 GIT motility Intestinal transit time: no effect age observed No information found about the maturation of 
the intestinal transit time 
Huygelen et al. (2015) 
 Surface area Upsurge in functional intestinal surface area  An increase in the length of the small (5-fold) 
and large intestine (2-fold) was observed during 
the first 4 weeks of age 
Widdowson (1985), 
Van Peer et al. (2015) 
 Enzymes    
    Sucrase Non-existing at birth and an increasing activity 
during week 1 to 9 
Increased significantly with age during week 1 
to 6 (only in ileum) 
Manners and Stevens (1972), Adeola and King 
(2006), Hartman et al. (1961),  
Shulman et al. (1988) 
    Lactase High level of lactase present at birth, followed by 
a decrease during week 1 to 8 of age 
High levels of lactase present at birth, followed 
by a decrease during week 1 to 6 of age 
Manners and Stevens (1972), Hartman et al. 
(1961), 
Shulman et al. (1988) 
    Maltase Present at birth, declined at 1 week and gently 
increased after 1 week of age 
Increased significantly with age during week 1 
to 6 (jejunum, ileum) 
Hartman et al. (1961),  
Shulman et al. (1988) 
 Transporters No information found about the maturation of 
the different transporters 
Statistical difference in P-gp expression 
between the age group of 84 days of gestation 
and the older age groups (small intestine), P-gp 
was found in all liver samples (similar intensity 
in all samples). No information found about the 
maturation of the other transporters 
Van Peer et al. (2014) 
 Gastric emptying Biphasic (rapid, slow), faster emptying in suckling 
in comparison to weaned piglets 
Biphasic (rapid, slow), faster emptying in 
suckling in comparison to weaned piglets  
Decuypere et al. (1986), Snoeck et al. (2004) 
Van Cruchten and Van Ginneken (2012) 
     
     
     




Distribution Plasma protein    
    Albumin Low at birth (<20%), increases until 2 years of age 
(60%) 
The levels of albumin were lower in younger 
pigs (55% at 6 months) 
Ramirez et al. (1963), 
Yeom et al. (2012) 
Ellegaard background data 
    α High at birth (60%), decreases until 6 months of 
age (15%) 
Remains constant over age (7 weeks to 6 
months)(17%), no data at birth 
Ramirez et al. (1963), 
Ellegaard background data 
    β Constant over age (15-20%) Remains constant over age (7 weeks to 6 
months)(13%), no data at birth 
Ramirez et al. (1963) 
Ellegaard background data 
    ϒ High at 2 days of age (40%), decreases until 6 
weeks of age (20%) 
Remains constant over age (7 weeks to 6 
months)(11%), no data at birth 
Ramirez et al. (1963) 
Ellegaard background data 
 Body composition    
    Water High at birth (84%), decreases over age (64%) No information found about the percentages of 
water over age 
Armsby and Moulton (1925),  
Lewis and Southern (2000) 
    Lipid Low at birth (2%), increases over age (35%) Adult: 10% body fat, no further information 
found about the percentages of water over age 
Armsby and Moulton (1925),  
Lewis and Southern (2000) 
Johansen et al. (2001) 
    Protein Constant over age (15-18%) No information found about the percentages of 
protein over age 
Lewis and Southern (2000) 
    Ash Constant over age (2-4%) No information found about the percentages of 
ash over age 
Armsby and Moulton (1925),  
Lewis and Southern (2000) 
Metabolism Phase I    
    CYP3A Increase of CYP3A activity with age in the liver, no 
information about the kidney or the intestine 
The immunoreactivity for CYP3A increased in 
both liver and intestine during postnatal 
development, no information about the kidney 
Millecam et al. (unpublished data), 
Van Peer et al. (2014), 
Van Peer et al. (2017) 
    CYP1A Detectable in the liver but low at day 1, increases 
with age, no information about the kidney or the 
intestine 
Increase of CYP1A biotransformation capacity 
over age in the liver, no information about the 
kidney or the intestine  
Hu (2014), 
Van Peer et al. (2017) 
    CYP2A Not present day 2 till week 2, present at week 5 
and increases afterwards in the liver, no 
information about the kidney or the intestine 
No information about the CYP2A maturation in 
the liver, the kidney and the intestine 
Hu (2014) 
 
    CYP2C Increase CYP2C activity with age in the liver, no 
information about the kidney or the intestine 
Increase of CYP2C biotransformation capacity 
over age in the liver, no information about the 
kidney or the intestine  
Millecam et al. (unpublished data), 
Van Peer et al. (2017) 
    CYP2D No information about the CYP2D maturation in 
the liver, the kidney and the intestine 
Increase of CYP2D biotransformation capacity 
over age in the liver, no information about the 
kidney or the intestine 




    CYP2E Increase of CYP2E activity with age in the liver, no 
information about the kidney or the intestine 
No information about the CYP2E maturation in 
the liver, the kidney and the intestine 
Millecam et al. (unpublished data) 
 
 Phase II    
    Acetylation Mature at birth No information found about the maturation of 
the acetylation 
Nouws (1992) 
    Glucuronidation Mature at 2 to 6 weeks No information found about the maturation of 
the glucuronidation 
Nouws (1992) 
Excretion GFR Low at birth, mature at 8 weeks No information found about the maturation of 
the GFR 
Friis (1979) 
 RBF Low at birth, mature at 8 weeks No information found about the maturation of 
the RBF 
Friis (1979) 
 Reabsorption Increase of water and sodium reabsorption when 
comparing prenatal (105-112 d gestation) and 
postnatal (5-9 d) piglets, no information in older 
conventional pigs 
No information found about the maturation of 
the reabsorption 
Alt et al. (1984) 
 Tubular secretion No information found about the maturation of 
the tubular secretion 
No information found about the maturation of 
the tubular secretion 
 




2.2 Age categories  
When performing paediatric preclinical trials, it is important to consider the age of the 
intended population and to determine the developmental stage of the organs affected 
by the test compound (Mulberg et al., 2013). The stage of development in the human 
paediatric population should be comparable to the proposed animal model (FDA, 2006). 
In 2006, the FDA documented a detailed overview based on available literature of the 
comparative developmental timing of the different organ systems between humans and 
different animal species (FDA, 2006). Table 2 gives an example of the comparative age 
categories across the important preclinical animal species based on the development of 
the central nervous system and the reproductive system.  
 
Table 2. Comparative age categories across important preclinical animal species 
(adapted from Buelke-Sam, 2003).  
Species Neonate Infant/toddler Child Adolescent 
Rat Birth-10 days 10-21 days 21-45 days 45-90- days 
Pig Birth-2 weeks 2-4 weeks 4-14 weeks 14-26 weeks 
Dog Birth-3 weeks 3-6 weeks 6-20 weeks 20-28 weeks 
Nonhuman Primate Birth-0.5 months 0.5-6 months 6-36 months 36-48 months 
Human Birth-0.08 years 0.08-2 years 2-12 years 12-16 years 
 
2.3 Routes of administration 
When performing juvenile animal studies, it is important to select the most appropriate 
species for the intended clinical route of administration and dosage of the test 
compounds. A clear idea about the feasibility of the animal at different age categories, 
the methodologies to perform the preclinical studies, the equipment required for the 
studies and adequate training of the technical staff are required before starting any 
preclinical animal studies. The HESI-DART document gives a detailed overview of the 
earliest day post-partum a certain species can be used for various routes of 
administration (Zoetis and Walls, 2003) (Table 3) and can be a useful tool when 







Table 3. Earliest day post-partum for various routes of administrations in juvenile animal 
species (adapted from Mulberg et al., 2013). 
Route of administration Rat Dog Non-human primate Pig 
Per os/oral 1 1 >2w 1 
Subcutaneous 1 1 >2w 1 
Intravenous 15 7 >2w 7 
Inhalation 7 10 >2w 7 






3. Comparative drug disposition between humans and pigs: ontogeny of 
the main ADME processes 
When conducting paediatric drug research, physiological and anatomical changes that 
influence PK (what the body does to the drug) and PD (what the drug does to the body) 
behaviour of drugs need to be taken into account. Consequently, there is a necessity for 
research about the ontogeny of the variables controlling the PK processes, namely 
absorption, distribution, metabolism and excretion (ADME). Until today, there is still a 
lack of knowledge about this topic. Because of this information gap, the FDA and EMA 
request paediatric adapted juvenile animal models showing a good correlation with 
humans, both anatomically and physiologically. For many years, the use of piglets as 
potential animal models has been well established in different research fields, such as 
nutrition (Elango et al., 2008; Herfel et al., 2008; Sangild et al., 2013), surgery (Tirilomis 
et al., 2011; Twal et al., 2013; Wei et al., 2013) and immunology (Butler et al., 2009). 
Over the last decades, also the interest in piglet models to study the PK/PD of drugs 
began to grow (Table 5). In order to genuinely decide whether pigs are appropriate, 
comparative research about the ontogeny of ADME processes is crucial. 
 
3.1 Growth 
To be suited as appropriate biomedical models, a first prerequisite is that the growth 
and maturation of the whole body and specific body components of piglets correlate 
with those of children. The measurement of the growth patterns is of great importance, 
although there is currently no gold standard available. A typical growth curve in piglets 
can be represented as a sigmoid line, with live body weight (BW) plotted against 
time/age (Figure 2) (Lewis and Southern, 2000). The curve consists of two main phases, 
namely an increase and a decrease of the growth rate (Whittemore et al., 2006). 
Whittemore and Green (2001) consider the Gompertz function as the best fitting 
mathematical equation for the sigmoid growth in pigs: growth rate = live weight x B x 
ln(A/live weight), with A being an asymptote representing mature size and B a growth 
coefficient. Both A and B factors are dependent, for an increase of one leads to an 
increase of the other (Pluske et al., 2003). The mathematical function gives a general 




body components, implying the need for more comprehensive functions (Koops and 
Grossman, 1991; Schinckel and deLange, 1996; Strathe et al., 2009; Vautier et al., 2013). 
Such complex equations are beyond the scope of this doctoral thesis. Therefore, the 
presented growth correlations are based on the Gompertz function, and are shown in 
Table 4. Only two research papers mention a possible age or BW correlation between 
humans and domestic pigs (Gad, 2007; Guilloteau et al., 2010). Two reasons can be 
opted for the absence of correlating age categories for both species. First, if pigs are 
classified by age, another classification system is used than in humans (newborn, 
suckling, weaning, rearing, growing and finishing pigs). Second, maturation can differ 
between the specific body components, which complicate the classification (Van Peer et 
al., 2016). Therefore, there is a need for a new and an improved growth classification 
correlation between both species. 
 
Figure 2. Growth curve domestic and Gottingen miniature pigs (adapted from Swindle, 
2007). 
 
Table 4. Age and body weight (BW) correlations in humans and pigs. 
Species Age Neonate Infant Child Adolescent Reference 
Human Age 0-28 d 1m-2 y 2-12 y 12-21 y FDA, 2004; ICHS, 2000 
Human Age 0-27 d 28 d-23 m 2-11 y 12-16/18 y EMA, 2001 
Human Age 0-28 d 1-23 m 2-12 y 12-16 y Barrow et al., 2007 
Pig Age 0-15 d 2-4 w 4-14 w 4-6 m Gad, 2007 
Species Age/BW Newborn Infant or child Adolescent Adult Reference 
Human Age 0 d 0.5-12 y 13-18 y >20 y Guilloteau et al., 2010 
BW  2.5-4.5 kg 6-50 kg 40-65 kg 65-80 kg 
Pig Age 0 d 2 d-10 w 4-7 m 1-2 y 

































Table 5. Potential of piglets as animal models in human pharmacology research 
Drug Breed Age BW (kg)  Conclusions and suitability  Reference 
Aminophylline and 
terbutaline and tobramycin 
- - 20-25  human clinical studies are needed to evaluate intraperitoneal route Asheim et al., 2008 
Artesunate Landrace x large white 12 w 38.3  suitable model for PK of artemisinin derivate Sinou et al., 2008 
Caffeine/theophylline Landrace-Camborough 2-25 d 1-6.5 kg may not be suitable for model for disposition caffeine/theophylline Kearns et al., 1986 
Captopril Yorkshire 10-14 d 3.8-4.2  suitable model for PK/PD modelling of captopril Pereira et al., 1996 
Cefonicid - 3 and 6 d - may not be a suitable model for PK of cefonicid, increased total clearance Kearns et al., 1987 
Cefpodoxime Camborough cross 10-20 d - species differences in plasma PK parameters, suitable model for penetration into 
CSF 
Abdel-Rahman et al., 
2000 
Cyclosporine A Danish Landrace 11-15 w 29  might be a suitable model Cibulskyte et al., 2006 
DEET and oxybenzone - 3 w 5  suitable model for analysis of DEET and oxybenzone Kasichayanula et al., 
2005 
Dexmedetomidine - <24h 1.6-2.0  suitable dose determination for preclinical neonatal human studies Ezzati et al., 2014 
Diuretics  - 5-10 d 1.5-2.5 suitable model for renal function of immature mammals  Noordewier et al., 1978 
Epigallocatechin gallate Angeln Saddleback 4w 8-15  no conclusions about the usefulness of the model Twal et al., 2013 
Etoposide Yorkshire - 16-18  suitable model for etoposide infusion into the fourth ventricle Sandberg et al., 2010 
Fentanyl Yorkshire 1-3 d 1.3-1.6  no conclusions about the usefulness of the model Rajan et al., 1998 
Fentanyl - 2-4 d 1.7  suitable model for fentanyl disposition, respiratory and cardiovascular effects Rey-Santano et al., 2013 
Glipizide - 3.5-4 m 21-27  suitable model for PK of modified release monolithic formulations Kulkarni et al., 2012 
Heparin mixed breed 1d and adult 1.44 and 44.9 suitable model for PK of soluble heparin Andrew et al., 1989 
Ibuprofen-proloxamer Farm raced - 11-14 Suitable model for microdialysis experiment Paavola et al., 2016 
Insulin aspart Crossbred - 76-89  more appropriate model than rat or dog Plum et al., 1999 
Ketoprofen Mexican hairless 12 m 9.8-30.8  suitable model for PK of topically applied ketoprofen Horie et al., 2009 
Lidocaine with Epinephrine French large white 7.8 w 18.8 same PK parameters, except shorter T1/2elimination Lacoste et al., 1996 
Morphine sulphate - newborn - suitable model for PK of morphine sulphate and effect on cerebral circulation Tumbaga et al., 1998 
Nifedipine and metoprolol - 3-13 w 6-30  no conclusions about the usefulness of the model Cheng et al., 1996 
Ortho-phenylphenol Yorkshire/Landrace  - 16.8-26.4 Disposition of OPP in pigs different from humans Nixon et al., 2017 
Rifampin Crossbred 2 m and 4 m 20/40  suitable model but further research necessary  Roth et al., 2013 
Sodium hydrosulphide mixed breed 1-5 d 1.5-2.5 species differences, the model does not reflect the unique changes at birth Chueng et al., 2013 
Teicoplanin Large White - 39.7-46.7 Suitable model to administer teicoplanin in mechanical ventilation Guillon et al., 2015 





Oral ingestion is the main route of drug administration in the paediatric subpopulation. Next 
to the formulation of the drug, many physiological factors influence the rate and extent of 
oral absorption of drugs, such as gastric and intestinal pH, gastric emptying, intestinal 
motility, intestinal surface area and enzyme functions. The development of the gastric pH 
differs between both species, but is comparable between piglets and humans at the age of 
five days and two years, respectively. In human neonates, the hydrochloric acid production is 
lower in comparison with adults, leading to higher gastric pH values and facilitated 
absorption of weak bases and acid-labile drugs (de Zwart et al., 2004). In pigs, the pH 
reaches adult values at five days after birth, leading to less influence of this parameter on 
the absorption of the previously mentioned drugs (Sangild et al., 1992; Sangild et al., 1995). 
No significant differences in intestinal pH were observed over age in the ileum, jejunum, 
duodenum and colon of growing minipigs. However, a significant decrease in pH was 
observed in the caecum (Van Peer et al., 2016). Studies about the development of the 
intestinal pH of conventional piglets and humans are lacking. Fallingborg et al. (1990) 
measured the pH in children aging eight to fourteen years. The pH was 1.5 in the stomach, 
rose to 6.4 in the duodenum, decreased towards 5.9 in the cecum and rose again to 6.5 in 
the rectum. These results are comparable with results obtained in adult studies (Fallingborg, 
1999).  
 
The emptying of the adult porcine stomach is incomplete and appears biphasic, namely at 15 
min and 1 h postprandial (Pond et al., 1978). The gastric emptying in piglets did not differ 
according to age (Huygelen et al., 2015). The neonatal human gastric emptying is prolonged 
in comparison with six to eight month old children (= adult pattern). Groner et al. (1990) 
evaluated the piglet as potential model for neonatal GIT motility and concluded that the 
motility of piglets is similar to humans. The neonatal intestinal motility is immature, leading 
to longer transit times (Kearns et al., 2003; T’Jong, 2014). Due to the prolonged gastric 
emptying and reduced intestinal motility, an increase in gastric absorption of the drug could 
be expected, but studies of different drugs revealed a delayed and incomplete absorption in 
human neonates and infants (T’Jong, 2014; Meissner and Smith, 1979; McCracken et al., 




months (Morselli et al., 1983). Both humans and pigs have a discernible upsurge in 
functional intestinal surface area, resulting in a possible increase of drug absorption. The 
development of the intestinal enzymes (sucrase, lactase and maltase) shows comparable 
patterns between both species. P-glycoprotein (P-gp) can influence the bioavailability of 
drugs, but research about the ontogeny of these efflux transporters is scarce. Van Peer et al. 
(2014) (immunochemistry) and Van Kalken et al. (1992) (immunochemistry, polymerase 
chain reaction) investigated the P-gp presence in liver and small intestine of minipigs and 
humans, respectively. In piglets, P-gp was found in the liver after 12 weeks of gestation and 
was noted two days later in the intestine (Van Peer et al., 2014). In humans, P-gp m-RNA and 
protein were observed in the liver after 11 to 14 weeks of gestation, but were only present 
in the intestine after 28 weeks of gestation (Van Kalken et al., 1992). 
 
3.3 Distribution 
Distribution of drugs is influenced by plasma and tissue protein binding, physicochemical 
characteristics of the drug (pKa, lipid solubility and molecular weight), and body 
composition. The body water/fat ratio changes with development and differs between pigs 
and humans from birth till infancy. However, the discrepancies between both species 
diminish when reaching infancy. Pigs have a higher water and lower fat content at birth in 
comparison with humans. The amount of total body water decreases with age in both 
species. Due to a higher body water volume in children, polar drugs tend to have higher 
volumes of distribution (Vd) in comparison with adults. The opposite is true for non-polar 
drugs (de Zwart et al., 2004; Mangoni and Jackson, 2004). In contrast with body water, 
human body fat increases during the first year and starts to decrease until adult values are 
reached at 12 years of age. In pigs, only an increase in fat content can be noted. As a result 
of the differences in the water/fat ratio, the neonatal distribution of drugs between both 
species is different. These differences will diminish when reaching infancy. Next to water/fat 
ratio, the plasma and tissue protein binding of drugs have a major effect on Vd since this 
influences the free drug fraction available for distribution. Plasma albumin mainly binds 
acidic drugs, while α1-acid glycoprotein binds basic drugs. A drop in the plasma protein 
concentrations, will lead to higher free fractions of strongly protein bound drugs and higher 




competition between endogenous substances (e.g. bilirubin and free fatty acids) and drugs 
could be noted for the albumin binding sites, leading to higher free fractions (Kearns et al., 
2003). A clear difference in neonatal plasma albumin concentrations of pigs (± 20%) and 
humans (± 50-60%) can be observed (Gasthuys et al., 2016). The discrepancies diminish 
when reaching infancy. The concentrations of α1-acid-glycoprotein differ at birth, but the 
differences diminish after 48 h. Next to the protein concentrations, the binding capacities of 
plasma proteins are lower in neonates in comparison with infants and adults (Gasthuys et 
al., 2016). This can influence the Vd of highly protein bound drugs, which emphasizes the 
need for plasma and tissue protein binding determinations (Benedetti and Baltes, 2003). 
 
3.4 Metabolism 
The liver is one of the most important organs responsible for the metabolism or 
biotransformation of exogenous compounds into inactive or active metabolites. These 
biotransformation reactions can be divided in phase I or phase II reactions. The key 
component in the phase I reactions is the CYP450 enzyme superfamily. In most of the human 
drug metabolism the CYP1, CYP2 and CYP3 families are involved (Benet et al., 1996). The 
abundance, activity and role of the different CYP subfamilies and isoforms were investigated 
in different animal models and were correlated with humans (McGinnity et al., 2000; Achour 
et al., 2011; Puccinelli et al., 2011). Several literature reports are available which correlate 
CYP enzymes between human adults and mature pigs (Anzenbacher et al., 1998; Myers et 
al., 2001; Thorn et al., 2011; Helke and Swindle, 2013). Literature has demonstrated 
homology between human and porcine CYP1A, 2A, 2C, 2D, 2E, and 3A in adults, namely at 
least 85, 87, 71, 83, 82 and 75% amino acid sequence identity, respectively (Puccinnelli et al., 
2011). Although the results showed the existence of human CYP homologues, the metabolic 
profiles and molecular weight of certain CYPs are different (Myers et al., 2001). For instance 
dextromethorphan, debrisoquine and bufuralol, well known substrates of human CYP2D6, 
are not metabolized by the porcine CYP2D but CYP2B subfamily, which makes the pig an 
unsuitable model for examining CYP2D activity (Thorn et al., 2011; Skaanild and Friis, 2002). 
Although extensive research is performed about the CYP enzymes in mature pigs, studies 
about the ontogeny of the CYP enzymes and corresponding biotransformation processes in 




described in foetal and neonatal pigs (Hermann and Skaanild, 2011; Van Peer et al., 2014). 
The main human CYP3A hepatic enzymes in foetuses and neonates are CYP3A7 and CYP3A4, 
whereas CYP3A4 becomes more dominant after birth (Lacroix et al., 1997; Danielson, 2002; 
Kearns et al., 2003). An orthologue in pigs, with the same enzymatic activity to the human 
CYP3A4, is CYP3A29 (Shang et al., 2009). Hermann and Skaanild (2001) studied whether 
there was a shift from CYP3A7 like enzyme towards CYP3A29 in neonatal minipigs. A similar 
increase in expression of CYP3A29 was observed, implicating that the minipig is an 
appropriate model to evaluate the neonatal CYP3A activity development. Furthermore, Van 
Peer et al. (2014) examined the ontogeny of CYP3A expression in the liver and small 
intestine of Gottingen minipigs. A similarity between humans and pigs CYP3A ontogeny was 
suggested based on immunohistochemical analysis. Hu (2014) examined the impact of age 
on the CYP1A, 2A, 2C, 2D, 2E and 3A activity in three domestic male piglets. There was an 
elevation in total CYP450 content during the first two weeks and five weeks after birth. The 
CYP450 activities for all the enzymes, except CYP2A, were low at birth and increased rapidly 
during the first two weeks. A second upsurge has been noted after five weeks of age. CYP2A 
was not detectable until five weeks of age. In contrast with pigs, human ontogeny of the CYP 
enzyme activity was more extensively investigated (Kearns et al., 2003; de Zwart et al., 
2004). During the first year the total P450 content is about 30 to 50% of the adult level (de 
Zwart et al., 2004). CYP2E1 and CYP2D6 activities were already present during the first 24 h 
of life. CYP3A4 and CYP2C activities were detectable at one week of age, while CYP1A2 
activity appears between the first and third month after birth (Kearns et al., 2003; de Zwart 
et al., 2004). Due to lacking experimental methods, the characterization and ontogeny of 
phase II reactions are less known compared to phase I reactions. In pigs, the acetylation 
capacity is fully developed at term and the glucuronide synthesis is mature at two to six 
weeks (Nouws, 1992). In men, sulfation is mature at birth and acetylation appears during the 
first month (Hazinski, 1992; de Zwart et al., 2004). Glucuronidation is present to a limited 
extent before birth and reaches adult activity levels at an age of three to six months (de 









Biliary and renal excretion are the predominant route of excretion for drugs. In the kidney, 
glomerular filtration, tubular secretion and/or reabsorption can take place. Glomerular 
filtration depends on the glomerular filtration rate (GFR) and renal blood flow (RBF). The GFR 
of both species is low at birth and increases during the first weeks of life. The maturation of 
the GFR function is slower in pigs (adult: eight weeks) in comparison with humans (adult: 
one year), but is comparable during infancy. This can be explained by a slower porcine 
nephrogenesis (anatomical maturation of the kidney completed in humans at week 36 of 
gestation and in pigs at three weeks after birth). Like the GFR, an augmentation of the RBF 
can be noted in both species during development. An increase of the GFR is attributed to an 
increase of the RBF. Alcorn and McNamara (2002) examined the evolution of the RBF in 
growing children. At birth, the human RBF is 5 to 6% of the cardiac output and increases 
towards adult values at two years of age (Fernandez et al., 2011). Suenderhauf and Parrott 
(2013) summarized the organ blood perfusion in pigs (25 kg) and humans (70 kg). The liver 
and kidney perfusion were comparable in both species (pig liver 107 mL/min/100 g versus 
80.5 mL/min/100 g in humans, pig kidney: 429 mL/min/100 g versus 400 ml/min/100 g in 
humans). Further research in pigs about the development of the kidney blood flow is needed 
in order to compare both species. Age-related changes in kidney function can influence the 
plasma clearance of drugs, whereby adaptations of the dose could be necessary. In general, 
the elimination half-life of most drugs is prolonged in human neonates, but reaches adult 
values at 2 to 6 months (Bartelink et al., 2006). No studies were found about the evolution of 
the elimination half-life of human paediatric drugs in piglets. 
 
To conclude, Table 6 shows a summary of the developmental species comparison in pigs and 
humans with respect to the main ADME processes. This table clearly demonstrates the need 
for additional information about the maturation of the different organ systems in both 
species. Therefore the focus of this doctoral thesis is to unravel the ontogeny of the 
excretion in conventional pigs, more specifically the GFR, and correlate it with humans. 
Moreover, desmopressin, a drug mainly excreted by the kidney, was chosen as a model 





Table 6. Summary of developmental species comparison in pigs and humans with respect to ADME 
processes (adapted from Gasthuys et al., 2016). 
  
ADME  Comparison pig/human PK implications 
Absorption pH stomach Different: newborn + neonate 
Comparable: infant 
Newborn + neonate: 
different ionization of acidic drugs, 
different absorption rates possible 
pH intestine No information: piglet No comparison possible 
GIT motility Comparable: all age categories No differences. 
Both species newborn + neonate: 
incomplete + delayed absorption,  
delayed drug action  
P-gp Scarce information: both species No comparison possible 
Distribution Water/fat ratio Different: newborn + neonate 
Comparable: infant 
Newborn + neonate:  
different Vd 
Plasma protein Different: newborn + neonate 
Comparable: infant 
Newborn + neonate: 
different free fraction highly protein-bound drugs,  
different Vd 
Metabolism Phase I enzymes Different: newborn + neonate (only 
CYP1A/2A/2D) 
Comparable: infant (all CYPs) 
Newborn + neonate: 
altered plasma drug clearance,  
increased elimination half life 
Phase II enzymes Scarce information: both species No comparison possible 
Excretion GFR/RBF Different: newborn + neonate 
Comparable: infant 
Newborn + neonate:  
reduced plasma clearance renally cleared drugs,  
increased elimination half-life renally cleared drugs 




4. Glomerular Filtration Rate 
The kidneys play a major role in the preservation of the water balance and the elimination of 
metabolic waste products, drugs and toxic substances (Price and Finney, 2000). Renal 
excretion is thrived by the effective RBF, GFR, tubular absorption and secretion (Kerl and 
Cook, 2005). The assessment of the GFR is considered the best overall index of the kidney 
function (Schwartz et al., 2009). The determination of the GFR is pivotal for preclinical PK, PD 
and safety studies, e.g. to determine age-dependent dosing schedules for drugs excreted by 
and/or acting on the kidney and, to evaluate drug toxicity. GFR can be measured with 
endogenous and exogenous filtration markers, or can be estimated using equations.  
 
4.1 Measurement of glomerular filtration rate 
A variety of endogenous and exogenous markers are available to assess the GFR. Each 
marker has its advantages and disadvantages. The ideal marker should meet the following 
criteria: (i) produced at a constant rate, (ii) circulated stably, not confounded by pathological 
changes, (iii) not bound to plasma proteins, (iv) freely filtered by the glomerulus, (v) not 
reabsorbed nor secreted (Price and Finney, 2000). An overview of the most frequently used 
endogenous and exogenous markers is provided below.  
 
4.1.1 Endogenous markers 
4.1.1.1 Creatinine  
The use of serum creatinine as GFR marker was introduced by Popper and Mandel (1937). 
Today, in clinical practice, creatinine is the most widely used endogenous marker to assess 
the GFR. Creatinine (113 Da) is the metabolic waste product of phosphorylcreatine. The 
highest concentration of creatinine and phosphorylcreatine can be found in tissues that 
require most energy, such as skeletal muscles and the brain. The production rate of 
creatinine is in proportion to the phosphorylcreatine pool (Oh, 1993). Generation of 
creatinine is dependent on muscle mass and dietary intake (Stevens et al., 2006). The 
dependency to muscle mass, can lead to substantial inter- and intra-patient variability (Vinge 
et al., 1999). Production of creatinine was assumed to be constant (1 to 2% of creatine in 




BW), however more recent research showed that the production rate is not constant and 
the turnover is variable (Filler et al., 2014). Negligible plasma protein binding of creatinine 
occurs. Creatinine is freely filtered by the glomerulus and is not reabsorbed by the renal 
tubules. Creatinine is also actively secreted by the proximal tubular cells, which increases 
with declining GFR (Filler et al., 2014). Extrarenal clearance of creatinine is low in healthy 
patients (less than 2% of normal renal clearance), but is more profound (two third of total 
daily creatinine) in patients with chronic kidney diseases (CKD). This can lead to confounded 
GFR values (Mitch and Walser, 1978). The use of creatinine to detect early impairment of 
kidney function is debatable, since the GFR should be dropped to less than 30% of the age 
and sex corresponding normal mean values until renal impairment can be observed 
(Brochner-Mortensen, 1985).  
 
The most widely used techniques to assess the creatinine concentrations are the alkaline 
picrate method (Jaffe method), enzymatic assays or high-performance liquid 
chromatography methods (HPLC). The alkaline picrate method was discovered in 1886 by 
Jaffe (Jaffe, 1886) and is still the preferred technique in clinical practice. The Jaffe assay is 
based on the reaction of creatinine with picric acid in an alkaline medium, leading to a red 
colour and formation of needle-formed crystals (Delanghe and Speeckaert, 2011). Since this 
assay is confounded by different non-creatinine chromogens, such as glucose, ketones, urea, 
proteins and, ascorbic acid, an overestimation of the serum creatinine of 15-25% was 
observed (Myers et al., 2006). Therefore enzymatic methods were developed as alternative 
to reduce interferences (Rosenthal et al., 2007). These methods are based on the enzymatic 
reaction with creatinine amidohydrolase (creatinine to creatine) or creatinine 
iminohydrolase (creatinine to ammonia and N-methylhydantion) (Suzuki and Yoshida, 1984; 
Fossati et al., 1994). The accuracy of the enzymatic method is less confounded in comparison 
with Jaffe, but interfering compounds, such as bilirubin and catecholamines are still present 
(Peake and Whiting, 2006; Saeger et al., 2009). Creatinine concentrations can also be 
determined using HPLC-UV (Brown et al., 1977). Both direct injection on the column as 
plasma deproteinization have been described, and have proven to be sensitive for creatinine 
without interferences, rendering this technique superior to the conventional Jaffe and 
enzymatic techniques (Myers et al., 2006). However, the feasibility to implement this 




Creatinine production is subject to intra-and inter-individual differences, especially in the 
paediatric, geriatric and severely ill patients, rendering creatinine measurements less reliable 
in comparison to other markers. In newborns, the ‘exogenous’ (maternal) creatinine can also 
confound the accuracy of the GFR measurements (Schwartz et al., 1987). Moreover, to 
measure the GFR in clinical practice, 24 h creatinine concentration in urine is required, which 
can be difficult to attain in the paediatric subpopulation. Also, the determination of plasma 
creatinine with Jaffe is not reliable when the total plasma protein content is lower than 75 
g/L. 
 
4.1.1.2 Cystatin C 
Cystatin C is a non-glycosylated basic low-molecular-weight protein (13.36 kDa) belonging to 
the cystatin superfamily of cysteine proteinase inhibitors, that are involved in the 
intracellular protein catabolism (Grubb et al., 1982). Cystatin is produced by all nucleated 
cells at a constant rate. The rate of production is not influenced by muscle mass, sex or race 
(Barett et al., 1984). Cystatin C is freely filtered by the glomerulus, followed by reabsorption 
and catabolisation by the tubular epithelial cells. Consequently, the urinary excretion of 
cystatin C is low and urinary clearance cannot be measured (Stevens et al., 2006). No 
extrarenal excretion has been observed (McPherson and Pincus, 2011). Intra-subject 
variability in serum cystatin C levels is expected to be less in comparison to creatinine (e.g. 
no influence of body composition). However, like creatinine, inter-subject variability is 
expected, which is related to age, sex, BW, height, smoking status, level of C-reactive 
protein, thyroid function and corticosteroid use (Stevens et al., 2006). A meta-analysis was 
performed in both children and adults comparing both the diagnostic performance of 
cystatin C in comparison with creatinine. This meta-analysis demonstrated that cystatin C is 
superior to creatinine to detect impaired kidney function (Dharnidharka et al., 2002).  
 
Four different methods based on immunoassays are described to determine the cystatin C 
concentrations (Lofberg and Grubb, 1979; Poulik et al., 1983; Kyhse-Andersen et al., 1994; 
Newman et al., 1995; Finney et al., 1997). Today, the particle-enhanced nephelometric 
immunoassay using Dade Behring nephelometers or immune-turbidimetric assays are the 




cystatin C is not widely used in clinical practice, since the analysis is expensive and difficult to 
perform (Massey, 2004). Moreover, standardization of the techniques is still lacking 
(Delanghe et al., 2008). 
 
Plasma cystatin C concentrations are high at birth (2.8 mg/L) and decline thereafter, 
demonstrating maturation of the kidney function (Filler, 2011). The cystatin C concentration 
reaches adult values at two years of age (Bokenkamp et al., 1998). The reference values are 
0.75 ± 0.09 mg/L (children aged 4-19 years (♂ and ♀)), 0.74 ± 0.10 mg/L for males and 0.65 ± 
0.09 mg/L for females (20-59 years) (Finney et al., 2000; Filler et al., 2014).  
 
4.1.1.3 β2-microglobulin 
β2-microglobulin (11.6 kDa) is a polypeptide which belongs to the histocompatibility complex 
class I molecules. It can be found in all nucleated cells and is required for the production of 
cluster of differentiation-8 (CD-8) cells (McPherson and Pincus, 2011). Use of β2-
microglobulin to determine the GFR was first proposed by Wibell et al. (1973). As seen for 
cystatin C, β2-microglobulin is also freely filtered by the glomerulus and completely 
reabsorbed and metabolized by the proximal tubules (McPherson and Pincus, 2011). The use 
of β2-microglobulin has also some drawbacks, such as high serum concentrations found in 
some malignant disorders (e.g. lupus nephritis and, lymphoproliferative disorders), the 
samples need to be immediately stored in the refrigerator, analysis is expensive (alkanisation 
is required) and not available in routine laboratories (Brochner-Mortensen, 1985). β2-
microglobulin was first determined in serum and urine using single radial immunodiffusion 
(Peterson et al., 1969). Since the sensitivity of this assay was too low, alternative 
radioimmunoassay methods were developed (Ervin et al., 1971; Shuster et al., 1976). 
 
No age dependent variation in β2-microglobulin serum concentrations has been observed 
(Nolte et al., 1991). Moreover, Ikezumi et al. (2013) demonstrated (Japanese children aged 
0-17 years) muscle-mass independence of the β2-microglobulin serum concentration values, 
offering an advantage in comparison with serum creatinine. El-Frargy et al. (2015) studied if 




concluded that β2-microglobulin is an accurate marker of renal function impairment in this 
subpopulation.  
 
4.1.2 Exogenous markers 
4.1.2.1 Inulin  
The renal clearance of inulin (5 kDa) is considered as the gold standard to assess the GFR. 
Inulin is a group of polysaccharides belonging to the fructans. Valentine Rose discovered 
inulin in 1804 by boiling the roots of Inula helenium in water and extracting the resultant 
solution (Black and Black, 1842). Inulin is not plasma protein bound. Inulin is freely filtered 
by the glomerulus and not secreted, metabolized nor reabsorbed by the renal tubules (Filler 
et al., 2012; Schwartz and Work, 2009), rendering inulin an ideal GFR marker.  
 
To determine the clearance of inulin, an IV priming dose followed by constant rate infusion is 
required. Clearance of inulin can be calculated after steady-state plasma concentrations are 
established by measuring urinary (every 10 to 20 min) or plasma concentrations (seven time 
points up to 4 h post administration) (Swinkels et al., 2000). Different colometric methods 
have been developed to determine the inulin concentration, all based on the hydrolysis of 
inulin by incubating with hot acid (diphenylamine assay and resorcinol assay) (Zalups and 
Lash, 1996). The clearance of inulin is best described using a two-compartmental PK model 
(van Rossum et al., 2005). Inulin clearance determination is cumbersome, since timed urine 
or blood collections are required, it is difficult to obtain constant inulin plasma 
concentrations (Schwartz and Work, 2009). In an effort to simplify the GFR determination, 
single-injection methods were established to measure the inulin clearance (Florijn et al., 
1994; van Rossum et al., 2005). Florijn et al. (1994) described a good reproducibility of the 
single IV injection, however a constant overestimation of the urinary clearance by the total 
body clearance was observed. Schwartz and Work (2009) also concluded that single IV 
administration is possible and less time consuming, however, continuous infusion is more 
accurate to predict the GFR.  
 
Inulin is still considered the gold standard for assessment of the GFR in adults and children. 




always potty-trained and some children have neurogenic bladders, dysfunctional voiding, or 
vesico-ureteral reflux (Winterborn et al., 1977; Schwartz and Work, 2009). Moreover, the 
difficulty to reach steady-state and to measure concentrations, renders the inulin technique 
less feasible in paediatric nephrology (Schwartz and Work, 2009).  
 
4.1.2.2 Radioisotopes 
Since the 1970s, radiolabelled isotope techniques were introduced to measure the GFR. The 
most frequently used radiolabelled compounds are: 125I-iothalamate, 51Cr-EDTA and 99mTc-
diethylenetriamine penta-acetic acid (99mTC-DTPA). No significant differences between the 
clearance of inulin and 51Cr-EDTA were demonstrated (Krutzen et al., 1984; Lundqvist et al., 
1994). However, at high values of GFR, the clearance of 51Cr-EDTA slightly underestimates 
the GFR and at low values of GFR, it slightly overestimates the GFR (Brochner-Mortensen 
and Rödbro, 1976). Barbour et al. (1976) compared the clearance of inulin, 125I-iothalamate 
and 99mTC-DTPA for measurement of the GFR in dogs and concluded that the clearances 
were comparable between the three techniques. In children, the plasma protein binding of 
125I-iothalamate, 51Cr-EDTA and 99mTC-DTPA is 9.55%, 12.15% and 10.99%, respectively (Filler 
et al., 1999; Filler et al., 2002; Barbour et al., 1976). This plasma protein binding could lead 
to an underestimation of the GFR. Moreover, EDTA and DTPA clearance is affected by 
disorders such as nephrotic syndrome, since the negatively charged glomerular basement 
membrane forms a restriction for the ultrafiltration (Filler et al., 2014). Iothalamate 
undergoes tubular secretion, which was proven in a study where iothalamate was 
administered after pretreatment of probenecid (Odlind et al., 1985). 
 
To determine the GFR using 99mTC-DTPA, the uptake of 99mTC-DTPA by the kidney can be 
measured with a scintillation camera or timed blood samples can be taken to measure the 
plasma clearance of 99mTC-DTPA after a single IV injection (Piepsz et al., 1978). 51Cr-EDTA and 
125I-iothalamate can both be determined using plasma or a combination of plasma and 
urinary clearance methods (Filler et al., 2014). To measure the plasma clearance of the 
radioisotopes, at least three blood samples are required (Filler et al., 2014). When 
comparing both methods, the plasma clearance method overestimates the GFR with lower 




These techniques are not suitable for repeated GFR measurements in children, since 
radiation exposure can occur and could lead to long term effects, e.g. the beta-particles of 
51Cr-EDTA are potentially carcinogenic (Filler et al., 2014). Moreover, when determining the 
urinary clearance or the radioisotopes, it is difficult to accurately determine the urinary 
output, since children are not always able to quantitative empty their bladder (Hellerstein et 
al., 2006). However, a single injection of 99mTC-DTPA to 190 children (median age 8 years) 
demonstrated the usefulness of this technique in children, especially in children less than 
one year of age (Du et al., 2009). 
 
4.1.2.3 Iohexol 
Iohexol (821 Da) is a non-ionic low osmolar X-ray contrast agent which is used for 
angiographic and urographic imaging. Iohexol consists of two isomers (endo- and exo-
iohexol), of which exo-iohexol is the most abundant (approximately 90%). A good correlation 
between the clearance of iohexol and other exogenous markers, i.e. inulin and 51Cr-EDTA 
was demonstrated in humans (Lundqvist et al., 1994; Krutzen et al., 1984). The plasma 
protein binding is found to be very low (<2%) (Krutzen et al., 1990). Iohexol is not 
reabsorbed, metabolized nor secreted by the kidney (Schwartz and Work, 2009). Iohexol is 
excreted unmetabolized in urine and the recovery rate of iohexol is 100% within 24 h after IV 
injection.  
 
Iohexol is administered IV using a single-injection bolus (0.1 mL/kg BW ≈ 64.7 mg/mL 
iohexol). Only four sampling points are required to adequately determine the clearance of 
iohexol (10, 30, 120, 300 min). This was determined by Schwartz et al. (2006), who 
demonstrated a good agreement between the four blood sampling point and nine blood 
sampling point iohexol clearance determination. Iohexol concentrations are determined 
using HPLC-UV methods. The best description of the plasma concentration-time profiles of 
iohexol is obtained with a two-compartmental disposition model (Schwartz et al., 2006).  
 
Berg et al. (2011) determined the plasma clearance of iohexol in children with different 
kidney disorders and compared the obtained values with the urinary clearance of inulin. The 




the usefulness of iohexol in clinical practice since no urine collections are required. However, 
Berg et al. (2011) also mentioned to be extra careful in the lower range of GFR (< 30 
mL/min/1.73 m²), since the accuracy of iohexol as a marker is reduced.  
 
4.2 Estimation of glomerular filtration rate 
Since the measurement of GFR using urinary data is time-consuming and not always clinical 
applicable, researchers have tried to find means to estimate the GFR based on serum or 
plasma creatinine concentrations and readily available characteristics, such as age, sex, race, 
BW. These equations can be used to detect and monitor CKD, adjustment of the dose of 
drugs acting on or excreted by the kidney, evaluation and management of complications 
associated with hypertension, anaemia, malnutrition, etc. (Stevens et al., 2006). Over the 
years, several equations have been developed of which the Cockcroft and Gault (adults, 
creatinine clearance), Modification of Diet in Renal Disease (MDRD) (adults, eGFR) and, 
Schwartz (children, eGFR) equation are the most widely used in clinical practice. An overview 
of these equations is given below. 
 
4.2.1 Cockcroft and Gault 
The Cockcroft an Gault equation was developed in 1976 from 24 h creatinine excretion data 
(two urine collections) obtained in 249 adult men with a creatinine clearance between 30 to 
130 mL/min (Cockcroft, 1976). Since no women were included in the study, a correction 






(140 − 𝑎𝑔𝑒(𝑦)) × 𝐵𝑊(𝑘𝑔)(× 0.85 (♀))





Cr: serum creatinine concentration, BW: body weight 
 
The creatinine clearance is not adjusted for body surface area (BSA) since BW was included 
in the equation. This can lead to difficulties in estimating the GFR in laboratory settings, 
since accurate BW measurements are required, which is not always available in the 
laboratory software (Herget-Rosenthal et al., 2007). An overestimation of the GFR was 




for in the estimation equation (Shemesh et al., 1985). Moreover, the Cockcroft-Gault 
equation does not account for possible deviating creatinine production due to variation in 
muscle mass caused by diseases states (McPherson and Pincus, 2011). The predictability of 
the equation in patients without CKD was found to be less accurate, leading to an 
underestimation of the GFR (Herget-Rosenthal et al., 2007).  
 
4.2.2 Modification of Diet in Renal Disease 
The modification of diet in renal disease (MDRD) equation was developed in 1999 from the 
renal clearance of a single-bolus subcutaneous (SC) injection of 125I-iothalamate obtained in 
1628 adults with CKD and a mean serum creatinine concentration of 2.3 ± 1.2 mg/dL (Levey 
et al., 1999). The study was validated in 1775 adults in the African-American study of kidney 
disease (Lewis et al., 2001). A revision of this formula was required in 2007, since the serum 
creatinine values with a standardized serum creatinine assay were 5% lower in comparison 





1.73𝑚2) =  175 × 𝐶𝑟 (
𝑚𝑔
𝑑𝐿
)−1.154 × 𝑎𝑔𝑒 (𝑦)−0.203  × 0.742 (♀) × 1.212 (𝑖𝑓 𝐴𝑓𝑟𝑖𝑐𝑎𝑛 𝐴𝑚𝑒𝑟𝑖𝑐𝑎𝑛)  
Cr: serum creatinine concentration 
 
The race (black or not) is included in the equation, since African-American patients tend to 
have more muscle mass and consequently higher serum creatinine concentrations (Stevens 
et al., 2006). Like the Cockcroft-Gault equation, the MDRD equation does not account for 
possible deviating creatinine production due to variation in muscle mass caused by disease 
states (McPherson and Pincus, 2011). The accuracy of the MDRD equation has been 
evaluated in different populations and appears to be relatively accurate to estimate the GFR 
in patients with CKD (Rule et al., 2004; Froissaert et al., 2005; Poggio et al., 2005). However, 
the predictability of the GFR in patients without CKD was found to be less accurate 
(underestimating the GFR beneath 60 mL/min/1.73 m²) (Stevens et al., 2006). Another 
drawback of the MDRD study equation is that the equation is not tested in children, elderly 






4.2.3 Schwartz  
Schwartz et al. (1976) developed the original Schwartz equation in children by performing an 
inulin clearance study in 186 children suffering from CKD aging six months to twenty years. 
Since the serum creatinine concentrations were analysed with a Jaffe technique, leading to 
confounded concentrations and overestimated GFR values, a follow-up study was 
performed. In 2009, Schwartz administered a single-dose IV bolus of iohexol to children 
suffering from CKD (median age: 10.8 years). The serum creatinine values were analysed 












k: constant, Cr: serum creatinine concentration 
 
Since the equation is based on serum creatinine concentrations, the GFR will be 
underestimated in children with high muscle mass and overestimated in children suffering 
from anorexia, neuromuscular or severe chronic diseases (Schwartz et al., 1987). Moreover, 
the study was performed in children with mild to moderate CKD instead of a normal 
population and the tested GFR range was only 15 to 75 mL/min per 1.73 m². Consequently, 
this formula should be used with extra care in children without CKD or in children with 
higher GFR.  
 
4.2.4 Other equations  
Since the Schwartz equation has its drawbacks as well, to date, multiple research groups try 
to develop more appropriate equations or improve the existing equations to estimate the 
GFR in growing children. Other markers, sampling strategies and analysis techniques were 
used to develop and validate these equations. Two examples are the Counahan-Barrett and 
Leger equation. 
 
Counahan et al. (1976) estimated the GFR by administering a single-shot injection of 51Cr-
EDTA to 103 children aging two months to fourteen years and suffering from a renal disease. 















Cr: serum creatinine concentration 
 
Leger et al. (2002) estimated the GFR using the population PK approach. Plasma 51Cr-EDTA 
concentrations were determined in 64 children aging 0.8 to 18 years (38♂/26♀). Non-linear 













BW: body weight, Cr: serum creatinine concentration 
 
To the author’s knowledge no equations to estimate the GFR have been established in 
growing piglets. Development of an equation can be useful for preclinical paediatric porcine 
studies and determination of correct dosage strategies for drugs that are renally excreted in 
growing piglets.  
 
4.3 Anatomical and physiological ontogeny of the kidney and GFR in humans and piglets 
In general, the anatomy of the mature pig kidney resembles that of humans, which is 
multilobular with a more flattened shape compared to the basic bean-shaped form and with 
a smooth surface (Sisson, 1975; König et al., 2014). The weight is 180-260 g each in pigs (the 
length is almost twice the width) (Sisson, 1975), whereas in adult human males and females 
it is around 300 g and 280 g, respectively (Barone, 1978). Sisson (1975) stated that the ratio 
of the combined weight of both kidneys to that of the BW is about 1:150 to 1:200 in humans. 
The kidneys are both multirenculate and multipapillate with true calices, and have 
approximately the same size (length: ± 10 cm, width: ± 5 cm) (Swindle et al., 2012; Swindle, 
2007). Concerning the position of both kidneys, in pigs and men the left kidney is located a 
bit more cranial compared to the right one (Nickel et al., 1973; Sisson, 1975). However, there 
is a distinct difference between piglets and infants concerning the anatomical postnatal 
development of the kidney. The pig’s nephrogenesis proceeds approximately up to three 




of gestation (four weeks before birth) (Solhaug et al., 2004). Vodenicharov and Simoens 
(1998) indicated the absence of a direct connection between the afferent and efferent 
arterioles in pigs, in contrast to humans (Elias, 1957). In humans, diaphragms closing the 
fenestrae of the glomerular capillaries are absent (Farquhar, 1975). However, in the earlier 
stages of the development of the pig glomerulus, diaphragms close the fenestrae, but in 
mature glomerulae diaphragms are present only occasionally (Friis, 1980). Concerning the 
branches of the renal artery from the aorta, Bauer (1968) stated that all arteries have a 
lateral aortic origin in swine, which is not the case in humans. 
 
The physiology of the mature porcine renal function is similar to that of humans (Dalmose et 
al., 2000). In general, physiological development occurs postnatal in both species, 
underlining the importance of age when comparing both species. The development of the 
renal function in piglets, more specifically GFR was documented in several studies (Vogh and 
Cassin, 1966; Gruskin et al., 1970; Friis, 1979; Osborn et al., 1980). Friis (1979) (Danish 
Landrace breed) and Kaskel and Kleinman (1976) (breed not mentioned) described the 
postnatal development of the GFR measured as inulin clearance in piglets aging 1 to 62 and 
14 to 40 days, respectively. The GFR gradually increased from 0.27 to 0.59 (adult value) 
mL/min/g kidney. This augmentation was attributed to an increasing RBF, the formation of 
new glomeruli, and a higher capillary pressure (Gruskin et al., 1970; Friis, 1979). Similar to 
piglets, the human GFR increase was attributed to an augmented RBF. The GFR is low at 
birth and increases during the first weeks of life, until it reaches adult values at eight to 
twelve months of age (Figure 3) (Kearns et al., 2003). The GFR values in humans are 39 
mL/min/1.73 m² (2-8 days), 47 mL/min/1.73 m² (4-28 days), 77 mL/min/1.73 m² (1-6 
months), 77 mL/min/1.73 m² (6-12 months), 127 mL/min/1.73 m² (12-19 months) (Heilbron 
et al., 1991; Hazinski, 1992; Solhaug et al., 2004). Overall, the GFR increases over time and at 
the age of one year for humans, and eight weeks for pigs, adult GFR values are reached (De 






Figure 3. Postnatal development of the glomerular filtration rate in humans (blue line) 








































5.1 Structure and physiochemical properties 
Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) is the synthetic analogue of 
the natural antidiuretic hormone arginine vasopressin. Desmopressin was first synthetized in 
1967 by deamination of the cysteine residue (prolonged activity due to a lipophilic N-
terminal) and replacing the L-arginine configuration with the D-arginine configuration 
(reduced vasopressor activity due to changes in polarisation of the molecule) (Figure 4) 
(Zaoral et al., 1967). The molecular formula of the nonapeptide desmopressin is 
C46H64N14O12S2, with a molecular mass of 1069.224 g/mol. The active ingredient of the 
different formulations is desmopressin acetate. Desmopressin has a negative clog P (-7.711), 
which demonstrates the extreme hydrophilicity of this drug (Lawton and Witty, 2013). 
Desmopressin is a base with a pKa of 11.8.  
 
 
Figure 4. Chemical structure of vasopressin (left) and desmopressin (right). Deamination 
(green circle) and L-arginine versus D-arginine configuration (red circle).  
 
5.2 Vasopressin Receptor 
The arginine vasopressin receptor (AVP) belongs to the G-protein coupled receptor (GPCR) 
superfamily, more specifically the rhodopsin-like class A receptors. Michel et al. (1979) 
distinguished two AVP receptors based on expression in the liver (hepatic AVP receptors, V1) 
and the kidney (renal AVP receptors, V2). Jard et al. (1986) further subdivided the V2 
receptors in V1a (hepatic receptor) and V1b (adenohypophysis receptor). As all GPCRs, the 
AVP receptor contains seven hydrophobic transmembrane α-helical segments, 
interconnected with alternating intracellular and extracellular loops, an extracellular N-















Figure 5. Schematic representation of the amino acid sequence of the human vasopressin 2 
receptor (adapted from Faerch et al., 2009; Juul et al., 2014).  
 
The V2 receptor has been characterized in humans, rats, pigs and cattle (Ufer et al., 1995). 
The amino sequence homology between the bovine receptor and the human, rat and pig V2 
receptor was 85%, 82% and 88%, respectively. Ufer et al. (1995) stated that the aspartate 
(Asp) molecule in position 103 (highlighted bold in Figure 6), which is located at the first 
extracellular loop of the receptor, is responsible for the high affinity binding of desmopressin 
to its receptor.  
 
Figure 6. Schematic representation of the first extracellular loop of the amino acid sequence 
of the bovine, porcine, human and rat vasopressin 2 receptor (adapted from Ufer et al., 
1995). 
 
Literature reports about the ontogeny of the V2 receptor are scarce. Sarmiento et al. (2005) 
determined the expression of the V2 receptor during kidney maturation in Sprague-Dawley 
rats. They concluded that a close correlation between expression of the receptor and age 
was observed. The renal V2 receptor up-regulation exists already prenatally (prenatal day 
16), preceding urine-concentrating capacity of the kidney (mature 2 to 4 weeks after birth). 




Xing and Norregaard (2016) investigated the prenatal V2 receptor expression in the pig fetal 
kidney. An increase in V2 receptor expression was observed. Maturation of urinary 
concentrating capacity might be attributed to this increase.  
 
5.3 Mechanism of action 
Desmopressin is used to treat polyuria in patients suffering from central diabetes insipidus 
and PNE by acting on the V2 receptors of the collecting ducts (Edwards et al., 1973; 
Robinson, 1976; Schulman, 2001). Desmopressin binds to the V2 receptor in the basolateral 
membrane of the collecting duct, stimulating the Gs-coupled protein to activate adenylate 
cyclase, leading to the formation of cyclic adenosine monophosphate (cAMP) from 
adenosine triphosphate (ATP). cAMP binds to protein kinase A, activating the 
phosphorylation cascade, whereby the exocytosis of aquaporin-2 water channels from 
cytoplasmic aquaporin water channel-containing vesicles towards the apical membrane of 
the collecting ducts is stimulated. Osmotic pressure between the lumen and the interstitium 
facilitates the water reabsorption through the water channels, resulting in urine 













Figure 7. Mechanism of action of desmopressin. 1: AVP binds to receptor, 2: receptor 
activates second messenger system, 3: cAMP binds PK, 4: exocytosis aquaporin channels, 5: 
water absorption; AVP: arginine vasopressin, V2 receptor: V2 vasopressin receptor, ATP: 
adenosine triphosphate, cAMP: cyclic adenosine monophosphate, AC: adenylate cyclase, PK: 
protein kinase A, AQP2WCV: aquaporin 2 water channel-containing vesicles, AQP: aquaporin 




Desmopressin is also used in high doses in the treatment of congenital bleeding disorders, 
namely haemophilia A and von Willebrand disease, since it induces vasodilation and 
increases the von Willebrand factor, coagulation factor VIII and tissue plasminogen activator 
(Mannucci et al., 1975). To date, the exact mechanism of action of desmopressin in the 
treatment of haemophilia A and von Willebrand disease is still not completely unravelled. 
The main focus of this doctoral thesis is the use of desmopressin as treatment for nocturnal 
enuresis and not for bleeding disorders. Consequently, the latter will not be further 
discussed in this thesis.  
 
5.4 Pharmacokinetics 
Over the years, various pharmaceutical formulations of desmopressin were commercialized, 
i.e. nasal spray, nasal drops, oral tablet, oral lyophilisate (sublingual or melt tablet) as well as 
IV injectable. The nasal route of administration is preferred for peptide drug delivery, since 
the relatively large surface area, thin epithelium and rich vascularisation facilitate the 
absorption of these peptides. However, higher inter- and intra-subject variability in PK was 
observed following intranasal (IN) administration (Joukhadar et al., 2003). Subsequently, 
alternative routes of administration, such as the lyophilisate, were explored. Table 7 gives a 
literature overview of the PK parameters of the different formulations in humans. Only four 
papers described PK studies performed in the paediatric subpopulation, whereas only two 
papers mention the PK parameters (highlighted in table 7) (Néveus et al., 1999; Osterberg et 
al., 2006; De Bruyne et al., 2014; Michelet et al., 2016). Hence, there is a general lack of 
information on the PK characteristics in this population. Consequently, no size-dependent 
dosing regimens are available for this population. Additional and more extensive studies in 
the youngest age groups should be performed, ideally taking more blood samples in the 
initial phase after administration. On the other hand, animal trials, such as the piglet model 
might provide supplementary information to complement the information gap since more 








5.4.1 Absorption  
Desmopressin is absorbed relative rapidly in a paracellular fashion in the duodenum and 
proximal jejunum reaching maximum peak plasma concentration (Cmax) between 0.6 to 1.5 
hours post administration (Tmax) (Lundin and Vilhardt, 1986; d'Agay-Abensour et al., 1993). 
Overall, the oral bioavailability is extremely low (0.1%), since desmopressin is enzymatically 
degraded in the lumen of the gastrointestinal and the high molecular weight of 
desmopressin makes the paracellular absorption inefficient (Lawton and Witty, 2013). The 
bioavailability following IN administration is better (3-5%) in comparison with PO 
administration (Fjellstad-Paulsen et al., 1993). Osterberg et al. (2006) stated that the 
absorption process of desmopressin might be different for children, since the mean transit 
time was significantly different in comparison to adults (children: 0.21 h, adults: 0.48 h). This 
observation could be attributed to a change in absorptive surfaces, gastric emptying and/or 
intestinal motility. Rittig et al. (1998) investigated the effect of food intake on the absorption 
after PO administration of 400 µg desmopressin to patients aging 20 to 35 years. 
Concomitant administration of desmopressin and a standard meal (2199 kJ, Big Mac® 
hamburger) and administration of desmopressin 1.5 h after eating a standard meal resulted 
in a reduced (50% lower Cmax) and delayed absorption (longer Tlag and Tmax with an increase 
from 0.25 to 0.5 h and 1 to 1.5 h, respectively) in comparison with fasted patients. Two 
possible explanations were opted for these observations, namely the binding of 
desmopressin to food or the interaction of food with intestinal metabolic activity. Callréus et 
al. (1999) investigated the effect of the gastrointestinal motility and gastrointestinal 
secretion by administering erythromycin (increasing motility, 250 mg every 6 h, first dose 3 d 
before the study and last dose at -1 h) and loperamide (slowing motility, 4 mg, -24, -12 h and 
-1 h) prior to PO administration of 400 µg desmopressin. A significant increase in Cmax and 
Tmax was observed when desmopressin was administered after pre-treatment with 
loperamide, no significant difference in absorption was observed with erythromycin. 
Michelet et al. (2016) pooled paediatric data from two PK desmopressin trials in children and 
developed a model using a pop-PK approach on a sparse sampling set to understand the 
effect of food intake on the absorption of desmopressin (both the 150 µg lyophilisate and 
the 200 µg tablet). The effect of concomitant food intake was found to be clinically 





The volume of distribution of desmopressin after IV injection is 28.2 L in 22 to 46 year old 
humans and 11.2 L in 55 to 75 year old humans (Odeberg et al., 2004; Rembratt et al., 2004). 
In children aging six to twelve years, the mean pop-PK estimate of apparent volume of 
distribution after administration of an oral lyophilisate was 8510 L (Osterberg et al., 2006). 
This result was in accordance with the result (8237 L) obtained by Michelet et al. (2016). The 
latter authors also observed an effect of BW on volume of distribution, indicating that dose 
adjustment might be required. Information about the plasma protein binding of 
desmopressin is rather scarce. Lawton and Witty (2013) mentioned that 50% of the 
absorbed desmopressin binds to plasma proteins (Lawton and Witty, 2013). Desmopressin 
does not cross the blood-brain barrier after IV administration to patients aging 36 to 72 
years (Sørensen et al., 1984). Burrow et al. (1981) determined desmopressin concentrations 
in breastmilk in a 23 year old woman with diabetes insipidus. They concluded that 
desmopressin seems to be an appropriate therapy, since only traces of desmopressin were 
found in breastmilk. However, it should be noted that this study was only performed in one 
patient, so additional studies are required.  
 
5.4.3 Metabolism 
An in vitro study in rats demonstrated that 20% of desmopressin was inactivated by the liver 
and only a small fraction by the kidney (Shimizu et al., 1980). Fjellstad-Paulsen and Lundin 
(1996) determined the degradation of arginine vasopressin and desmopressin in human 
renal microvilli brush-border membranes and human liver membranes. Arginine vasopressin 
was found to be degraded in the kidney at both C- and N-terminus as well as by disulphide 
cleavage when the cofactor glutathione was present, and was found to be stable without 
this cofactor. Degradation of desmopressin in the kidney was negligible even when 
glutathione was present. No degradation was observed when desmopressin was incubated 
with purified liver plasma membranes, since desmopressin might undergo receptor-
mediated endocytosis followed by intracellular metabolism. This theory was also supported 
by Lundin et al. (1991), were rapid removal of desmopressin from the incubation medium 
was observed after incubation of desmopressin with liver tissue slices. This removal can be a 




intracellular degradation. Enzyme-dependent proteolysis of desmopressin by pancreatic 
enzymes in jejunal and ileal juice will occur. This degradation of desmopressin appears 
slower in jejunal than ileal juice, since it was pH dependent. Desmopressin is more stable at 
acidic pH (Fjellstad-Paulsen et al., 1995). To confirm the theory of enzyme-dependent 
proteolysis of desmopressin, concomitant administration of aprotinin (broad spectrum 
proteinase inhibitor) and desmopressin was studied. A concentration-dependent inhibition 
of desmopressin degradation was observed, enhancing the efficacy of orally administered 
desmopressin (Fjellstad-Paulsen et al., 1996). 
 
5.4.4 Excretion 
The mean pop-PK values of apparent clearance for children (6 to 12 years) and adults (18 to 
54 years) was 2330 L/h and 2930 L/h (Osterberg et al., 2006). The main route of excretion of 
desmopressin is renal excretion. Fjellstad-Paulsen et al. (1993) determined the urinary 
excretion after IN, SC and PO administration of desmopressin (IN: 20 µg; SC: 2 µg; PO: 200 
µg) in patients aging 20 to 57 years. Forty-eight percent, 92% and 65% of the amount 
absorbed after SC, IN and PO administration, respectively, was excreted in urine within 24 h. 
The renal fraction of desmopressin after IV administration (4 µg) was 39% (Agerso et al., 
2004). Moreover, Agerso et al. (2004) investigated the correlation between creatinine 
clearance and renal clearance in both healthy and renally impaired patients and found that 
both renal and non-renal excretion of desmopressin were found to vary with creatinine 
clearance. This observation could possibly be attributed to the association of renal 
impairment and a decrease in hepatic metabolism. Moreover, a prolongation of the 
elimination half-life was observed. Since desmopressin is only partially eliminated by the 
kidney, the total clearance of desmopressin is less affected by renal function. Consequently, 
desmopressin is still well tolerated in patients suffering from an impaired renal function. 
However, when administering high doses of desmopressin, adverse effects may occur in 
those patients, so great caution should be exercised when establishing the exact dosage 
regimen. Lundin et al. (1991) determined the excretion of desmopressin in bile after various 
routes of administration (intraduodenal, intrajugular and intraportal) in one conscious pig 
(Swedish Landrace, 4 months old). Only low concentrations of desmopressin were retrieved 




desmopressin (T1/2el) is prolonged in comparison with endogenous arginine vasopressin, 
since the enzymatic degradation in liver and kidney are slower (Cvetkovic and Plosker, 2005). 
 
5.4.5 Contra-indications and interactions 
Administration of large doses of desmopressin in combination with pressor agents or drugs 
that may cause hyponatremia (e.g. tricyclic antidepressants, selective serotonin re-uptake 
inhibitors, opiate analgesics, Non-steroidal anti-inflammatory drugs (NSAID)) should be done 
with extra care, since the PD effects of desmopressin could be amplified (increased pressor 
effect and potential water intoxication with hyponatremia) (Zhou and Meibohm, 2013). 
Odeberg et al. (2004) investigated the interaction of NSAIDs, namely piroxicam (PO, 20 mg at 
day one and 10 mg at day two to four), with IV desmopressin (2 µg) administration and 
found that piroxicam has no influence on the PK parameters of desmopressin, but can 
interfere with the antidiuretic effects. The clinical relevance of this observation should be 
further investigated in long-term treatment studies and with more common routes of 
administration. Desmopressin is contraindicated in patients with moderate to severe renal 
impairment (creatinine clearance below 50 mL/min), since the mean total body clearance is 
2.9 L/h in those patients in comparison with 10 L/h in healthy patients. Consequently, the 
mean terminal half-life is prolonged from 5.7 h in healthy patients to 10 h in patients with 
renal impairment. When administering desmopressin to this population great caution should 
be taken to avoid drug overdosing and adverse events (Rembratt et al., 2004). Desmopressin 
is also contra-indicated in patients with hyponatremia or a history of hyponatremia, since 
patients treated with desmopressin can experience hyponatremia. Desmopressin should 
only be used during pregnancy when clearly needed, because to date only limited fertility 
studies with females suffering from diabetes insipidus and receiving desmopressin have 
been performed. Studies in rats and rabbits (0.05 to 10 µg/kg/day) did not reveal any 
teratogenic and foetal toxicity following administration of desmopressin, but those studies 





















Route of Age Dose CL Vd T1/2el AUCinf Cmax Tmax F Reference 
administration years µg L/h L h pg*h/mL pg/mL h %  
PO tablet 20-57 200 - - - 25.4 13.6 1.2 0.1 Fjellstad-Paulsen et al., 1993 
 30-43 200 - - 2.0 50.3 16.2 1.5 - Lam et al., 1996 
 30-43 200 - - 2.0 50.3 16.2 1.5 - Lam et al., 1996 
 30-43 200 - - 2.0 50.3 16.2 1.5 - Lam et al., 1996 
 55-75 200 - - - 23 6.2 1.5 0.08 Rembratt et al., 2004 
 23-45 400 - - 2.5 90.4 25.4 1.3 - Calréus et al., 1999 
 65-78 400 - - 3.3 70.7 14.2 1.5 - Hvistendahl et al., 2005 
 18-49 400 - - - 85.5 23.2 1.2 - Kaehler et al., 2006 
 18-49 400 - - - 91.2 28.2 1.1 - Kaehler et al., 2006 
 20-35 400 - - 2.3 70.8 22.0 1.0 - Rittig et al., 1998 
 19-45 600 - - 2.3 132.0 32.0 1.2 - Argenti et al., 2001 
PO spray 21-29 160 - - - 59.0 15.5 1.0 - Steiner et al., 2006 
 21-29 240 - - - 110.9 29.8 0.7 - Steiner et al., 2006 
 21-29 320 - - - 137.3 41.6 0.9 - Steiner et al., 2006 
IN powder spray 20-32 19 - - 2.8 372.0 103.3 0.8 - Fransén et al., 2009 
IN liquid spray 20-57 20 - - - 63.0 21.3 1.0 3.4 Fjellstad-Paulsen et al., 1993 
 20-32 9.5 - - 2.7 135.4 34.1 0.8 - Fransén et al., 2009 
 20-34 20 - - - 116.9 31.2 0.7 - Joukhadar et al., 2003 
 20-34 20 - - - 108.9 30.0 0.6 - Joukhadar et al., 2003 
 30-43 20 - - 2.2 79.9 25.8 0.7 - Lam et al., 1996 
SC injection 20-57 2 - - - 202.5 62.3 0.7 - Fjellstad-Paulsen et al., 1993 
IV injection 20-57 2 - - 1.3 122.3 - -  Fjellstad-Paulsen et al., 1993 
 22-46 2 10.4 28.2 2.0 197 - - - Odeberg et al., 2004 
 55-75 2 6.6 11.3 3.1 302 181 - - Rembratt et al., 2004 
SL tablet 20-32 240 - - 2.1 67.4 17.9 1.5 0.25 Fransén et al., 2009 




 - - - - - Michelet et al., 2016
*3 




 - - - - - Osterberg et al., 2006 
CL: clearance, Vd: volume of distribution, T1/2el: elimination half-life, AUCinf: area under the plasma concentration-time curve, Cmax: maximal plasma concentration, Tmax: time at maximal plasma 
concentration, F: absolute bioavailability, PO: per os, IN: intranasal, IV: intravenous, SL: sublingual, - data missing, *1Cl/F, *2Vd/F, *3Population PK estimated based on Osterberg et al., 2006 and De 





The main cause of PNE is the lack of normal nocturnal secretion of vasopressin, whereby 
occurrence of nocturnal polyuria is possible (Aikawa et al., 1998). Ideally, the duration of 
action of desmopressin for treating PNE should vary between 8 to 11 h, since longer 
durations could induce adverse effects (hyponatremia, seizures, abdominal pain). Various 
formulations of desmopressin have been used to treat PNE. De Guchtenaere et al. (2011) 
compared an oral lyophilisate tablet (120 µg) to a conventional tablet (200 µg) in children 
aging 12.1 ± 2.5 years and concluded that the lyophilisate has a higher concentrating 
capacity and shorter time to reach maximal effect in comparison to the tablet. De Bruyne et 
al. (2014) performed a bioequivalence study of a 200 µg tablet compared to a 120 µg 
lyophilisate in children aging 5 to 18 years. Bioequivalence between both formulations was 
achieved, but the smaller inter- and intra-subject variability in plasma concentration and 
better prediction of plasma concentrations makes the lyophilisate more reliable in 
comparison with the tablet. Lottman et al. (2007) also compared efficacy and safety 
between the lyophilisate (120 µg to 240 µg) and tablet (0.2 mg to 0.4 mg) in children (five to 
fifteen years) suffering from PNE. Both formulations were well tolerated and no adverse 
effects related to the study treatment were observed. The incidence of nocturnal enuretic 
events measured during a six-week cross-over study (three weeks formulation one followed 
by three week formulation two) was comparable between both formulations. Higher 
compliance was achieved with the lyophilisate, since no water intake is required. Rembratt 
et al. (2004) determined the PD parameters of desmopressin (PO: 0.2 mg; IV: 2 µg) and the 
influence of the circadian rhythm on those parameters in male patients aging 55 to 75 years 
(high incidence of nocturia). The PD effects were almost identical for both formulations 
during the first 6 h, however, the duration of action of the IV administration lasted longer. 
When the PD parameters of desmopressin administration during daytime or night-time are 
compared, the effects on urine production and osmolality were prolonged to 12 h at night-








Rittig et al. (1998) investigated the effect of food intake on the antidiuretic action of 
desmopressin after PO administration of two 200 µg tablets to patients aging 20 to 35 years. 
Despite the reduced and delayed absorption of desmopressin, concomitant administration 
of a standard meal and desmopressin did not significantly alter the antidiuretic response to 
400 µg desmopressin during the first four hours post administration. However, the duration 
of action was prolonged in fasted patients in comparison with nourished patients, since the 
plasma drug concentrations were significantly higher.  
 
Vande Walle et al. (2006) performed one of the first dose-titration studies (30, 60, 120, 240, 
360 and 480 µg) of desmopressin lyophilisate to assess the PD measurements in children 
aging six to twelve years (urinary volume, osmolality and duration of action). A decline in 
urinary output and maximum osmolality (>800 mOsm/kg) was observed one hour post 
administration for the 60 to 480 µg dosing. Maximum effect of the 30 µg dose was also 
achieved after one hour, but maximum osmolality was lower in comparison with the other 
doses. Since the maximum effect is reached one hour after dosing, it is important to 
administer the lyophilisate one hour prior to bedtime. The duration of action is around 6 h 
for 120 µg and > 8 h for > 120 µg doses, enabling to control diuresis for 7 to 11 h (≈ 
approximately one night). Since the maximum osmolality, duration of action and urinary 
output are comparable between the 240, 360, 480 µg doses and most enuretic events occur 
during the first 2 h of sleep (Norgaard, 1991), a dose range of 120 µg to 240 µg should be 
sufficient. The lower doses also reduce the risk of adverse effects.  
 
About 6 to 10% of the children aging seven to eight years suffers from PNE, however, only 60 
to 70% are responders to the desmopressin treatment (Järvelin et al., 1988; Hjälmas and 
Bengtsson, 1993, Norgaard et al., 1995). Different pathologies of PNE could explain the 
differences in response to desmopressin (Norgaard, 1999). Nevéus et al. (1999) studied the 
difference in PD effects after IV injection of desmopressin (2 mg) to children aging 7.6 and 
16.2 years. Half of the study population (n = 6) were responders and half (n = 6) were non-
responders to the treatment. Bedwetting only occurred in the non-responder group. It 
appears that in both responders and non-responders a low nocturnal urine production and 




was produced by the responders, whereas non-responders voided with smaller bladder 
volumes. The latter is probably due to instability of the bladder.  
 
The PD response of desmopressin is different between male and female patients, with a 
higher antidiuretic efficacy observed in females (Odeberg et al., 2004; Goessaert et al., 
2015). Juul et al. (2011) examined the gender difference in antidiuretic response in patients 
suffering from nocturnal enuresis (> 2 voids/night and serum sodium concentration > 135 
mmol/L) and healthy volunteers. The mean decrease in nocturnal urine volume was higher 
in females than males. Moreover, the decrease in sodium plasma concentrations was more 
profound in females, potentially causing hyponatremia in those patients, whereby a 
narrower therapeutic window should be applied. The exact mechanisms to explain those 
differences are still unidentified, but different expression of the V2 receptor in male and 
females could be a possible explanation. Liu et al. (2011) examined the expression of V2 
receptor mRNA and protein in kidneys of female and male Sprague-Dawley rats, and linked 
the dimorphic traits between the genders and phenotypic variability among female 
heterozygotes to the second ‘silenced’ X-chromosome. Some genes escape the inactivation 
of the second X chromosome, whereby a variability in gene expression could be observed. 
Carrel and Willard (2005) demonstrated that the V2 receptor has a high probability to escape 
inactivation, potentially leading to expression of this gene from both X-chromosomes in 
females. However, further research is required to completely understand the sex differences 
in antidiuretic response of desmopressin.  
 
5.6 Therapeutic use and adverse events 
Desmopressin is the pharmacological therapy of choice to treat polyuria in patients suffering 
from central diabetes insipidus and PNE. Despite the low oral bioavailability, the plasma 
concentration levels are sufficient to achieve antidiuretic effects. This can be attributed to 
high receptor affinity and binding capacity of desmopressin to the V2 receptor (Lawton and 
Witty, 2013). The conventional route of administration of desmopressin in adults and 
children used to be intranasally (drops or spray), since this route bypasses the GIT, leading to 
an increase in absolute bioavailability. However in 2007, the FDA reported a post-marketing 




based on several case reports demonstrating that IN administration of desmopressin could 
potentially lead to severe hyponatremia and seizures (Robson et al., 2007). These adverse 
events could be attributed to the variability in absorption and unintentionally overdosing 
when using the nasal spray (Vande Walle et al., 2010; Goessaert et al., 2015). Consequently, 
the use of IN formulations was no longer approved for treating PNE in children in the United 
States of America and most of the European countries. Therefore, a switch to oral 
formulations was required, despite the limited number of data on the PK of desmopressin in 
children, the lack of bioequivalence studies between the tablet and the oral lyophilisate, and 
no availability of size-dependent dosing regimens in the paediatric subpopulation.  
 
Antidiuretic doses of the different formulations are depicted in Table 8. One week after 
starting desmopressin therapy, dosages should be individually adapted according to 24 h 
diuresis and urinary osmolality. In PNE, the therapy should be re-evaluated every three 
months to monitor if further treatment is required (De Guchtenaere et al., 2009). A gradual 
withdrawal is required when discontinuing desmopressin treatment, to evaluate if enuresis 
reoccurs.  
 
Table 8. Antidiuretic doses of different desmopressin formulations (adapted from SPC 
Minirin® Ferring) 
Formulation Indication Age Dose  Dosing interval 
Lyophilisate PNE Adult/Child (> 5 y) 120 - 240 µg 1 pd, evening 
CDI Adult/Child (> 5 y) 60 – 120 µg 3 pd 
Nocturia Adult/Child (> 5 y) 60 – 240 µg 1 pd, evening 
Nasal spray CDI Adult 10 – 20 µg  2 pd 
Nasal drops CDI Adult 10 – 20 µg  2 pd 
IV/IM/SC injection CDI Adult 1 – 4 µg 1 pd 
 CDI Child 400 ng 1 pd 
PO tablet PNE Adult/Child (> 5 y) 0.2 – 0.4 mg 1 pd, evening 
 CDI Adult/Child (> 5 y) 0.1 – 0.2 mg 3 pd 
 Nocturia Adult/Child (> 5 y) 0.1 – 0.4 mg 1 pd, evening 
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1. General objective 
Development of appropriate preclinical juvenile animal models is pivotal for proper conduct 
of paediatric clinical trials. This was also recognized by the European Medicine Agency (EMA) 
in the ‘Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals 
for paediatric indications’. Traditional animal species such as rodents, dogs and non-human 
primates are not always appropriate models to study age-related pharmacokinetic (PK), 
pharmacodynamic (PD) and safety parameters. Therefore, alternative models such as the 
conventional piglet might offer advantages for paediatric drug development, especially since 
the similarities in anatomy and physiology between pigs and humans are striking. The adult 
pig has been demonstrated to be a suitable animal model for adult preclinical studies. 
However, studies investigating the suitability of a paediatric pig model are still lacking. It was 
therefore hypothesized that the conventional piglet could be a convenient juvenile animal 
model to perform preclinical PK, PD and safety studies. To evaluate this, maturation 
processes of several organ systems involved in the absorption and disposition of drugs 
should be unravelled. Moreover, full PK, PD and safety studies with marketed drug 
compounds should be carried out to correlate the results and observations obtained in 
piglets with those obtained in humans.  
 
Therefore, the general aim of this doctoral thesis is to evaluate if the conventional piglet is a 
suitable juvenile animal model for preclinical paediatric studies of renally excreted and/or 
acting drugs. Before being able to perform complete PK/PD modelling it was necessary to 
develop appropriate blood and urine collection techniques which could be used in the 
different age categories. The following age categories according to Gad (2007) were included 
in the experiments and applied throughout the entire doctoral thesis: 
 
Category Age pig 
Neonate 8 days 
Infant 4 weeks 
Child 8 weeks 
Adolescent 6 months 
 
The focus of this doctoral thesis was excretion of drugs, more specific the maturation of the 
glomerular filtration rate (GFR) and a full PK/PD study of a test compound mainly excreted 
by the kidney, namely desmopressin. 
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2. Specific objectives 
2.1 Optimisation of blood and urine collection techniques 
A first prerequisite to be able to adequately perform PK/PD studies is the optimisation of 
blood and urine collection techniques in the different age categories. Therefore, a 
longitudinal study is needed in conventional piglets starting from the age of six days till eight 
weeks of age. The following research objectives are addressed: 
1. To establish a methodology for repetitive blood collection (both jugular vein catheter 
and direct venepuncture) in growing piglets (Chapter I). 
2. To establish a non-invasive urine collection technique (urine pouches) in growing piglets 
(Chapter I). 
 
2.2 Ontogeny of the glomerular filtration rate 
Determination of the GFR is pivotal for preclinical PK/PD and safety studies to determine 
age-dependent dosing schedules for drugs excreted by and/or acting on the kidney and to 
evaluate drug toxicity. The aim of this study is to determine the maturation of the GFR in 
growing piglets. The following research objectives are addressed: 
1. To compare two different GFR markers, namely endogenous creatinine (both Jaffe and 
enzymatic assay) and exogenous iohexol in conventional piglets. The acquired results of 
both markers are correlated with the GFR values obtained in humans (Chapter II.i).  
2. To establish a formula to estimate the porcine GFR based on plasma creatinine 
concentrations and BW, similar to the formula developed by Schwartz et al. (2009) for 
children (Chapter II.i).  
3. To develop a population-PK model that adequately describes the iohexol plasma 
concentration-time profiles across a population of conventional piglets (Chapter II.ii). 
4. To establish an equation to estimate the GFR in growing conventional piglets by 
obtaining the relationship between the clearance of iohexol, using non-linear mixed 









To evaluate piglets as an appropriate juvenile animal model, the synthetic analogue of the 
natural antidiuretic hormone vasopressin, namely desmopressin was chosen. The main 
reasons why desmopressin was chosen as a model compound are: (1) appropriate clinical 
trials conducted in the paediatric population are lacking despite the worldwide use of 
desmopressin (only two sparse sampling studies were performed); (2) the nasal spray was 
withdrawn from the market due to severe adverse effects. Therefore, a switch to oral 
formulations was required, despite the limited number of data on the PK of oral 
desmopressin in children and the lack of availability of size-dependent dosing regimens in 
the paediatric population; (3) desmopressin is mainly renally excreted, which enables to 
correlate maturation of the renal function with renal excretion of the drug. The following 
research objectives are addressed: 
1. To determine the population-PK parameters of desmopressin in growing conventional 
piglets (Chapter III). 
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Piglets are considered to be suitable animal models for predicting the pharmacokinetics and 
pharmacodynamics (PK/PD) of test drugs for potential use in the paediatric population. Such 
PK/PD studies require multiple blood and urine samplings. The goal of the present study was 
to determine a suitable blood collection strategy applicable in the youngest age categories 
of six days, four weeks and eight weeks of age, as well as a urine collection technique for 
male piglets in the same age categories. Blood was collected either by a surgically-placed 
jugular vein catheter (six days old [n=4] and four weeks old [n=2] piglets) or by direct 
venepuncture of the jugular vein (four weeks old [n=2] and eight weeks old [n=4] piglets). A 
non-invasive method for total volume urine collection in male piglets was also developed 
using a urine pouch. Due to the inability to attach these pouches to the perineum of female 
piglets, no urine collection could be performed in these piglets. No specific complications 
were encountered during anaesthesia or surgery for jugular catheter placement. After a 24 h 
recovery period, urine and blood were easily collected without technical complications. One 
piglet was humanely killed at week 2 because of septicaemia. Histological analysis of both 
veins in all four piglets revealed negligible damage to the blood vessel wall. In conclusion, 
the presented techniques for blood (jugular catheter and direct venepuncture) and urine 
collection (pouches) are suitable for PK/PD studies in piglets. 
 
Keywords 
Blood sampling, intravenous catheterization, neonate, piglet, urine collection 




The human paediatric population is often neglected during the process of drug 
development. This omission is due to a variety of factors, including biological challenges 
resulting from physiological changes and maturation. Moreover, ethical concerns of 
experimenting within this population result in a lack of complete pharmacokinetic (PK) and 
pharmacodynamic (PD) data (De Bruyne et al., 2014). The piglet has been proposed as a 
suitable paediatric animal model for PK/PD research because of the anatomical and 
physiological resemblances between pigs and humans (Helke and Swindle, 2013; Ezzati et al., 
2014; Gasthuys et al., 2016). Complete PK/PD modelling requires multiple blood and urine 
samplings over a short period of time, which demand appropriate collection techniques. 
Several techniques for placing intravenous catheters in pigs have been described in the 
scientific literature (Schwartz and Smallwood, 1977; Van Leengoed et al., 1987; Hu et al., 
1998; Caroll et al., 1998; Forauer et al., 2006; Usvald et al., 2008; Gasthuys et al., 2009; 
Flournoy and Mani, 2009). Although intravenous catheterization of 8- and 10-week-old pigs 
is routinely conducted in different research facilities, such catheterization in neonatal and 
younger pigs is challenging. Moreover, most research papers reporting the use of 
intravenous catheters in these age categories do not provide adequate details of the 
catheterization protocol, limiting the ability of other researchers to adopt these techniques 
(Wykes et al., 1993; Nguygen et al., 1999; Bauer et al., 2000; Chin et al., 2001; Kansagra et 
al., 2003; John et al., 2008). Palmisano et al. (1989) described intravenous catheterization in 
nine 3–4-day-old piglets using vascular access ports that were surgically placed three days 
after birth and were maintained over the following 54 days. It was possible to collect blood 
from all piglets at different time points, but during the study by Palmisano et al. (1989), 
technical complications occurred with four out of nine catheters. Caroll et al. (1998) 
performed a non-surgical cannulation technique of the jugular vein in two-week-old piglets. 
The intravenous catheters remained in place for 2–5 days. This technique was successful in 
all animals but was not evaluated in piglets aged less than two weeks. Flournoy and Mani 
(2009) developed a method for percutaneous external jugular vein catheterization in four-
week-old piglets using a triangulation technique that uses palpable landmarks to facilitate 
the percutaneous insertion of the catheter. However, the determination of anatomical 
palpable landmarks in younger piglets may be difficult due to their immature 
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musculoskeletal development, as also reported in human infants (Han et al., 2004). Overall, 
most of these intravenous catheterization procedures were performed in animals in various 
age categories and technical complications were frequently encountered. Moreover, the 
reuse of piglets for blood sampling at different ages was not described. 
In addition to blood sampling, urine collection is often of interest for both PK and PD studies. 
Wykes et al. (1993) Bauer et al. (2000) and Kansagara et al. (2003) described the insertion of 
a urinary catheter in male and female piglets, aged 1–3 days, for 12–27 h and for 12 h, 
respectively. Wijtten et al. (2011) used non-invasive urine pouches to collect the voided 
urine (at 2, 8 and 18 h post-administration for one or more days) at the age of 3–5 weeks. In 
these studies, urine collection was successful, but the use of these techniques at different 
ages was not investigated, and the usefulness of these techniques in age-related PD studies 
remains to be determined. Nguyen et al. (1999) and Chin et al. (2001) performed cystostomy 
in 7–10-day-old piglets, but no details about their procedures were provided. Shoveller et al. 
(2006) and John et al. (2008) also described urine sampling in piglets but did not mention the 
exact procedures used. The major reason for the lack of a straightforward and easy-to-apply 
urine collection technique is the anatomy of the urogenital system of the pig; (Kurien et al., 
2004) both the glans (corkscrew shape) and the corpus (sigmoid flexure) of the pig penis 
makes it difficult to catheterize the male urethra (Rowen et al., 2009). The female urethra 
can be catheterized with a Foley catheter, but localization of the external urethral orifice can 
be challenging (Ettrup et al., 2011; Musk et al., 2015). Additionally, the suburethral 
diverticulum in female piglets renders catheter placement even more difficult (Musk et al., 
2015). Furthermore, long-term catheterization of the urethra can lead to complications such 
as urinary tract infections, urinary tract damage, and catheter defects. The method of urine 
sampling depends on the PK or PD parameters needed for the PK/PD modelling. Certain 
studies require quantitative urine collection (e.g. to determine the cumulative urinary drug 
excretion), whereas others only need spot samples (e.g. to investigate the effect of drugs 
targeting the kidneys and urinary tract). Bacteriological and faecal contamination may also 
affect the choice of a particular collection method. Both invasive (cystocentesis, 
catheterization and suprapubic cystostomy) and non-invasive techniques (pouches, 
collecting spontaneous urination, manual emptying of the bladder and metabolic cages) can 
be used to determine PK/PD parameters in urine. Detailed reports about a standardized, 
Experimental Studies – Chapter I 
82 
 
easy-to-apply method for urine collection in newborn and growing piglets are scarce. As a 
result, there is a need for safe, reproducible and easy-to-perform techniques for collecting 
blood and urine in piglets. 
The aim of the present pilot study was to optimize blood and urine collection techniques to 
adequately perform repetitive PK/PD studies in piglets. Therefore, a longitudinal study was 
done in four piglets starting when they were six days old until they were eight weeks old. 
The age groups tested (six days, four and eight weeks) correspond to the same important 
age categories of the human paediatric subgroups (neonate, infant and child) (Gad, 2007). 
 
2. Materials and Methods 
2.1 Animals 
The study was approved by the ethical committee of the Faculties of Veterinary Medicine 
and Bioscience Engineering of Ghent University (EC 2014/47). Care and use of animals was in 
full compliance with the most recent national legislation (Belgian Royal Decree of 29 May 
2013) and European Directive (2010/63/EU). The study comprised four homozygote stress-
resistant piglets with a common health status (less sensitive to malignant hyperthermia, 
landrace x large white), two females (piglets number one and two) and two intact males 
(piglets number three and four) which were purchased from Seghers Hybrid (Wuustwezel, 
Belgium) when they were five-day-old (2.10 ± 0.07 kg body weight (BW)). Before surgical 
procedures were performed, the animals were group-housed in rescue decks (0.9 m x 1.40 
m) (Provimi, Rotterdam, The Netherlands) (five days to three weeks old) and standard pig 
stables with partially slatted floors (2.30 m x 2.40 m) (three to eight weeks old). The piglets 
were housed individually after catheterization to prevent catheter removal. Group housing 
was reintroduced after removal of the intravenous catheters. The piglets had ad libitum 
access to milk at 5-21 days of age (RescueMilk®, Provimi). At day 21, milk was gradually 
reduced simultaneously with the introduction of pig starter feed and drinking water 
(HeavyPig 1®, Provimi). At 28 days of age, the piglets had ad libitum access to the pig starter 
feed and drinking water. Natural light was provided by translucent windows, and the stable 
temperature was 23.3 ± 1.1°C. Higher temperatures were obtained in the rescue decks by 
heating lamps. One day prior to surgery, a cotton towel was added to the decks and stables. 
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The piglets were given the towel after surgery to mimic the smell of the other piglets when 
they were singly housed. The piglets could also see (Plexiglass®), hear and smell each other. 
The stables were enriched with hanging chains, rubber toys and different sizes of balls. The 
environmental enrichment was rotated daily. 
 
2.2 Experimental Design 
The general overview of the experimental design is presented in Figure 1. Briefly, a double-
lumen catheter was surgically placed in the jugular vein of the four six-day-old piglets (see 
below, section catheterization), and a urine pouch was additionally placed around the 
prepuce of the two male piglets (see below, section urine collection). After one day of 
acclimatization, multiple urine and blood collections were performed within a 12 h time 
period. The intravenous catheters and urine pouches were removed after the last collection 
point. At four weeks of age, the catheterization procedure was repeated in two of the four 
piglets (one male and one female; randomly selected) in the opposite vein. Blood collection 
from the remaining piglet was performed by direct puncturing of the opposite jugular vein 
(see below, section venepuncture). Urine was also collected in urine pouches from the same 
male piglets. At eight weeks of age, blood collection was performed by venepuncture in all 
animals instead of via catheters, and urine was again collected in pouches. After the last 
sampling point, the piglets were killed, and the jugular veins were collected for histological 
evaluation (see below, section histological parameters). 
Figure 1. Experimental design. 
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2.3 Anaesthetic Protocol 
The six-day-old piglets were not fasted before the surgical intervention to reduce the risk of 
hypoglycaemia. The four-week-old piglets were fasted 12 h prior to surgery to prevent food 
regurgitation. After intramuscular premedication in the lumbar muscles with morphine (0.1 
mg/kg BW) (Morphine.HCl®, Sterop, Anderlecht, Belgium), midazolam (0.5 mg/kg BW) 
(Dormicum®, Roche, Vilvoorde, Belgium) and ketamine (10 mg/kg BW) (Nimatek®, Dechra, 
Lille, Belgium), a catheter was placed in the marginal ear vein (24 standard wire gauge (SWG) 
in the six-day-old piglets, 22 SWG in the four-week-old piglets). General anaesthesia was 
then induced using propofol (Propovet®, Abbott Animal Health, Maidenhead, UK), 
administered slowly intravenously until endotracheal intubation was possible (cuffed 
endotracheal tube, 2.5-3 mm internal diameter (ID) in six-day-old piglets, 6-6.5 mm ID in 
four-week-old piglets). Anaesthesia was maintained with sevoflurane in an oxygen/air 
mixture (inspired oxygen fraction 60%) administered in a semi-closed circle system (AV-1, 
Dräger, Lübeck, Germany). Monitoring included pulse oximetry, inspired and expired gas 
analysis, electrocardiography and measurement of body temperature and blood pressure 
(oscillometry) using a multiparameter monitor (S/5, D-LCC15-03, Datex Ohmeda, OR, USA). 
During surgery, the body temperature was stabilized between 37°C and 39°C using a 
resistive polymer warming device (Hot Dog®, Augustine Biomedical, Eden Prairie, MN, USA). 
 
2.4 Blood Collection 
Catheterization. Catheterization of the right and left jugular veins was performed at six days 
(n=4) and four weeks (n=2) of age in the same piglets, respectively. The most optimal type 
and length of the intravenous catheter were first determined in cadavers. A double-lumen 
catheter (two-lumen central venous catheterization set, Arrow International, Cleveland, USA 
- at six days: 4 Fr., 30 cm, at four weeks: 7 Fr., 60 cm) was surgically placed according to the 
procedure described by Gasthuys et al. (2009) They performed the technique successfully in 
older and heavier pigs (approximately 8-10 weeks, 20-25 kg BW) but did not test the 
procedure in younger piglets. In the current study, the external jugular vein was surgically 
exposed, and the heparinized catheter was introduced using the Seldinger technique. In 
brief, the jugular vein was punctured with a trocar, and a guide wire was advanced through 
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the trocar towards the vena cava. The catheter was advanced over the guide wire, and the 
guide wire was then removed. The catheter was tunnelled towards the neck region, 
immediately cranial to the withers, and attached to the skin with sutures (Figure 2). After 
catheter placement, the incisions were closed in a three-layer continuous pattern, and 
adhesive dressings were applied over the wounds. Pre-operatively the catheters were 
flushed at regular time intervals with sterile diluted heparin in saline solution (six days: 
0.04% v/v, four weeks: 1% v/v; Heparin Leo® 5000 I.U./mL, LEO Pharma A/S, Denmark) to 
verify the functionality of both lumens. After one day of acclimatization, blood was sampled 
at 12 time points (5, 15, and 30 min; and 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h) within a 12 h time 
period, drawing one mL of blood each time from the distal lumen and flushing the catheters 
afterwards. 
Figure 2. Catheterization procedure of the left jugular vein at four weeks of age. 
Venepuncture. Blood was also collected by direct venepuncture of the jugular vein in the 
four-week-old (n=1) and eight-week-old (n=3) piglets. One mL of blood was sampled with a 
Venoject system (Venoject® multisampling needle, Terumo, Leuven, Belgium) at 12 time 
points (5, 15, and 30 min; and 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h) within a 12 h time period. 
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2.5 Urine Collection 
A non-invasive urine collection technique, based on the method described by Wijtten et al. 
(2011), was tested in male piglets at eight days and four and eight weeks of age (Figure 3). 
Urine collection in both studies was performed using human stoma rings and pouches 
(Esteem Synergy Uro®, 48 mm, kindly donated by ConvaTec, Braine-l’Alleud, Belgium). At the 
end of anaesthesia, the piglets were shaved around the preputial opening and an adhesive 
spray (Medical Adhesive 7730®, Hollister, Belgium) was applied. The stoma rings were then 
placed around the prepuce. After three minutes, the rings were fixed on the preputial skin, 
and Leukoplast® (BSN Medical, Hamburg, Germany) was used to tape around the collar. The 
pouches were attached to the ring during the urine sampling period according to the 
manufacturer’s instructions. The urine pouches were additionally fixed to the skin with 
Hypafix® (BSN Medical) bandages. Multiple urine collections (four time points, with renewal 
of the urine pouches at 0, 3, 6, 9 h) were performed within a 12 h time period. 
Figure 3. Urine collection technique in male piglets at four weeks of age. 
2.6 Bacteriological, clinical and histological parameters 
At arrival at our research facility, the piglets’ noses and perinea were swabbed for 
bacteriological screening (blood agar and methicillin-resistant Staphylococcus aureus (MRSA) 
selective plate). A susceptibility test according to the CLSI (Clinical and Laboratory Standards 
Institute) standard regulation was performed to determine the antimicrobial sensitivity of 
the bacteria (CLSI, 2013). Once the intravenous catheters were in place, the health and 
condition of the animals were monitored daily. Clinical parameters were assessed, including 
rectal body temperature, white blood cell (WBC) count (catheterized piglets, flow 
cytometry), BW, behaviour (feed and water consumption, clinical appearance) and wound 
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healing. The intravenous catheters were flushed once daily with a sterile diluted heparin 
solution (six days: 0.04% v/v, four weeks: 1% v/v), and sealing caps and bandages were 
changed when needed. After the catheters were removed, the piglets were monitored daily 
by assessing the clinical appearance, observing their behaviour (feed and water 
consumption) and measuring rectal body temperature. Euthanasia was performed by 
intramuscular injection with a mixture (0.22 mL/kg) of xylazine hydrochloride (Xyl-M 2%®, 
VMD, Arendonk, Belgium) and tiletamine-zolazepam (Zoletil 100®, Virbac, The Netherlands), 
followed by intracardiac injection with an overdose of sodium pentobarbital (Sodium 
pentobarbital 20%®, Kela, Hoogstraten, Belgium). The jugular vein tissue of the four piglets 
was sampled, fixed immediately in 4% formaldehyde for 48 h, and dehydrated in an ethanol 
series before embedding in paraffin using a Microm tissue processor STP 420D (Prosan, 
Merelbeke, Belgium) and Microm embedding station EC 350-1 (Prosan). Sections (8 µm 
thick) were cut using a Microm H360 microtome (Prosan) and then stained with 
haematoxylin and eosin (HE) and Van Gieson’s stain. Subsequently, light microscopy 
(Olympus BX61, Olympus DP50 camera, Olympus Cell software series) was used to 
determine whether there was any inflammation of the jugular vein at the site of intravenous 
catheter insertion and the surrounding tissues. 
 
3. Results 
The nasal cavities of all piglets and the perinea of three of the four piglets were MRSA 
positive. All recovered MRSA strains were resistant to penicillin G, ceftiofur, 
fluoroquinolones, tetracyclines, and streptomycin and sensitive to neomycin, gentamicin 
and potentiated sulphonamides.  
Anaesthesia and surgery were well tolerated by all piglets, although catheterization of the 
ear vein before induction of anaesthesia was challenging in the six-day-old piglets due to 
vasoconstriction and the small size of the ear veins. The mean total (range) anaesthetic time 
was 45 min (30 to 60 min) for the six-day-old and 37.5 min (30 to 45 min) for the four-week-
old piglets. During surgery, the jugular veins were easily accessible for placement of the 
catheter, and no complications were encountered throughout the entire surgical procedure. 
The mean total surgical time (range) was 35 min (20 to 50 min) for the six-day-old and 30 
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min (25 to 35 min) for the four-week-old piglets. Recovery from sevoflurane anaesthesia was 
quick and quite smooth in all piglets, although paddling was regularly observed before the 
piglets regained sternal recumbency.  
Figures 4 a and b show the rectal body temperature and BW, respectively. The daily analysis 
of the WBC count of the catheterized piglets is shown in Figure 5. The growth rate of the 
male piglets (piglet three and four) was consistent with the normal growth rate curve 
described in Swindle (2007), starting from 2.13 ± 0.02 kg at arrival and increasing to 8.24 ± 
0.48 kg at four weeks and 21.80 ± 2.30 kg at eight weeks of age. One female piglet (piglet 




Figure 4. Evolution of rectal body temperature (a) and body weight (b) after surgical 
procedures in the six-day-old (n=4) and four-week-old (n=2) piglets.  
(b) 
(a) 




Figure 5. Evolution of white blood cell (WBC) count after surgical procedures in the six-day-
old (n=4) and four-week-old (n=2) piglets.  
 
One piglet (piglet 2, catheterized only at six days of age) showed clinical signs of an infection 
three days after catheter removal (fever (> 40°C), lameness, swollen joints). After 
unsuccessful antimicrobial treatment with sulphadiazine-trimethoprim (Borgal®, Virbac, 
Leuven, Belgium - intramuscular, five days, 15 mg/kg BW/day), the piglet was killed, and 
both jugular veins were collected for histological examination. The three remaining piglets 
(piglet 1, 3 and 4) showed no clinical signs of infection; with normal behaviour, including a 
good appetite and gain in BW during the entire experiment. Mild local swelling of the 
surgical wound was observed and disappeared over the further course of the experiment.  
The intravenous catheters were functional during the experiment (i.e. tested for 48 h after 
placement), and all blood collections were easily performed in all the animals. Sealing caps 
and bandages were changed when needed. The piglets did not show signs of pain or distress 
during the removal of the catheters. The wounds around the catheter entrance healed 
within days after the removal of the catheters. All blood collections by venepuncture of the 
jugular vein were performed with no complications, and only signs of minimal distress were 
observed.  
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 The attachment and removal of the urine pouches were easily done, and no leaks were 
observed. Moreover, no skin irritation was noted during and after detachment of the ring 
system. This non-invasive technique allowed urine to be collected at different time points in 
male piglets.  
Histological analysis of the left and right jugular veins of the eight-week-old piglets, which 
were catheterized at the age of six days and four weeks, respectively, did not reveal any 
signs of inflammation. One of four right jugular veins was damaged, but remodelling of the 









Figure 6. Histological analysis of the left (a) and right (b) jugular veins. Remodelling (arrow) 
of the right jugular vein (c) and (d) (haematoxylin and eosin and Van Gieson staining) in a 










The aim of the current study was to determine optimal blood and urine collection 
techniques for repetitive sampling of piglets.  
Before performing any interventions, the piglets were bacteriologically screened for MRSA. 
This screening was necessary because of the age of the animals on arrival and the inherent 
risk of bacteriological contamination of the intravenous catheters (Gasthuys et al., 2009; 
Goetz et al., 1998; Lebeaux et al., 2013). Indeed, the immaturity of the immune system of 
piglets increases their susceptibility to opportunistic infections such as MRSA species. 
Moreover, MRSA is present in most conventional pig farms in Belgium (Verhegge et al., 
2013). Therefore, it is important to screen piglets from a new farm before starting trials and 
to determine the antimicrobial sensitivity of the bacteria. Both Gasthuys et al. (2009) and 
Palmisano et al. (1989) reported bacteriological contamination of intravenous catheters. 
Despite the strict hygienic precautions used in this study, one piglet showed clinical signs of 
septicaemia five days after intravenous catheterization. The infection may have been caused 
by the young age of the animal, i.e. the immaturity of the piglet’s immune system, the 
catheterization procedure and/or the environment. The susceptibility of the piglets to 
opportunistic MRSA infections, especially at the age of six days, made it even more 
challenging to optimize the catheterization technique.  
Blood collection from the six-day-old piglets was only performed with a commercialized 
double-lumen jugular vein catheter because the collection of multiple blood samples using 
the classic venepuncture technique was considered to be difficult and ethically less feasible 
in neonatal piglets. Catheterization was successful, despite the relatively large diameter of 
the catheter compared with the diameter of the jugular veins. At the age of four weeks, 
catheterization and direct venepuncture were compared to determine the most appropriate 
technique for blood collection. Both these procedures are suitable for multiple blood 
samplings, however, each method had its advantages and disadvantages. Venepuncture 
does not require anaesthesia and surgery of the animals, however restraining the animals 
can induce minimal stress responses. Furthermore, damage to the jugular veins is possible. 
Blood collection with intravenous catheters is easy to perform and requires minimal 
restraint of the piglets. In the eight-week-old piglets, only the venepuncture technique was 
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tested. This procedure was chosen instead of a new surgical intervention because two of the 
three piglets had already been anaesthetized twice and both veins had already been 
catheterized. The piglets had also become familiar with human contact, so minimal restraint 
was needed. Histological analysis of the jugular veins did not reveal inflammation around the 
catheterized veins, and the damage to both veins was negligible. Taking these observations 
into account, it is possible to catheterize the jugular vein without severe damage. 
Consequently, recatheterization of the vein may be possible.  
In the future, if feasible, microsampling (≤ 50 µL) of the marginal ear vein might also be 
considered to refine non-clinical paediatric porcine studies. Blunt et al. (2014) performed 
capillary micro blood sampling in the Göttingen minipig aged seven to eight months and 
successfully collected six blood samples over 24 h (0, 1, 2, 4, 6, 24 h). Penard et al. (2015) 
collected multiple blood microsamples in juvenile minipigs aged 1, 8, 15, 22 and 28 days (1-8 
days: saphenous vein, 15-28 days: ear vein). This technique could be a valuable alternative 
to catheterization of the jugular vein in the conventional pig if a suitable experimental design 
(number of samples, frequency of sampling, total volume required) and analytical assay can 
be applied.  
The urine collection technique used in the study is non-invasive and has multiple advantages 
compared with invasive techniques (Wykes et al., 1993; Nguyen et al., 1999; Bauer et al., 
2000; Chin et al., 2001; Kansagara et al., 2003). First, no surgery is needed. The pouches can 
be easily applied to the abdomen with minimal restraint of the animal. Second, no urinary 
tract infections were observed during the entire experiment. Finally, the technique can also 
be used in neonatal piglets. A disadvantage is the inability to attach the urine pouches to the 
perineum of female piglets, causing the pouches to be loosened and, consequently faecal 
contamination of the urine. Hence, a non-invasive technique to collect urine from female 
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In conclusion, the present study shows that the evaluated blood and urine collection (male 
piglets) techniques can be used successfully in piglets. Both intravenous catheterization at 
the ages of six days and four weeks as well as direct venepuncture at the ages of four and 
eight weeks were successfully performed in piglets. However, catheterization of piglets is 
preferred since this is a more ethical method of collecting multiple blood samples. 
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Adequate animal models are required to study the preclinical pharmacokinetics (PK), 
pharmacodynamics (PD) and safety of drugs in the paediatric subpopulation. Over the years, 
pigs were presented as a potential animal model, since they display a high degree of 
anatomical and physiological similarities with humans. To assess the suitability of piglets as a 
preclinical animal model for children, the ontogeny and maturation processes of several 
organ systems have to be unravelled and compared between both species. The kidneys play 
a pivotal role in the PK and PD of various drugs, therefore, the glomerular filtration rate 
(GFR) measured as clearance of endogenous creatinine (Jaffe and enzymatic assay) and exo-
iohexol was determined in conventional piglets aging eight days (n = 16), four weeks (n = 8) 
and seven weeks (n = 16). The GFR data were normalized to body weight (BW), body surface 
area (BSA) and kidney weight (KW). Normalization to BSA and KW showed an increase in GFR 
from 46.57 to 100.92 mL/min/m² and 0.49 to 1.51 mL/min/g KW from eight days to seven 
weeks of age, respectively. Normalization to BW showed a less pronounced increase from 
3.55 to 4.31 mL/min/kg. The postnatal development of the GFR was comparable with 
humans, rendering the piglet a convenient juvenile animal model for studying the PK, PD and 
safety of drugs in the paediatric subpopulation. Moreover, to facilitate the assessment of the 
GFR in growing piglets in subsequent studies, a formula was elaborated to estimate the GFR 




Piglet, glomerular filtration rate, iohexol, creatinine, paediatric animal model  




One of the key components of the optimization of clinical trials is the development and 
validation of appropriate preclinical animal models showing a high degree of anatomical and 
physiological resemblances to humans. In this respect, over the years, the interest has grown 
to use adult pigs as translational animal models in biomedical research (Bode et al., 2010; 
Helke and Swindle, 2013; Gasthuys et al., 2016). The considerable anatomical and 
physiological similarities with humans render the adult pig a valuable alternative to rodents, 
rabbits, dogs and nonhuman primates for preclinical pharmaceutical research. In contrast, 
the suitability of growing piglets as a preclinical model for the paediatric population still 
needs to be evaluated. In order to contribute to the development of such a porcine model, 
the maturation processes of several organ systems involved in the disposition of drugs, such 
as the kidney, as well as a comparison with the human paediatric subpopulation need to be 
determined. To date, most of the research papers describing the renal function in piglets 
only focus on one age category using one or more biochemical markers (McCane and 
Widdowson, 1956; Hansen et al., 1997; Frennby et al., 1997; Bauer et al., 2000). Literature 
about the ontogeny of the glomerular filtration rate (GFR) in piglets is rather scarce. Friis 
(1979) (Danish Landrace breed) and Kaskel and Kleinman (1976) (breed not mentioned) 
described the postnatal development of the GFR measured as inulin clearance in piglets 
aging 1 to 62 and 14 to 40 days respectively. An increase in GFR indexed to body weight 
(BW) and kidney weight (KW) was noted, but more extensive research should be done to 
further elucidate if the piglet is a suitable preclinical model to study the renal function of the 
paediatric subpopulation. 
The determination of the GFR in the paediatric subpopulation is pivotal for preclinical 
pharmacokinetic (PK), pharmacodynamic (PD) and safety studies, e.g. to determine age-
dependent dosing schedules for drugs excreted by and/or acting on the kidney, to evaluate 
drug toxicity, etc. Moreover, the assessment of the GFR is considered the best overall index 
of glomerular function, although renal function is more than just glomerular filtration. The 
GFR can be measured with endogenous and exogenous filtration markers, such as creatinine, 
cystatin C, urea, inulin, 51chromium-ethylenediamine tetra acetic acid, 125I-iothalamate and 
iohexol (Hood et al., 1971; Stevens et al., 2006; McPhersen and Pincus, 2011). Clearance of 
inulin is the gold standard to determine the GFR, but this technique is not routinely 
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applicable as it requires intravenous infusion, timed urine collections and expensive inulin 
measurements (Herget-Rosenthal et al., 2007). Therefore, in practice, GFR is often estimated 
from the serum concentrations of endogenous creatinine for both males and females. 
Notwithstanding that the determination of this marker has multiple confounding factors 
such as body composition, age, dietary protein intake, chronic illness and interferences with 
creatinine assays (e.g. ketones, glucose, bilirubin, catecholamines) (Stevens et al., 2006; 
McPhersen and Pincus, 2011). Various equations were established to circumvent these 
confounding factors and have been developed to estimate the GFR (Modification of Diet in 
Renal Disease, Chronic Kidney Disease Epidemiology Collaboration formula) or creatinine 
clearance (Cockcroft and Gault) in adults (Cockcroft and Gault, 1976; Levey et al., 1999; 
Levey et al., 2009). However, these equations are not suitable for the pediatric 
subpopulation. Therefore, alternative equations were developed, of which the revised 
Schwartz formula (0.413 x height (cm)/serum creatinine (mg/dL)) is the most widely used 
(Schwartz et al., 2009).  
The primary aim of the current study was to define the maturation of the GFR in growing 
conventional piglets aging eight days, four weeks and seven weeks. For comparative 
purposes, the GFR was determined as the clearance of both the conventional marker 
endogenous creatinine (both Jaffe and enzymatic method), and the alternative exogenous 
marker exo-iohexol, since iohexol is not secreted, metabolized nor reabsorbed by the 
kidney. The results were normalized to BW, BSA and KW, since KW is the gold standard for 
normalization of the GFR and both BSA and BW are correlated to KW. Furthermore, the 
porcine and human postnatal development of GFR was compared. The secondary aim of the 
present study was to establish a formula to estimate the porcine GFR based on plasma 
creatinine concentrations and BW, similar to the formula developed by Schwartz et al. 
(2009) for children. This equation would simplify the determination of the GFR in growing 
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2. Material and methods 
2.1 Animals  
The current study was conducted with consent of the ethical committee of the Faculty of 
Veterinary Medicine and Bioscience Engineering of Ghent University (EC2014/184). Care and 
use of animals was in full compliance with the most recent national legislation (Belgian Royal 
Decree of 29 May 2013) and European Directive (Anonymous, 2010/63/EU). Forty-eight 
healthy stress resistant male piglets aging eight days (n = 16), four weeks (n = 8), seven 
weeks (n = 16) and six months (n = 8) were obtained (Belgian landrace x large white, Seghers 
Hybrid®, Wuustwezel, Belgium). The piglets of eight days, four and seven weeks of age were 
included in both the GFR study and for the estimation of the creatinine formula, the six-
month-old piglets only for the elaboration of the creatinine formula. The eight-day-old 
piglets were housed individually in Rescue Decks (0.9 m x 1.40 m) (Provimi, Rotterdam, The 
Netherlands), whereas the older age categories were housed individually in standard pig 
stables (2.30 m x 2.40 m). Throughout the experiment, the animals had free access to milk 
(eight days; Rescuemilk®, Provimi), feed (four and seven weeks; Piggistart Opti®, six months: 
Optivo Pro®, Aveve, Leuven, Belgium) and drinking water. Stable temperature was 23.2 ± 
0.56°C and a natural light scheme was provided by transparent windows. During the 
experiments, the stables were enriched with hanging chains, rubber toys and balls of 
different sizes. The environmental enrichment was rotated daily. One day after arrival, a 
urine collection bag (Esteem Synergy® Uro, 48 mm, ConvaTec, Belgium) was adhered around 
the prepuce of the piglets (except the six-month-old pigs) and a double-lumen catheter was 
inserted in the jugular vein (all age groups) of the piglets according to the surgical 
procedures in Gasthuys et al. (2017).  
 
2.2 Experimental design 
One day after the surgery, endogenous creatinine concentrations were determined by 
collecting one millilitre of blood at three different time points, namely 10 am, 2 pm and 6 pm 
(K3EDTA tubes, Vacutest®, Kima, Italy) and collecting urine at three different time intervals 
(one hour), namely 10 am - 11 am, 2 pm - 3 pm and 6 pm - 7 pm. These three different time 
points/intervals were chosen to compare the influence of time of the day on the creatinine 
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concentrations. The blood samples were immediately transferred on ice and centrifuged 
within two hours (2095 x g for 10 min at 4°C). Plasma was aliquoted and stored at -20°C until 
analysis (all age groups within one week except the four weeks within one month). The urine 
bags were weighted to determine the volume and an aliquot was stored at -20°C until 
analysis (all age groups within one week except the four weeks within one month). The 
following day, a single dose of 64.7 mg/kg BW of iohexol (0.1 mL/kg BW, Omnipaque® 300 
mg I/mL, GE Healthcare, Belgium) was administered intravenously using the proximal lumen 
of the jugular catheter. Blood samples (1 mL) were collected from the distal lumen of the 
catheter at 0 minutes (just before administration), and at 5, 15, 30, 60, 120, 180, 360, 480, 
600, 1440 minutes post administration. The samples were drawn into 9 mL K3EDTA 
collection tubes (Vacutest®), immediately kept on ice and centrifuged for 10 minutes at 2095 
x g within two hours after blood collection. Supernatant was aliquoted, frozen and stored at 
-20°C until analysis (all age groups within one month). After the experiment, euthanasia was 
performed by administering an overdose of sodium pentobarbital (sodium pentobarbital 
20%®, Kela, Belgium) through the proximal lumen of the jugular catheter. Both kidneys were 
collected for further analysis (see section 2.3). 
 
2.3 Laboratory analyses for creatinine and exo-iohexol quantification 
Creatinine concentrations were determined in plasma and urine using both a kinetic rate-
blanked Jaffe compensated assay for reactive proteins according to the manufacturer’s 
instructions (Wuyts et al., 2003) and an enzymatic creatinine assay using the Creatinine Plus 
method (Goren et al., 1986) (Laboratory of Clinical Chemistry, Ghent University Hospital, 
Ghent, Belgium). The GFR was calculated using the following equation: clearance of 
creatinine (mL/min) = (Ucr * Uvol)/(Pcr * Tmin), where Ucr is urinary creatinine concentration in 
mg/dL, Uvol is volume of urine in mL, Pcr is plasma creatinine concentration in mg/dL, and Tmin 
is timed urine collection interval in minutes. Serum total protein was assayed using the 
biuret method with commercial available reagents (Roche) (Laboratory of Clinical Chemistry) 
to correct the Jaffe results for the protein error in the alkaline picrate reaction (Speeckaert 
et al., 2012). When the total plasma protein content was lower than 75 g/L a correction 
factor was implemented to calculate the GFR (corrected Pcr Jaffe = (Pcr + 0.23)-
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((0.23/75)*total protein content)). To determine possible outliers in the urinary Jaffe results, 
the 24h-creatinine content in urine (creatinine load) was calculated 
(Ucr*(Uvol/100)/24*(Tmin/60)). The 24h-creatinine content was divided by the BW and 
potential outliers were determined after visual inspection of the data.  
Exo-iohexol plasma concentrations were determined by an in-house validated high-
performance liquid chromatography method with ultraviolet detection (HPLC-UV) (De Baere 
et al., 2012) (Laboratory of Pharmacology and Toxicology, Ghent University, Merelbeke, 
Belgium). In brief, 25 µL of internal standard (1 mg/mL in methanol, iohexol impurity J, 
Chemical Reference Substance of the European Pharmacopoeia, Strasbourg, France) was 
added to each sample (100 µL of plasma and 100 µL of HPLC water), followed by a 
deproteinization step with trifluoroacetic acid and centrifugation of the plasma sample. The 
supernatant was transferred to an autosampler vial and 50 µL was injected onto the HPLC-
UV instrument (Thermo Separations Products, Thermo Scientific, The Netherlands). The area 
under the plasma concentration-time curve (AUC0-inf) was determined by the logarithmic 
trapezoidal method with extrapolation to infinity. The plasma exo-iohexol clearance was 
calculated by dividing the dose of exo-iohexol (determined by the ratio of exo-iohexol and 
endo-iohexol in plasma) by this AUC0-inf.  
Both the creatinine as the exo-iohexol clearances were normalized and indexed to BW 
(mL/min/kg), body surface area BSA (mL/min/m²) and KW (mL/min/g). The body surface of 
the piglets (eight days, four and seven weeks) was imaged using a four-slice helical CT-
scanner, where the piglets were placed in ventral recumbency (Lightspeed QC/I, GE Medical 
systems, USA, New York). The CT-scans were processed using VGStudioMax (Volume 
Graphics GmbH, Heidelberg, Germany) and the BSA was determined after visualization and 
selection of the body surface in 3D (UGCT-Department of Physics and Astronomy, Ghent 
University, Ghent, Belgium). To determine the KW, both piglets’ kidneys were removed 
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2.4 eGFR creatinine formula  
For the elaboration of the porcine GFR estimation formula (eGFR), regression models were 
calculated to predict the GFR based on Pcr, BW, age and time of blood sampling (SPSS 23, 
IBM, USA). Four different age categories were included, e.g. eight days, four weeks, seven 
weeks and six months. The general regression model was drafted after log-transformation of 
the continuous variables (Pcr, BW and age): 
Log (eGFR) = a + b log(Pcr) + c log(BW) + d log(age) + e log(age)*log(Pcr) + f log(age)*log(BW)  
Regression analyses (SPSS 23, IBM, USA) were performed in stepwise order (inclusion 
criterion: p < 0.05; exclusion criterion: p > 0.10). Regression analyses were performed based 
either on the Pcr values at a specific time of blood sampling (Pcr10am, Pcr2pm, and Pcr6pm), 
or on the mean Pcr over the different times of blood sampling. The appropriateness of the 
GFR estimating equation was assessed for each equation by determining the adjusted R², 
which reflects the percentage of variability in GFR explained by the regression equation. 
Moreover, the relative accuracy was determined as the percentage of eGFR values falling 
within 10% and 30% of the measured GFR. 
 
2.5 Statistical analysis 
Statistical analysis of creatinine and exo-iohexol clearance was carried out separately for the 
different normalization methods and was performed on the log-transformed GFR data (SPSS 
23, IBM, USA). The global effect and interaction of the factors age and clearance technique 
(creatinine determined by Jaffe and enzymatic method and exo-iohexol) was analysed in a 
mixed model with repeated measurements on technique. For each of the normalization 
methods, the interaction between age and technique revealed statistically significant 
differences. Within each technique, the effect of age was further analysed using one-way 
analysis of variance (ANOVA). Within each age, the effect of technique was further analysed 
in a mixed model with repeated measurements on technique. Post-hoc comparisons test 
was performed according to Bonferroni. The level of significance was set at 0.05.   
 




All piglets survived catheterization of the jugular vein without any complications. Two out of 
16 piglets aging eight days were withdrawn from the study (after surgery) due to low BW (< 
1.50 kg). Table 1 summarizes the descriptive statistics of the piglets included in the study 
with respect to BW, BSA and KW at the age of eight days, four weeks, seven weeks and six 
months. GFR (mean ± SD) values indexed to BW, BSA and KW for the different age categories 
are presented in Table 2. No influence of time of the day on the Pcr was observed, 
consequently the mean Pcr was used to calculate the GFR for Jaffe and the enzymatic 
method. The mean renal clearance of exo-iohexol indexed to BSA showed a significant 
increase (p < 0.05) from 46.57 mL/min/m² at eight days of age to 100.92 mL/min/m² at 
seven weeks of age. The increase in GFR was also significant for the youngest age categories 
(eight days versus four weeks, eight days versus seven weeks) for the conventional 
creatinine measurement methods (Jaffe and enzymatic), but did not differ significantly 
between four and seven weeks of age. When GFR was indexed to BW, only the exo-iohexol 
clearance of the youngest age category was significantly lower compared to the older age 
categories. Normalization of GFR to KW showed the same trend for the different clearance 
techniques, namely significantly lower GFR values for the eight-day-old piglets in comparison 
with the four-week-old and seven-week-old piglets. Determinations of the GFR with the 
three different techniques were statistically equivalent, except at the age of four weeks, 
where the clearance of creatinine (Jaffe and enzymatic) was significantly higher than the 
clearance of exo-iohexol.  
Table 1. Descriptive statistics of the piglet study population. Values are mean ± SD. 






Number of piglets 14 8 16 8 
Body weight (kg) 2.01 ± 0.43 10.0 ± 1.69 13.9 ± 2.74 112.88 ± 9.11 
Body surface area (m²) 0.16 ± 0.02 0.46 ± 0.05 0.59 ± 0.08 2.42 ± 0.13  
Kidney weight (g) 14.0 ± 2.94 20.25 ± 3.30 38.0 ± 3.16 121.24 ± 20.97 
Plasma creatinine (mg/dL) 0.43 ± 0.08 0.46 ± 0.11 0.45 ± 0.10 0.99 ± 0.11 
Total plasma protein (g/L) 28.4 ± 5.60 31.7 ± 5.59 31.6 ± 6.39 49.2 ± 6.83 
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Table 2. Glomerular filtration rate measurements (GFR, mean ± SD) with Jaffe, enzymatic 
creatinine assay and exo-iohexol in growing piglets aging eight days (n = 14), four weeks (28 
days, n = 8), seven weeks (49 days, n = 16). The GFR is indexed to body weight, body surface 
area and kidney weight. Results with the same alphabetical character superscript are 
considered significant different (p < 0.05) between the different age categories within one 
technique. Results with the same numerical character superscript are considered significant 
different (p < 0.05) between the different techniques used within one age category. 









































































































































*1: mL/min/kg, *2: mL/min/m², *3: mL/min/g 
 
A regression model was determined to predict the GFR based on Pcr, BW, age and time of 
blood sampling (Table 3). The inclusion of the continuous variables Pcr and BW was 
significant (p < 0.05) and the variability in GFR that can be predicted by the equation was 
97.7%. No improvement of GFR estimation was observed by including the time of blood 
sampling (for example Pcrmean versus Pcr2pm, Table 3) and age (model I) within the 
regression model. Consequently, these variables were omitted from the equation. After 
adjustment of the full regression model, an adapted significant regression equation 












BW: body weight, PCr: plasma creatinine concentration 
 
Table 3. Properties (adjusted R² and the relative accuracy) of eGFR equations derived from 
coefficients of different regression models. 
 





a b c R² (%) 
% of eGFR within 
30% of GFR 
% of eGFR within 10% 
of GFR 
Pcrmean        
Age mean age mean - - 0.0 72.7 34.1 
Model I 1.879 1.092 -0.600 97.7 90.9 36.4 
Pcr2pm       
Age mean age mean - - 0.0 72.7 34.1 
Model I 2.339 1.052 -0.442 97.6 90.7 34.9 
Age was not included within the regression model, because the coefficients d,e,f were not significant (p 
< 0.05) for both models (Pcrmean: p = 0.408 (d), p = 0.114 (e), p = 0.565 (f); Pcr2pm: p = 0.087 (d), p = 
0.338 (e), p = 0.095 (f)).  




Gaining insight in the maturational changes of the kidney function is important for properly 
conducting preclinical animal trials for paediatric drug development. The current study 
describes the postnatal maturation of the GFR determined with endogenous creatinine 
(Jaffe and enzymatic method) and exo-iohexol in growing piglets. It was opted to choose 
conventional piglets instead of minipigs, since the use of neonatal minipigs for repetitive 
urine and blood collections remains challenging. It was not possible to determine the GFR 
with endogenous creatinine in female and six-month-old piglets, since an optimal non-
invasive urine collection technique is still lacking (Gasthuys et al., 2017). Therefore, this 
study focused on male piglets aging eight days to seven weeks. Scaling of the GFR to a 
standard reference is necessary to compare GFR values among populations. In human 
clinical practice, the GFR is traditionally normalized to a standardized BSA (1.73 m²), since 
BSA correlates closely with kidney size (McIntosh et al., 1928). However, the 
appropriateness of normalizing to BSA is arguably in the paediatric subpopulation, as the 
formula to calculate the BSA tends to underestimate the true BSA and standardization to 
GFR/1.73 m² was 20% lower than GFR/12.5 L extracellular fluid volume (Geddes et al., 2008). 
In veterinary clinical practice, the GFR is normalized to BW, nonetheless this normalization 
was outdated in human clinical practice, because BW is mainly influenced by body fat 
content which has a limited influence on PK and PD for most drugs (Bird et al., 2003). Scaling 
to KW should be more appropriate, but is not clinically applicable (Schwartz and work, 
2009). In the current study, all GFR values were adjusted for BW, BSA or KW. When indexed 
to BSA and KW, a statistical significant increase in GFR was observed. The increase in GFR 
indexed to BW was less pronounced than the GFR indexed to KW and BSA. Friis (1979) and 
Kaskel and Kleinman (1976) also measured the GFR as inulin clearance in growing piglets 
indexed to KW (Friis, 1979 and Kaskel and Kleinman, 1976) and BW (Friis, 1979). The 
increasing GFR in those studies was similar to the trends observed in the current study. In 
humans, the GFR is 2 to 4 mL/min/1.73 m² at birth, increases rapidly to 39 to 47 
mL/min/1.73 m² during the first two weeks of life, continues rising to 58 to 103 mL/min/m² 
during the first year of life and reaches adult values (127 mL/min/1.73 m²) at the age of two 
years (Guignard et al., 1975; Heilbron et al., 1991). The age correlations between humans 
and pigs proposed by Gad (2007) were considered here to compare the GFR between 
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humans and piglets, namely neonate (human: 0-28 d, pig: 0-15 d), infant (human: 1-23 m, 
pig: 2-4 w), child (human: 2-12 y, pig: 4-14 w) and adolescent (human: 12-16 y, pig: 4-6 m). 
The postnatal maturation of GFR indexed to BSA in the current study (e.g. measured with 
exo-iohexol: eight days: 46.57 mL/min/m², four weeks: 67.36 mL/min/m², and seven weeks: 
100.92 mL/min/m²) was in accordance with the increasing trend observed in humans.  
It is generally accepted in paediatric clinical practice, that the use of the endogenous 
clearance marker creatinine to measure GFR is less accurate in comparison with the 
exogenous clearance marker iohexol (Filler et al., 2014). However, the data demonstrated in 
the present study show a good agreement between the three techniques, except at the age 
of four weeks. The differences between the techniques might be explained by the fact that 
creatinine in urine is the result of both glomerular filtration and tubular secretion, leading to 
an overestimation of the creatinine clearance (Carlier et al., 2015). The presence of tubular 
secretion function, is even more documented by administrating p-aminohippuric acid (PAH) 
to piglets, since the tubular functional capacity can be assessed by plasma clearance of PAH 
(Tett et al., 2003). Another possible explanation is the difference in storage period between 
the four weeks (one month) and the other age groups (one week), leading to confounded 
plasma and/or urine creatinine concentrations. There are also some disadvantages to the 
measurement of GFR by endogenous creatinine clearance in piglets, rendering this 
technique less reliable. First, ideally urine collection should be done over a 24h-period, but 
the collection of 24h-urine is difficult to perform, whereby a sparse sampling procedure was 
needed during the experiments. To tackle this problem in the current study, the creatinine 
load was calculated and outliers were excluded from the dataset. Second, the determination 
of plasma creatinine with Jaffe is not reliable when the total plasma protein content is lower 
than 75 g/L. Therefore, the total plasma protein concentration must be measured and a 
correction factor must be implemented to calculate the GFR, which was done in the present 
study. Third, Hansen et al. (1997) suggested the possibility that transport of endogenous 
creatinine by the renal tubules varies between breeds, rendering the endogenous creatinine 
determination less accurate. Iohexol is a more reliable marker, since it only needs blood 
sampling and no urine collection, and the determination of iohexol is less sensitive to 
confounding factors.  
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To date, the determination of the true GFR is time-consuming, costly and labour-intensive. 
Because GFR is difficult to measure in clinical practice, different equations for humans were 
developed to predict GFR using endogenous creatinine (e.g. Schwartz et al., 2009). 
Unfortunately up till now, no equations are available for piglets. Therefore, a formula was 
determined to estimate the creatinine clearance (eGFR) based on readily available 
parameters, such as creatinine plasma concentration, BW, age and time of blood sampling. 
The GFR estimation was based on the enzymatic endogenous creatinine determination, 
since the values obtained by the Jaffe technique are more affected by interferences, such as 
the presence of ketones, fructose, glucose, etc. in plasma (Stevens et al., 2006). The 
enzymatic assay reduced the problem of these interferences, but it should be emphasized 
that possible variation in calibration of the assays among laboratories may lead to different 
results. However, this variation is expected to be minimal (Stevens et al., 2006). The 
presented equation can be a useful tool for preclinical paediatric porcine studies, as well as a 
tool to determine correct dosage strategies for drugs that are renally excreted in growing 
piglets.  
In conclusion, the current study determined the maturation of the kidney function in 
growing piglets, which was comparable to humans. The values obtained with the different 
GFR techniques were comparable, except at the age of four weeks, although GFR measured 
by exo-iohexol clearance is preferred. To further proof the usefulness of the piglet as 
potential animal model, in future research, PK studies of mainly renally excreted drugs 
should be performed and results should be compared to published data in children. 
Moreover, an easy-to-apply creatinine equation was developed to estimate the GFR in 
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Over the years, the usefulness of juvenile animal models has already been demonstrated in 
paediatric nonclinical drug testing. Traditional animal models, such as rodents, dogs and 
non-human primates, are not always suitable as models to study the pharmacokinetics (PK), 
pharmacodynamics (PD) and safety of drugs. Consequently, alternative animal models, such 
as the conventional pig, might be a valuable alternative to these models. To assess whether 
the pig is also suitable as a juvenile animal model, maturation of the different organ systems 
should be determined and compared between both humans and pigs. Since the kidneys are 
pivotal in the PK and the PD of various drugs, the maturation of the kidney function, for 
instance glomerular filtration rate (GFR), should be unravelled. The current study 
determined the GFR as clearance of the exogenous marker exo-iohexol in male piglets aged 
eight days (n = 16), four weeks (n = 8), seven weeks (n = 16), and six months (n = 8). 
Population PK (popPK) analysis was performed to derive the PK parameter values, the 
between- and within-subject variabilities and the effects of the covariates body weight, body 
surface area and age. Exo-iohexol plasma concentration-time data were best described by a 
two-compartment PK model, with first order elimination. Body surface area was a significant 
covariate for clearance and volume of distribution of the central and peripheral 
compartment. Maturation of the GFR was observed and the postnatal development was 
comparable between humans and pigs (eight days: 41.95 mL/min/m², four weeks: 64.74 
mL/min/m², seven weeks: 99.00 mL/min/m², six months: 121.24 mL/min/m²), rendering the 
pig a suitable juvenile animal model for studying the GFR in the pediatric population, and to 
evaluate the PK of renally excreted drugs. Moreover, an estimation equation based on body 
surface area was developed using the popPK approach. This equation facilitates the 
assessment of the GFR in growing piglets, namely GFR or exo-iohexol clearance (mL/min) = 
67.98 (mL/min) * (BSA/mean(BSA))1.45. 
 
Keywords 
piglet, iohexol, glomerular filtration rate, population pharmacokinetics, estimation equation 




Development of appropriate juvenile animal models, which take growth and maturation into 
account, is pivotal for the optimization of clinical trials in the pediatric population. Over the 
years, adult pigs have been proposed as suitable animal models in biomedical research, since 
the anatomical and physiological resemblances to humans are striking (Bode et al., 2010; 
Gasthuys et al., 2016). To date, however, the suitability of growing piglets as juvenile animal 
models still needs to be explored. In order to be able to decide whether or not the pig may 
contribute as a model for preclinical pediatric studies, the ontogeny of different organ 
systems involved in the disposition of drugs, such as the kidney, should be determined and 
compared between both species. Glomerular filtration is one of the major processes, besides 
(active) tubular secretion and reabsorption, governing renal excretion. The glomerular 
filtration rate (GFR) can be determined to assess the ontogeny of glomerular filtration. Most 
research papers describe the GFR of piglets measured with different markers in only one age 
category (Kelleher et al., 1991; Frennby et al., 1996; Alexander et al., 2008). To the authors’ 
knowledge only two research papers described the postnatal development of the renal 
function in growing piglets using inulin clearance (Kaskel and Kleinman, 1976; Friis, 1979). An 
increase in GFR indexed to body weight (BW) and kidney weight was observed, but more 
extensive research should be performed in order to decide if the piglet is a suitable 
preclinical animal model to study the renal function of the pediatric population. 
The assessment of the GFR is important for pharmacokinetic (PK), pharmacodynamic (PD) 
and safety studies in order to determine correct dosage strategies for drugs excreted by 
and/or acting on the kidney and to determine drug safety. The reference method to evaluate 
the GFR is the renal clearance of inulin, since inulin is freely filtered by the glomerulus and 
not secreted, metabolized or reabsorbed by the renal tubules. Despite the worldwide use of 
inulin as the gold standard to measure the GFR, this method is not frequently used in clinical 
practice, as it requires timed urine collections and intravenous (IV) infusion (Herget-
Rosenthal et al., 2007). Therefore other exogenous markers such as a single intravenous 
bolus of the non-ionic contrast agent iohexol, have been opted as promising alternative 
markers for accurate GFR determinations. Like inulin, iohexol is not secreted, metabolized 
nor reabsorbed by the renal tubules (Schwartz and Work, 2009). Iohexol has been used 
frequently to calculate the GFR in different species, such as humans, cats and dogs (Goy-
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Thollot, 2009; Schwartz and Work, 2009; Smets et al., 2012; Paepe et al., 2015). Iohexol 
exists as two stereoisomers, i.e. endo- and exo-iohexol. Endo-iohexol, which is 
approximately 10% of the total dosage and exo-iohexol which is 90% of the total dosage. 
Exo-isomer is the most abundant and is mainly determined in practice. To date, only three 
studies have described the measurement of GFR using conventional compartmental PK 
analysis of iohexol in pigs in a single age category (48-55 kg BW, 21-27 kg BW, 18-29 kg BW) 
(Lundqvist et al., 1995; Frennby et al., 1996; van Westen et al., 2002). The usefulness of 
iohexol as exogenous GFR marker in pigs was demonstrated, however the suitability of this 
marker in other and multiple age categories, such as < 20 kg and > 60 kg, was not verified. 
Recently, the GFR values in pigs with three different techniques, namely exo-iohexol, 
creatinine Jaffe and creatinine enzymatic was determined by our research group (Gasthuys 
et al., 2017b). However, exo-iohexol data were analysed using conventional compartmental 
PK. To date, the population PK (popPK) approach to describe the GFR in growing piglets has 
never been used before in piglets. The advantage to use popPK approaches instead of 
conventional compartmental PK is that the covariate effects are included in the analysis and 
extrapolation within the studied population is possible.  
The objective of the present study was to determine the GFR of piglets of different age 
categories (eight days, four weeks, seven weeks and six months) based on non-linear mixed 
effects modelling (NLME) of exo-iohexol plasma concentration-time profiles. Furthermore, 
the effect of covariates on the primary PK parameters was evaluated. Finally, an equation to 
estimate the GFR in the porcine population was developed by obtaining the relationship 







Experimental Studies – Chapter II.ii 
124 
 
2. Materials and methods 
2.1 Animals  
The current study was in full compliance with the national (Belgian Royal Decree of 29 May 
2013) and European legislation of animal welfare and ethics (Anonymous, 2010/63/EU). The 
study was conducted with consent of the ethical committee of the Faculties of Veterinary 
Medicine and Bioscience Engineering of Ghent University (EC2014/184). Forty-eight male 
piglets (Landrace x Large White, Seghers Hybrid®, Wuustwezel, Belgium) aged eight days (n = 
16), four weeks (n = 8), seven weeks (n = 16) and six months (n = 8) were used to conduct 
this study. The animals were group-housed in rescue decks (eight days) (0.9 m x 1.40 m, 
Provimi, Rotterdam, The Netherlands) and standard pig stables (four/seven weeks, six 
months) (2.30 m x 2.40 m). The temperature of the stables was 23.2 ± 0.6 °C and additional 
heating was obtained using heating lamps for the youngest age category. A natural light 
cycle was provided using translucent windows. The stables were enriched with hanging 
chains, rubber toys and balls of different sizes and those toys were rotated daily. The piglets 
had ad libitum access to milk (eight days: RescueMilk®, Provimi), feed (four/seven weeks: 
Piggistart Opti®, six months: Optivo Pro®, Aveve, Leuven, Belgium) and drinking water. Two 
days prior to the exo-iohexol administration, the piglets received a jugular vein double-
lumen catheter according to Gasthuys et al. (2017a) to facilitate IV administration and blood 
collection. After the surgery, the piglets were housed individually to prevent catheter 
removal. All piglets received a cotton towel after surgery, which was placed in the stables 
one day prior to the surgery, to mimic the smell of the other piglets when they were single 
housed.  
 
2.2 Exo-iohexol clearance assessment 
All piglets received a single IV bolus of 64.7 mg/kg BW iohexol (Omnipaque® 300 I/mL, GE 
Healthcare, Diegem, Belgium) through the proximal lumen of a double lumen catheter. 
Afterwards, the lumen was flushed with heparinized sodium chloride 0.9% (eight days: 
0.04% v/v, four/seven weeks, six months: 1% v/v; Heparin Leo® 5000 I.U./mL, LEO Pharma 
A/S, Ballerup, Denmark). Blood was subsequently sampled through the distal lumen of the 
double lumen catheter into K3EDTA collection tubes (Vacutest®, Kima, Italy) at 0 (just prior to 
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administration) and 0.08, 0.25, 0.50, 1, 2, 3, 6, 8, 10, 24 h post administration. The samples 
were immediately transferred on ice and centrifuged within two hours (2095 x g, 10 min, 
4°C). Supernatant was aliquoted, frozen and stored at -20°C until analysis. An in-house 
validated high-performance liquid chromatography method with ultraviolet detection (HPLC-
UV) was used to determine the exo-iohexol plasma concentrations (De Baere et al., 2012). 
The body surface area (BSA) was determined using CT-scans followed by visualization and 
selection of the body surface in 3D (Centre for X-Ray Tomography-Department of Physics 
and Astronomy, Ghent University, Ghent, Belgium) (Gasthuys et al., 2017b). The body weight 
was determined one day prior to the exo-iohexol clearance administration, by weighing the 
piglets on a scale.  
 
2.3 Population pharmacokinetic analysis 
Plasma concentration-time data of exo-iohexol were analyzed with a nonlinear mixed-effects 
modeling approach using Quasi Random Parametric Expectation Maximization (QRPEM) as 
an estimation method in Phoenix NLME® (Certara, Cary, NC, USA). Plasma concentrations 
below the limit of quantification (0.44 ng/mL) were excluded from the analysis. The 
structural model for the IV data was a two-compartmental model with first order 
elimination. 
1/V1 x (dA1/dt) = -Cl x C-Q x (C-C2)  
1/V2 x (dA2/dt) = Q x (C-C2) 
for which dA1/dt is the rate of change of amount of drug in compartment 1, dA2/dt is the 
rate of change of amount of drug in compartment 2, Q is the inter-compartmental flow, V1 is 
the volume of distribution of the central compartment, V2 is the volume of distribution of 
the peripheral compartment, C is the concentration of the component in compartment 1 
and C2 is the concentration of the component in compartment 2. 
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Interindividual variability (IIV) was expressed using an exponential error model according to 
the equation: 
Pi = tvθ x e
η
Pi 
for which Pi is the parameter value in the i
th subject, tvθ is the typical value of the parameter 
in the population, and ηPi is a random variable in the i
th subject with a mean of zero and a 
variance of ω². ω² is reported as IIV. Residual variability (ε), with a mean of zero and a 
variance of σ², was evaluated within the best structural PK model. A multiplicative error 
model was used to describe the residual variability. 
Multiplicative: Cobs = Cipred x (1+ε) 
for which Cobs is the observed concentration for the individual and Cipred is the model 
predicted concentration plus the error value (ε). 
Structural and error model selection was guided by visual inspection of goodness-of-fit plots 
(observed vs. individual predicted plasma concentrations, observed vs. predicted plasma 
concentrations, weighted residuals vs. time after dose, and weighted residuals vs. time), 
objective function value (OFV), Akaike’s information criterion (AIC) and Bayesian information 
criterion (BIC), as well as precision of the parameter estimates. The models were chosen 
based on the smaller values of OFV, AIC and BIC, better precision of estimates, and superior 
goodness-of-fit plots. 
Evaluated continuous covariates on volume of distribution (V1/V2), inter-compartmental flow 
(Q) and total body clearance (CL) were age, BW and BSA. A covariate was considered 
significant when the addition of this covariate resulted in a decrease in the OFV of > 6.635 (P 
< 0.01), and elimination of this covariate resulted in an increase in the OFV of > 10.828 (P < 
0.001). Afterwards, the equation to estimate the clearance of exo-iohexol was derived from 
the popPK analysis and was used to calculate the mean GFR values in the respective age 
categories. The general form of the equation was: 
𝑒𝑥𝑜 − 𝑖𝑜ℎ𝑒𝑥𝑜𝑙 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (
𝑚𝐿
min







 for which tvCL and tvBSA are the typical value of the clearance and BSA, respectively.  




No technical complications were encountered during the PK study. Two out of sixteen piglets 
aged eight days, were withdrawn from the study after surgery because insufficient blood 
could be sampled due to low body weight (<1.50 kg). Table 1 Chapter II.i summarizes the 
characteristics of the piglets included in the study with respect to BW and BSA at the age of 
eight days, four weeks, seven weeks and six months. 
 
A two-compartmental structural model with first order elimination from the central 
compartment was the best fit for the plasma exo-iohexol time-concentration data in growing 
piglets (Figure 1). Plasma concentration-time curves of exo-iohexol in the four age categories 
are depicted in Figure 2. The model development path can be found in Table 2. The model 
was parameterized in terms of volume of distribution of the central compartment (V1), 
volume of distribution of the peripheral compartment (V2), clearance (CL) and inter-
compartmental flow (Q). The IIV (ω²), described with an exponential error model, was 
estimated on all parameters and the residual error was estimated to be 0.12. Forward 
inclusion and backward elimination in the structural model of the covariates BSA, BW and 
age for CL, V1, V2 and Q was evaluated. BSA as a covariate for the fixed effect parameters V1, 
V2, CL and Q significantly improved the model fit and was therefore included in the final 
model. The other covariates, BW and age, were not included in the final model, since they 
resulted in less improvement of the model fit. The final popPK parameter estimates are 
described in Table 3. The estimation of the parameters was performed adequately, since the 
standard error of the estimates (expressed as RSE%) was low. Model diagnostic plots show 
the overall goodness-of-fit of the final model (Figure 3). The individually predicted plasma 
concentration values (IPRED) versus observed plasma (Cobs) plots and predicted plasma 
concentration values (PRED) versus Cobs (Figure 3a, 3b) demonstrated no major deviations of 
the LOESS smoothed line from the line of unity, meaning that appropriate structural models 
could be fitted for the individuals and no major bias in the population components of the 
model were found. The scatterplot of the conditionally weighted residuals (CWRES) versus 
PRED and time after dose (Figure 3d) was symmetrically distributed around zero, indicating 
that no major bias was observed in the residual error model.  








Figure 1. Model structure of the final population pharmacokinetic model of exo-iohexol in 






Figure 2. Observed (red dots) and popPK predicted concentration-time profiles (blue line) of 
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Table 2. Development path of the pharmacokinetic model of exo-iohexol 
(Omnipaque 300®) in growing piglets.  
Run OFV Description ΔOFV 
1 2839.58 2-compartmental model, first order absorption - 
2 2686.37 2-compartmental model, BSA effect on CL 153.21 
3 2571.48 2-compartmental model, BSA effect on CL and V2 114.89 
4 2496.36 2-compartmental model, BSA effect on CL, V2 and V1 75.12 
5 2453.54 2-compartmental model, BSA effect on CL, V2, V1 and Q 42.82 
6 2528.64 2-compartmental model, BSA effect on V2, CL and Q -75.1 
7 2583.06 2-compartmental model, BSA effect on V1, CL and Q -129.52 
8 2611.37 2-compartmental model, BSA effect on V1, V2 and Q -157.83 
9 2496.36 2-compartmental model, BSA effect on V1, V2 and CL -42.82 
OFV: objective function value, V1/V2: volume of distribution of the central and peripheral compartment, respectively, Q:inter-

























     
Table 3. Population pharmacokinetic results after intravenous administration (64.7 
mg/kg BW) of iohexol (Omnipaque 300®) to piglets. 
Parameter Estimate 95% CI RSE (%) 
Structural model    
CL = tvCL*((BSA/mean(BSA))
dvdBSA
)*exp(ηCL)  4.08 L/h 3.68-4.48 4.97 
V1 = tvV1*((BSA/mean(BSA))
dvdBSA
)*exp(ηV1) 3.44 L 2.83-4.06 9.09 
V2 = tvV2*((BSA/mean(BSA))
dvdBSA
)*exp(ηV2) 3.51 L 3.22-3.81 4.29 
Q = tvQ*((BSA/mean(BSA))
dvdBSA
)*exp(ηQ) 12.38 L/h 7.66-17.10 19.36 
Covariate model    
Influence of BSA on CL 1.45 1.37-1.53 2.81 
Influence of BSA on V1 1.11 0.94-1.28 7.85 
Influence of BSA on V2 1.26 1.15-1.38 4.50 
Influence of BSA on Q 1.03 0.47-1.59 27.49 
Inter-individual variability    
IIV CL 0.06   
IIV V1 0.18   
IIV V2 0.002   
IIV Q 0.24   
Residual error    
Res. Error 0.12 0.12-0.13 2.51 
Θ: fixed effect parameter; tvθ: population typical value of the fixed effect parameter; 95% CI: 95% confidence interval of the 
population estimate; RSE%: relative standard error; V1/V2: volume of distribution of the central and peripheral 
compartment, respectively, CL: total body clearance, Q: inter-compartmental flow, Res. Error: residual error  





Figure 3. Diagnostic plots of the population model of exo-iohexol after intravenous 
administration to growing piglets: scatter plot of the dependent variable (DV), namely 
observed plasma concentration (Cobs) versus the individual predicted plasma concentration 
values (IPRED) (a) and population predicted plasma concentration values (PRED)(b), scatter 
plot of the conditional weighted residuals (CWRES) versus time after dose (c) and PRED (d). 
White circles represent the observed data, the full black lines are the lines of unity and the 
full red lines are the LOESS smoothed lines.  
 
The parameter values for the final model could be predicted with high precision (low RSE%). 
Therefore, the equation to estimate the GFR in growing piglets could be derived from the 
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The mean GFR values based on the popPK analysis were 41.95 (± 16.98) mL/min/m² (eight 
days), 64.74 (± 10.87) mL/min/m² (four weeks), 99.00 ± 21.69 mL/min/m² (seven weeks) and 








In the current study, the PK of exo-iohexol was described in growing piglets aged eight days 
to six months using NLME modelling. PK studies were performed in four different age 
categories corresponding to the same important age categories of the human pediatric 
subgroups, namely eight days (neonate), four weeks (infant), seven weeks (child) and six 
months (adolescent). A good correlation between the clearance of exo-iohexol and other 
exogenous markers, e.g. inulin and 51Cr-EDTA, as marker of GFR was demonstrated in 
humans (Lundqvist et al., 1994; Krutzen et al., 1984). Moreover, Lundqvist et al. (1995) and 
Frennby et al. (1996) found similar results obtained with 51Cr-EDTA and iohexol in pigs. Inulin 
is considered the gold standard to measure the GFR, however the use of exo-iohexol as 
exogenous marker has several advantages. There is only a single bolus injection needed to 
administer iohexol in comparison with the infusion required for inulin administration. No 
timed urine collection is needed, which is required for the clearance of inulin. Iohexol is also 
preferable to nuclear radioisotopes, such as 51Cr-EDTA, since no significant plasma protein 
binding could be found for iohexol (< 2.0%), whereas the plasma protein binding of 51Cr-
EDTA is much higher (12.2%), leading to possible confounding GFR measurements (Krutzen 
et al., 1990; Rehling et al., 1984). Moreover, analysis with 51Cr-EDTA involves radiation 
exposure and the beta-particles of this compound are potentially carcinogenic, while iohexol 
was found to have negligible toxicity (Filler et al., 2014; Schwartz and Work, 2009).  
Frennby et al. (1996), van Westen et al. (2001) and Lundqvist et al. (1995) determined the 
clearance of iohexol in piglets weighing 21-27 kg, 18-29 kg and 48-55 kg, respectively. 
Frennby et al. (1996) and van Westen et al. (2001) calculated the clearance of iohexol using a 
three-compartmental PK model, with a third, deeper tissue compartment included in the 
model. Lundqvist et al. (1995) calculated the clearance according to the final slope technique 
(clearance (mL/min) = (amount of tracer injected (mg)*disappearance rate (min-1))/ordinate 
intercept (mg/mL)). In that study, a two-compartmental model with first order elimination 
best described the plasma concentration-time data (concentrations of iohexol measured as 
iodine, using a Renalyzer PRX 90). These results were in accordance with the PK model 
obtained from human data (Schwartz and Work, 2009).  
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In the current study, the typical values of the total body and inter-compartmental flow after 
intravenous administration of exo-iohexol estimate in growing piglets was 4.08 L/h and 
12.38 L/h, respectively. The typical values of the volume of distribution of the central (V1) 
and peripheral (V2) compartment were 3.44 L and 3.51 L, respectively. A significant covariate 
effect of BSA was found, which was exponentially related to body clearances. This was in 
accordance with the results obtained by Kaskel and Kleinmann (1976) and Friis (1979), who 
measured the GFR as inulin clearance in growing piglets. When correlating the GFR values 
obtained in humans (Guignard et al., 1975; Heilbron et al., 1991) with the values obtained in 
piglets (neonate: pig: 42 mL/min/m², human: 39 mL/min/1.73 m²; infant: pig: 65 mL/min/m², 
human: 58 mL/min/1.73 m²; child: pig: 99 mL/min/m², human: 103 mL/min/1.73 m²; 
adolescent: pig: 121 mL/min/m², human: 127 mL/min/1.73 m²), the maturation between 
both species is comparable, rendering the piglet a convenient model to study the GFR and to 
evaluate the PK of renally excreted drugs in the pediatric population.  
Since the determination of the true GFR is cumbersome, time-consuming and costly, it is of 
interest to develop an equation to estimate the renal function in growing piglets. In the 
present study, the popPK approach has been applied to develop an equation for calculating 
the renal function in growing piglets. Multiple equations using popPK have been established 
in humans (Léger et al., 2002; Pai et al., 2010; De Cock et al., 2012). However, to date, no 
such equation has been developed in piglets. Therefore, this study provides an equation to 
determine the GFR based on the BSA of growing piglets. The equation enables to easily 
determine the GFR without the need of blood or urine collections, which can be a useful tool 
to perform pediatric porcine studies as well as to determine correct dosage strategies in 
growing piglets for renally excreted drugs. The BSA can be determined using the Meeh 
equation (BSA (dm²) = 9*BW (kg)2/3) (Meeh, 1879). When comparing the Meeh equation 
with the technique presented in the current study (CT-scans and visualization), no significant 
differences (p < 0.05) could be found between both techniques, rendering the Meeh 
equation a valuable tool to easily determine the BSA in growing piglets. The equation to 
estimate the GFR elaborated in this study (clearance (mL/min) = 67.98 (mL/min) * 
(BSA/mean(BSA))1.45) should be validated in a larger group of piglets to assess whether the 
equation is valid for all piglets within the BSA range cited above, and to evaluate if 
extrapolation to younger piglets (preterm and newborn) out of the BSA range is suited as 
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well. It should be mentioned that it is best to measure the GFR using exo-iohexol, since 
endogenous (creatinine, cystatin C, etc.) or other exogenous markers (inulin, 51Cr-EDTA, etc.) 
can give different GFR estimates (Schwartz and Work, 2009). 
No significant difference could be noted when comparing the mean exo-iohexol clearance 
values of each age category in using conventional compartmental modelling (Gasthuys et al., 
2017b) and popPK modelling, rendering the popPK a valuable alternative analysis to 
conventional PK modelling. Moreover, in both articles an equation was developed to 
estimate the GFR in growing piglets (Gasthuys et al. (2017b): GFR = 1.879*BW1.092/plasma 
creatinine concentration0.600). Both equations are easy to apply in practice, however the 
equation proposed in the current study does not require any blood sampling and plasma 
creatinine concentration measurement. It should be noted that both equations should be 
further validated and compared in a larger group of animals. 
In conclusion, the current study determined the maturation of the GFR using non-linear 
mixed effects modelling. A two-compartmental model with first order elimination best 
described the data. A significant covariate effect of BSA was found, which was exponentially 
related to total body clearances, suggesting maturation of the GFR over the age range of the 
pigs used in this study. Moreover, an easy-to-apply equation based on BSA was developed to 
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To validate the suitability of the conventional pig as a juvenile animal model full 
pharmacokinetic (PK) and pharmacodynamic (PD) studies should be performed. The data 
obtained in these studies should be compared with human paediatric data. Desmopressin 
was chosen as a model compound to determine the PK and PD in growing piglets, since full 
PK-data of the oral formulations are lacking in the paediatric population and the nasal spray 
is no longer approved for this population due to severe adverse events. An oral lyophilisate 
(120 µg) was administered to 32 male piglets aged eight days, four weeks, seven weeks and 
six months (each group n = 8). Eight additional piglets aged eight days (control group) were 
included to compare the PD parameters between control and desmopressin groups, i.e. 
urinary volume, osmolality, and plasma sodium concentrations. Population PK (pop-PK) 
analysis was performed to derive the PK parameters, the between- and within-subject 
variabilities and the effects of covariates. Desmopressin demonstrated two-compartmental 
PK, with a dual, sequential first-order absorption process, and first-order elimination. Body 
weight was the only significant covariate on clearance and on apparent volume of 
distribution of the central compartment. In human paediatric trials, no double peak was 
observed in the absorption phase of the plasma concentration-time curves, possibly due to 
the sparse sampling strategy applied in the available paediatric studies. Therefore, it is 
recommended to perform additional studies, based on the sampling protocol applied in the 
current study. No significant differences in PD between the control and desmopressin-
treated groups were observed, due to steric hindrance complicates binding of desmopressin 
to the porcine vasopressin receptor. 
 
Keywords 
Piglet, animal model, pharmacokinetics, desmopressin, paediatric, pharmacodynamics 




Paediatric clinical studies are pivotal to investigate inter alia age-dependent dosing 
schedules and age-appropriate formulations. In order to stimulate the industry to perform 
such paediatric clinical trials, the FDA (Food and Drug Administration) and EMA (European 
Medicines Agency) issued several regulations, such as the US Best Pharmaceuticals for 
Children Act (2002), Paediatric Research Equity Act (2003) and the Paediatric Regulation 
(2006). The lack of clinical trials in children, and consequently the lack of medicines labelled 
for children, results in a dilemma for the clinician: either depriving the child from the 
assumed clinical benefits of a medicine, or prescribing the drug off-label. 
 
A primary concern of paediatric drug development is the lack of a representative animal 
model for preclinical safety testing and pharmacological studies, which accurately estimates 
the in vivo developmental pharmacokinetics and pharmacodynamics (PK/PD) of a 
compound. Traditional animal species such as rodents, dogs and non-human primates are 
not always appropriate models to study age-related PK/PD parameters (Sjödin et al., 2011; 
Porsolt, 2013). Because of more ethical acceptance (non-human primates and dogs) and the 
similarities in anatomy and physiology between pigs and humans, a porcine animal model 
might offer huge advantages for paediatric drug development over other animal species. The 
adult conventional pig has been demonstrated to be a suitable animal model for adult PK/PD 
studies (Bode et al., 2010; Helke and Swindle, 2013). However, studies investigating the 
suitability of a paediatric conventional pig model are still lacking (Gasthuys et al., 2016).  
 
To evaluate piglets as an appropriate juvenile animal model, the synthetic analogue of the 
natural antidiuretic hormone vasopressin, namely desmopressin (1-desamino-8-D-arginine 
vasopressin, Figure 1) was chosen. Desmopressin has an antidiuretic effect through binding 
on the vasopressin 2 (V2) receptors of the kidney collecting ducts and it was initially 
developed for the indication of central diabetes insipidus in adults, but was subsequently 
used to treat primary nocturnal enuresis (PNE) in children (Cobb et al., 1978; Rittig et al., 
1989; Glazener and Evans, 2002). Over more than 30 years, two oral (tablet (1987) and 
lyophilisate (2005)) and a nasal formulation (spray (1972)) have been developed to reduce 
Experimental Studies – Chapter III 
143 
 
PNE in children. In 2007, the use of intranasal formulations was no longer approved for 
treating PNE in children in the USA and most European countries, because of reported cases 
of severe hyponatremia and seizures. Therefore, a switch to oral formulations was required, 
despite the limited number of data on the PK of oral desmopressin in children, the lack of 
bioequivalence studies between the tablet and the oral lyophilisate, and the lack of 
availability of size-dependent dosing regimens in the paediatric population. Osterberg et al. 
(2006) performed a PK/PD study (oral lyophilisate, 30; 60; 120; 360 or 480 µg) in 84 enuretic 
children aged six to twelve years and applied a sparse sampling protocol (2-3 blood 
samples/child). Also De Bruyne et al. (2014) applied a sparse sampling protocol after 
administration of conventional tablets (200 µg) and oral lyophilisates (120 µg) containing 
desmopressin to 23 children (five to eighteen years) suffering from monosymptomatic 
nocturnal enuresis. Blood was sampled at 1, 2 and 6 h post administration. The full PK profile 
was obtained through pop-PK simulation (Michelet et al., 2016), and likely does not capture 
all characteristics of desmopressin’s PK, such as the absorption phase. Hence, additional and 
more extensive studies in the youngest age groups should be performed, ideally taking more 
blood samples in the initial phase after administration. On the other hand, animal trials, such 
as in the proposed piglet model can provide supplementary information to complement the 
information gap since more blood samples can be collected. 
 
 
Figure 1. Structure of vasopressin (left) and desmopressin (right). Structural differences are 
marked (black circle).  
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In order to gain insight in the antidiuretic effect of desmopressin, PD trials should be 
performed. Nevéus et al. (1999), Vande Walle et al. (2006) and De Guchtenaere et al. (2011) 
measured the PD parameters of desmopressin in children aged six to sixteen years. These 
studies demonstrated a decrease in urinary output under desmopressin treatment, proving 
the antidiuretic effect in this age category. To determine whether the pig could be an 
appropriate model for PD studies with desmopressin, Ufer et al. (1995) studied the in vitro 
binding capacity of desmopressin to human, bovine, rat and porcine vasopressin V2 
receptors. They demonstrated that the affinity of desmopressin for the porcine receptor is 
200-fold lower in comparison with arginine vasopressin. This significantly decreased affinity 
can be attributed to steric hindrance of the D-arginine group in position 8 of desmopressin 
(Figure 1). Consequently, the idea to use the piglet as a potential model for PD analysis of 
desmopressin seems less interesting; however, an in vivo experiment is needed to confirm 
the findings of Ufer et al. (1995).  
 
The overall aim of the present study was to evaluate whether the domestic piglet is a 
potentially relevant animal model for PK/PD studies of desmopressin. The first objective was 
adequately describe the desmopressin plasma concentration-time profiles in piglets of eight 
days, four weeks, seven weeks and six months, using non-linear mixed effects modelling 
(NLME). These age groups correspond to the main age categories of the human paediatric 
population, namely neonate, infant, child and adolescent (Gad, 2007; Gasthuys et al., 2016). 
The estimated values of the primary PK parameters correlated with the values obtained in 
children, also obtained using pop-PK analysis. The second objective was to determine the PD 
parameters in the youngest age category at eight days of age, to confirm or refute the in 
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2. Materials and methods 
2.1 Animals  
The current study was approved by the ethical committee of the Faculties of Veterinary 
Medicine and Bioscience Engineering of Ghent University (EC2014/184). Care and use of 
animals was in full compliance with the national (Belgian Royal Decree of 29 May 2013) and 
European legislation (Anonymous, 2010/63/EU). A total of 40 stress-resistant male piglets 
(Landrace x large white, Seghers Hybrid®, Wuustwezel, Belgium) aged eight days (n = 16, 
2.01 ± 0.43 kg), four weeks (n = 8, 10.0 ± 1.69 kg), seven weeks (n = 8, 13.9 ± 2.74 kg) and six 
months (n = 8, 112.88 ± 9.11 kg) were used. Upon arrival, the eight-day-old piglets were 
randomly divided into two groups of eight animals (group one: desmopressin, group two: 
blank). The animals were group housed in rescue decks (eight days) (0.9 m x 1.40 m, Provimi, 
Rotterdam, The Netherlands) and standard pig stables (four and seven weeks, six months) 
(2.30 m x 2.40 m), and had ad libitum access to feed (eight days: RescueMilk®, Provimi; four 
and seven weeks: Piggistart Opti®, six months: Optivo Pro®, Aveve, Leuven, Belgium) and 
drinking water. Natural light was provided by translucent windows and the stable 
temperature was 23.2 ± 0.56°C. Higher temperatures were obtained in the rescue decks 
through heating lamps. In the eight days, four and seven weeks old piglets, a double lumen 
catheter was placed in the jugular vein (all age groups) and a urine stoma ring (eight days) 
adhered around the prepuce of the male piglets according to Gasthuys et al. (2017a). After 
surgery, the piglets were housed individually to catheters avoid displacement of the 
catheters and stoma rings. During single housing, a cotton towel was added to the decks and 
stables to mimic the smell of the other piglets. During the experiments, the stables were 
enriched with hanging chains, rubber toys and balls of different sizes. The environmental 
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2.2 Experimental design 
After one acclimatization day, a desmopressin oral lyophilisate (Minirin® Melt 120 µg, kindly 
donated by Ferring, Copenhagen, Denmark) was placed under the tongue of eight out of 
sixteen piglets (eight days) and eight out of eight piglets (other age groups). Afterwards, the 
snout was closed during 30 seconds to ensure full dissolution of the lyophilisate. Urine 
collection bags were attached to the stoma rings of the eight-day-old piglets. The animals 
were deprived of milk or feed 1 h before and 1.5 h after administration of desmopressin. 
Venous blood samples (1 mL) were collected through the distal lumen of the catheter at 0 
(just prior to administration), 5, 15, 30, 60 min and 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h (post 
administration). The samples were drawn into 9 mL K3EDTA collection tubes (Vacutest®, 
Piove di Sacco, Kima, Italy), immediately kept on ice and centrifuged for 10 minutes at 2095 
x g within 2 h after blood collection. The plasma was aliquoted, frozen and stored at -80°C 
until analysis within two months. Urine was collected hourly in falcon tubes for 10 h post 
administration. The urinary volume was measured and a urine aliquot (300 µL) was stored at 
-20°C until analysis within one week. The body surface of the piglets (eight days, four and 
seven weeks) was imaged using a four-slice helical CT-scanner (Lightspeed QC/I, GE Medical 
systems, USA, New York). The CT-scans were processed using VGStudioMax (Volume 
Graphics GmbH, Heidelberg, Germany) and the body surface area (BSA) was determined 
after visualization and selection of the body surface in 3D (UGCT-Department of Physics and 
Astronomy, Ghent University, Ghent, Belgium). The glomerular filtration rate (GFR) was 
determined as the clearance of the exogenous marker exo-iohexol (Gasthuys et al., 2017b). 
 
2.3 Desmopressin analysis 
Desmopressin plasma concentrations were determined at Aarhus University Hospital 
(Aarhus, Denmark) using a validated radioimmunoassay (RIA) method as described by 
Emmeluth et al. (1994) and Bie and Sandgaard (2000). A 1-desamino-8-D-arginine 
vasopressin antibody (C990728, Biogenesis Ltd., Poole, UK) was used at a final dilution of 
1:125,000. The limit of quantification (LOQ) was 4.2 pg/mL and the intra- and inter-assay 
coefficient of variation was 7.9% and 12.1%, respectively.  
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2.4 Pharmacokinetic analysis 
Software 
Model development and parameter estimation were performed by nonlinear mixed effect 
modelling using NONMEM® version 7.3. (Icon Development Solutions, Ellicott City, MD, 
USA). 
 
Structural model development 
The first-order conditional estimation (FOCE) method was used as the estimation algorithm 
for all analyses. Plasma concentrations below the LOD were excluded from the analysis (4 
pg/mL; n = 8%) and a logarithmic transformation of the remaining plasma concentrations 
was performed. A one-compartmental model with first-order absorption was chosen as the 
pop-PK base model, analogous to the human pop-PK model development (Michelet et al., 
2016). Subsequently, based on a visual exploration of the plasma concentration-time profiles 
obtained in the growing piglets, a two-compartmental disposition model and a dual-input 
were evaluated to describe the absorption of the sublingual desmopressin lyophilisate. 
Various input functions were additionally explored, for an optimal fitting of the observed 
input profile. Structural model selection was guided by visual inspection of goodness-of-fit 
plots, the objective function value (OFV), Akaike’s information criterion (AIC) and the 
condition number (CN). The models were chosen based on mechanistic plausibility and 
smaller values of OFV and/or AIC and acceptable CN. 
 
Stochastic model development 
The inter-individual variability (IIV) on clearance, volume of distribution and the absorption 
parameters was assumed to be log-normally distributed and was modelled using an 
exponential-error model. The residual variability was described using the log-transform both 
sides approach, which implies that the log of the concentrations was modelled with an 
additive error (proportional error model in the untransformed domain).  
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Covariate model development 
Once the structural and error models were obtained, continuous covariates were included 
using the stepwise covariate modelling (SCM) approach (forward selection followed by 
backward elimination). Evaluated continuous covariates on central volume of distribution 
(V1/F), apparent total body clearance (CL/F) and absorption-related parameters were body 
weight (BW), BSA, age and/or GFR. A covariate was considered significant when its addition 
resulted in a decrease in OFV of more than 6.635 (χ² test, df = 1, p < 0.01) and 10.828 (χ² 




The final model was evaluated based on diagnostic plots of the individual (IPRED) and 
population (PRED) predicted concentrations versus the observed concentrations (Cobs), and 
time after dose and PRED versus the conditional weighted residuals (CWRES). Evaluation of 
the diagnostic plots was based on visual inspection of the plots for scatter and bias. The 
precision of the parameter estimates was determined by calculating the relative standard 
error (%RSE). The fixed- and random-effect estimates with relative precision below 30% and 
40-50%, respectively, were considered as precisely estimated. A visual predictive check (VPC) 
was performed to evaluate the predictive properties of the final model based on 1,000 
simulations of the original dataset. The dependent variable Cobs (y-axis) was plotted against 
the independent variable time after dosing (x-axis). The 50th percentile (median) of the 
observed data and the simulated predictions were presented. Moreover, the 5th (lower) and 
95th (upper) percentiles were depicted, corresponding to an inter-percentile range of 90% (= 
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2.5 Secondary PK parameters 
The individual PK parameter estimates (= empirical Bayes estimates, EBE) were computed 
during the estimation of the final population parameters. The shrinkage was determined to 
evaluate the quality of the EBE estimation, since the EBE tends to shrink towards the 
population mean in case of non-informative data. Shrinkage below 30% was considered 
acceptable. The secondary parameters, namely area under the plasma concentration-time 
curve (AUC0→∞) and elimination half-life (T½el) were calculated. The individual AUC values 
were determined by the logarithmic trapezoidal method with extrapolation to infinity.  
 
2.6 Pharmacodynamic analysis  
During the acclimatization day, one day prior to the PK study, baseline values for the 
different PD parameters were established at three different time points (10 am, 14 pm, 18 
pm). Voided urinary volume was recorded hourly for 10 hours and osmolality was assessed 
in each urinary void. Plasma concentrations of sodium were determined for each plasma 
sample. The PD parameters were determined in urine and plasma samples by standard 
analytical methods (sodium concentration: Cobas c701 indirect potentiometry with ISE 
module®, Roche, Vilvoorde, Belgium; osmolality: freezing-point depression, Menarini, 
Diegem, Belgium) at Ghent University Hospital (Ghent, Belgium). 
 
3. Results 
3.1 Population characteristics  
All piglets survived catheterization of the jugular vein without any complications. Two out of 
sixteen piglets aged eight days, were withdrawn from the study (after surgery) due to low 
BW (two animals, < 1.50 kg). All piglets, except the blanks, received a desmopressin oral 
lyophilisate under identical circumstances (deprived from food, properly hydrated) and no 
general side effects were observed during the experiment. The descriptive (mean ± SD and 
median [range]) characteristics are detailed in Table 1. 
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Table 1. Descriptive characteristics of the piglet study population. Values are presented as 
mean ± SD and median [range]. 
Characteristic  8 days 4 weeks 7 weeks 6 months 
N° of piglets  14  8  8 8  
BW (kg) Mean  
Median 
2.01 ± 0.43 
2.21 [1.54-2.64] 
10.0 ± 1.69 
10.0 [7.0-12.0] 
15.8 ± 1.98 
15.0 [14.0-19.0] 
112.9 ± 9.11 
113.6 [100.0-124.0] 
BSA (m²) Mean 
Median 
0.16 ± 0.02 
0.17 [0.13-0.19] 
0.46 ± 0.05 
0.46 [0.36-0.52] 
0.59 ± 0.08 
0.63 [0.60-0.73] 
2.42 ± 0.13 
2.43 [2.23-2.58] 
GFR (mL/min/m²) Mean 
Median 
40.8 ± 8.62 
40.6 [24.5-50.5] 
67.4 ± 11.54 
66.2 [54.2-82.2] 
106.5 ± 18.69 
110.7 [77.8-133.9] 
136.3 ± 13.48 
135.5 [120.2-159.0] 
N°: number, BW: body weight, BSA: body surface area, GFR: glomerular filtration rate adapted from Gasthuys et al. (2017b) 
 
3.2 Pharmacokinetic analysis 
The model development path is described in Table 2. Figure 2 shows the plasma 
concentration-time profiles of desmopressin. The best description of the plasma 
concentration-time profiles of desmopressin in growing piglets was obtained with a two-
compartmental disposition model combined with a dual input function for the absorption. A 
zero-order release into a first depot followed by first-order absorption, and a first-order 
release from a second depot after a lag time (Tlag), both into the central compartment was 
chosen as the final model (Figure 3). This model was required since many plasma 
concentration-time profiles showed a 2nd peak in their profile implying that most probably, 
a part of the dose has been ingested (1-Bio) rather than directly absorbed through the 
buccal mucosae (Bio). The main parameters included in the model were apparent total body 
clearance (CL/F), apparent central and peripheral volume of distribution (V1/F; V2/F), 
apparent intercompartmental flow (Q/F), first-order absorption rate constants from the first 
and second depot (Ka1; Ka2), the fraction of the dose split over depot 1 and depot 2 (Bio), the 
lag time (Tlag) and duration of the zero-order release (D1). Since no intravenous data were 
obtained in piglets, the absolute oral bioavailability (F) could not be estimated. The IIV of Q, 
Ka2 and Tlag could not be estimated from the data, and was fixed to zero. The forward 
inclusion and backward elimination of the covariate effect BW on apparent clearance (CL/F) 
and apparent central volume of distribution (V1/F) demonstrated a significant improvement 
of the model (ΔOFV = 14.43 and 39.72, respectively). No other covariates, including renal 
function and age, were found to be significant for any of the parameters. The final pop-PK 
model parameter estimates are presented in Table 3.  
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Table 2. Development path of the pharmacokinetic model of desmopressin in growing piglets. 
Run OFV Description Comments ΔOFV 
1 -158.352 1-compartmental model, first-order absorption IIV on all parameters, covariance step successful  - 
2 -245.768 2-compartmental model, first-order absorption IIV on all parameters, covariance step not successful 87.4 
3 -245.769 2-compartmental model, first-order absorption IIV on V2 fixed to 0, covariance step successful, GOF not very good 0.0 
4 -227.928 2-compartmental model, first-order absorption IIV on Q fixed to 0, covariance step successful, GOF good -17.8 
5 -242.160 2-compartmental model, sequential zero-first order absorption IIV on Q fixed to 0, covariance step successful, GOF good 14.2 
6 -279.697 2-compartmental model, dual input IIV on Q fixed to 0, covariance step not successful 37.5 
7 -279.698 2-compartmental model, dual input IIV on Q, Ka2, Tlag fixed to 0, covariance step successful 0.0 
8 -319.418 2-compartmental model, dual input, BW effect on CL IIV on Q, Ka2, Tlag fixed to 0, covariance step successful 39.7 
9 -333.843 2-compartmental model, dual input, BW effect on CL and V1 IIV on Q, Ka2, Tlag fixed to 0, R matrix 14.4 
10 -338.492 2-compartmental model, dual input, BW effect on CL, V1 and Ka1 IIV on Q, Ka2, Tlag fixed to 0, covariance step successful 4.6 
11 -294.619 2-compartmental model, dual input, BW effect on V1 and Ka1 Backward deletion BW effect on CL, significant, covariance step not successful -43.9 
12 -315.999 2-compartmental model, dual input, BW effect on CL and Ka1 Backward deletion BW effect on V1, significant, R matrix 21.4 
13 -333.843 2-compartmental model, dual input, BW effect on CL and V1 Backward deletion BW effect on Ka1, not significant, R matrix 17.8 
14 -333.843 2-compartmental model, dual input, BW effect on CL and V1 IIV on Q, Ka2, Tlag fixed to 0, covariance step successful 0.0 
15 -302.068 2-compartmental model, dual input, BW effect on Cl and V1-full dataset IIV on Q, Ka2, Tlag fixed to 0, covariance step successful -31.8 
16 -306.990 2-compartmental model, dual input, BW effect on CL and V1 – GFR effect on CL IIV on Q, Ka2, Tlag fixed to 0, T matrix 4.9 
OFV: objective function value, IIV: inter-individual variability, V1/V2: apparent volume of distribution of the central and peripheral compartment; respectively, Q: apparent intercompartmental 
flow, Tlag: lag time depot 2, GOF: goodness of fit, Ka1/Ka2: first-order absorption rate constants from depot 1 and 2; respectively, BW: body weight, CL: clearance, GFR: glomerular filtration rate 
 
 







Figure 2. Mean (+ SD) desmopressin plasma concentration versus time curves without (a) 
and with (b) normalisation for body weight of piglets aged eight days (n = 8), four weeks (n = 
8), seven weeks (n = 8) and six months (n = 8) after receiving a desmopressin oral lyophilisate 
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Figure 3. Graphical representation of the applied model to describe the pharmacokinetics of 
a desmopressin oral lyophilisate in growing piglets. D1: duration 1, Tlag: lag time, Bio: fraction 
of the absorbed dose (buccal absorption), 1-Bio: fraction of the absorbed dose (assumed 
gastro-intestinal absorption), Ka1/Ka2: first-order absorption rate constants, Vc(V1): apparent 
volume of distribution of the central compartment, VP(V2): apparent volume of distribution 
of the peripheral compartment, Q: inter-compartmental flow, CL: apparent total body 
clearance. 
 
Table 3. Population pharmacokinetic model parameter estimates after administration of a 
desmopressin oral lyophilisate (120 µg) to growing piglets. Body weight is centred on the 
typical weight of 10 kg.  
Parameter Estimate  
(% shrinkage) 
SE  RSE (%) 





















 0.0272 9.89 
Q/F = θ
4










 0.16 h 0.0473 29.6 
Ka2 = θ
7
  0.399 h
-1
 0.0677 17.0 
Bio = θ
8
 86% 0.0488 5.67 
Tlag = θ
9
  1 h 0.00196 0.20 
Covariate model    
Influence of BW on CL 1.03 0.0627 6.09 
Influence of BW on V1 0.691 0.135 19.54 
Inter-individual variability    
IIV CL/F 0.175 (1.97%) 0.0462  13.20 
IIV V1/F 0.641 (25.4%) 0.264  20.59 
IIV Q/F 0 (FIX) 0  0 
IIV Ka1 0.0903 (16.0%) 0.0339  18.77 
IIV Ka2 0 (FIX) 0 0 
IIV V2/F 0.634 (61.8%) 0.202  15.93 
IIV D1 0.485 (47.4%) 0.255  26.29 
IIV Bio 0.627 (42.9%) 0.391  31.18 
IIV Tlag 0 (FIX) 0 0 
Residual error    
ADD = θ
10
 22.8% CV 0.0291 12.76 
CL/F: apparent total clearance after oral administration, V/F: apparent central (V1) and peripheral (V2) 
volume of distribution after oral administration, Ka1/Ka2: first-order absorption rate constants from 
depot 1 and 2, respectively, Q/F: apparent intercompartmental flow, D1: duration of the zero-order 
input, Bio: fraction passing through depot 1, Tlag: lag time depot 2, BW: body weight, IIV: inter-
individual variability, ADD: additive residual error, CV: coefficient of variation, SE: standard error, RSE: 
residual standard error  
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Model diagnostic plots presented in Figure 4 show the overall goodness-of-fit of the final 
model. The IPRED (Figure 4a) versus Cobs and PRED (Figure 4b) versus Cobs plots 
demonstrated no significant deviations of the LOESS smoothed line from the line of unity, 
meaning that appropriate structural models could be fitted for most individuals and no 
major bias in the population components of the model were found. The scatter plot of the 
CWRES versus time (Figure 4c) showed a symmetric distribution of the weighted residuals 
around zero across the entire range of time after dosing, implying that no major bias was 
observed. The scatter plot of the CWRES versus PRED (Figure 4d) showed positive WRES in 
the lowest PRED, indicating a slight overprediction of the lowest concentration values. The 
%RSE of the fixed- and random-effect parameters were regarded acceptable (even though 
for V2/F, it was just above 30% (31.4%)). Most of the observations are within the 90% 
prediction interval of the VPC (Figure 4) indicating that the model could reliably predict the 


















Figure 4. Diagnostic plots of the population model of desmopressin after oral lyophilisate 
administration to growing piglets: scatter plots of the dependent variable (DV), namely 
observed plasma concentrations (Cobs), versus the individually predicted plasma 
concentration values (IPRED)(a) and population predicted plasma concentration values 
(PRED)(b), scatter plots of the conditional weighted residuals (CWRES) versus time after dose 
(c) and PRED(d). Grey circles represent the observed data, the full black lines are the lines of 
unity and the full red lines are the LOESS smoothed lines. 
 













Figure 5. Visual predictive check for the final population PK model of a desmopressin oral 
lyophilisate. Grey circles represent the observed data. The lower and upper dashed lines and 
solid line represent the 5th, 95th and 50th percentiles, respectively. The shaded areas are 
the 95% confidence interval of the corresponding percentiles.  
 
The individual primary PK parameters were obtained directly from the model, through the 
posthoc step (Bayesian feedback step). The shrinkage of the primary parameters was 
acceptable (Table 3). The shrinkage of V2/F was above 30%, but since the shrinkage applies 
to the complete dataset, the values were still used to calculate the VSS. The values for the 
secondary PK parameters, AUC and T½ are depicted in Table 4.  
 
Table 4. Mean (±SD) secondary PK parameter estimates after administration of a 
desmopressin oral lyophilisate (120 µg) in growing piglets at eight days, four weeks, seven 
weeks and six months. 
Parameter 8 days 4 weeks 7 weeks 6 months 
AUC0→∞ (pg*h/mL) 1369 ± 485 436 ± 196 215 ± 94.1 32.7 ± 19.1 
T½el (h) 3.83 ± 2.56 1.40 ± 0.58 0.90 ± 0.32 0.10 ± 0.04 
AUC area under the plasma concentration-time curve, T1/2el half-life.  
 
Experimental Studies – Chapter III 
157 
 
3.3 Pharmacodynamic analysis 
PD data of the eight-day-old piglets, expressed as urinary volume, urinary osmolality and 
plasma sodium concentration, are presented in Figure 6a, b and c, respectively. No 
significant differences were identified between the desmopressin and the control groups, 
confirming the hypothesis that the piglet V2 receptor does not bind when there is a D-
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Figure 6. Urinary volume (a), urinary osmolality (b) and plasma sodium concentration (c) 
(desmopressin group after administration of a desmopressin oral lyophilisate (120 µg): 
white, control group: hatched) of eight-day-old piglets (n = 8).  
 
4. Discussion 
PK and PD studies in the paediatric population are essential to determine correct dosage 
strategies for optimal efficacy. Despite worldwide use of desmopressin to treat nocturnal 
enuresis in children, full PK studies taking growth and maturation into account are still 
lacking. To date, most studies investigating the PK of desmopressin in this population applied 
a sparse sampling protocol on a limited number of patients (Osterberg et al., 2006; De 
Bruyne et al., 2014). Informative animal models, such as the piglet, can be used to perform 
full PK studies to provide additional information such as sampling strategies and therapeutic 
ranges for human paediatric preclinical trials.  
In the present study, a desmopressin oral lyophilisate (120 µg) was administered to growing 
piglets of eight days, four weeks, seven weeks and six months old. A two-compartmental 
pop-PK model with absorption described by a dual input function best fitted the data. Such a 
dual input function was required to describe the double peak phenomenon in the plasma 
concentration-time curves. The first input function comprises a zero-order absorption rate, 
most probably related to buccal absorption of the oral lyophilisate. No lag time was required 
for the first input function, indicating that sublingual absorption occurred rapidly after oral 
administration of the oral lyophilisate. The second input function comprises a first-order 
absorption rate into the systemic circulation, possibly related to gastro-intestinal absorption 
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function, indicating that the gastro-intestinal absorption did not start immediately after oral 
administration of the oral lyophilisate. A double peak has not been observed in the plasma 
concentration-time curves of a desmopressin oral lyophilisate in paediatric clinical PK 
studies. However, in those studies, only two to three blood samples were collected from 
each patient, potentially missing the double peak if there is one present. Consequently, 
additional studies with more intensive sampling in the absorption phase are required. This is 
in accordance with Michelet et al. (2016), who concluded that additional clinical trials with a 
richer sampling strategy in the absorption phase are needed, since no IIV on the Ka could be 
estimated.  
Most articles describing the PK parameters of desmopressin administered to adults 
(Fjellestad-Paulsen et al., 1993; Agerso et al., 2004; Fransén et al., 2009) applied a two- or 
three-compartmental model to fit the data. Michelet et al. (2016) combined the data 
collected in children by Osterberg et al. (2006) and De Bruyne et al. (2016) and concluded 
that a one-compartmental model with first-order absorption best described the data. In the 
current study, a two-compartmental model was chosen based on a smaller OFV (ΔOFV = 
87.42) in comparison with a one-compartmental model, despite the high values of RSE and 
shrinkage for V2/F (31.4% and 61.8%, respectively). Since our experimental design comprised 
a rich sampling protocol, including a 24 h time point and younger age groups, it is possible 
that these factors favour a two-compartmental model, which was also fitted to the adult 
human data.  
The apparent CL/F population value is 395 L/h. BW was a significant covariate, suggesting 
that individuals with higher BW have a higher absolute clearance. Since renal excretion is the 
main route of elimination of desmopressin (Fjellstad-Paulsen et al., 1993) and catabolism of 
desmopressin appears after active uptake by the proximal tubules of the kidney (Maack et 
al., 1979), kidney maturation might thus explain the increased clearance with increasing BW. 
When including the covariate GFR, a significant improvement of the OFV was observed, but 
the covariate was not retained, since backward elimination did not reach the prespecified 
significance level. Consequently, maturation of the GFR could only partially explain the 
increase in clearance. When looking at the data, it should be noted that the apparent 
clearance is presented in the current study, since the F in piglets is not known. Therefore, 
the age-related difference in clearance might also be attributable to a significant difference 
Experimental Studies – Chapter III 
161 
 
in F as well. Since the F in humans is very low (<1%), this might also be the case in piglets. 
Consequently, when considering the F in growing piglets, a small difference in F could 
potentially lead to a significant difference in clearance. Therefore, a follow-up study should 
be performed, to determine the absolute oral bioavailability in growing piglets. In humans, 
the mean population value of CL/F after oral dosing of desmopressin in a fasted population 
of children was 2330 L/h (Osterberg et al., 2006) and 2098 L/h (Michelet et al., 2016). No 
significant effect of BW on CL/F could be observed in both studies. This might be explained 
by the age ranges, Osterberg et al. (2006): 6-12 years (Child), De Bruyne et al. (2014): 5-18 
years(child-adolescent), and consequently the BW ranges included in those studies that 
were smaller than in the current study (neonate-adolescent), whereby the covariate effect 
of BW on clearance might be underestimated. A good correlation can be found between the 
values obtained by Michelet et al. (2016) and the values obtained by allometric scaling, 
namely CL (human) = CL (pig)*(BW human/BW pig)0.75 (ratio: 1.70), rendering the piglet a 
good animal model to predict the clearance of desmopressin in humans.  
The apparent V1 population estimate is 131 L. As seen with clearance, a significant covariate 
effect of BW was found, suggesting that individuals with higher BW have also an increased 
volume of distribution of the central compartment. Since desmopressin has a negative clog P 
(-7.711), demonstrating the hydrophilicity of this drug, the maturational changes of the body 
composition could explain the covariate effect of BW on V1 (Lawton and Witty, 2013). 
However, it should be noted that the V1 is also the apparent volume of distribution, so the 
age-related difference could again be due to significant differences in F. Therefore, also 
here, follow-up studies should be performed, to determine the F in growing piglets. In 
humans, the mean population value of Vd/F after oral dosing of desmopressin in a fasted 
population of children was 8510 L (Osterberg et al., 2006) and 8237 L (Michelet et al., 2016). 
Osterberg et al. (2006) did not observe a significant effect of BW on Vd/F. However, Michelet 
et al. (2016) did describe a significant effect of BW on Vd/F, suggesting that dose 
adjustments might be necessary. However, Michelet et al. (2016) also stated that the extent 
of the covariate effect of BW is quite unclear from the data, since the exponent of the power 
relation exhibits a quite large uncertainty. When comparing the results of Michelet et al. 
(2016) and the allometric scaling of the Vd (Vd(human) = Vd (pig)*(BW human/BW pig)
1), the 
piglet is a good model to predict the Vd of desmopressin in humans (ratio: 3.88).  
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The AUC and T½ in the different age groups were estimated based on the final pop-PK model. 
The shrinkage for most important primary PK parameters was acceptable, since the 
shrinkage of only V2/F was higher than 30%. A significant difference between the AUC and T½ 
of the different age groups was observed. The Cmax of the eight-day-old piglets were higher 
and the elimination half-life was longer in comparison with the other age groups, which 
could possibly lead to more adverse effects in this age group. When comparing these results 
with the results obtained by Osterberg et al. (2006) (240 µg; Cmax: ± 40 pg/mL), it can be 
noted that the Cmax was much higher in the current study (120 µg; Cmax: ± 250 pg/mL). This 
can be explained, since this age group was not included in the study of Osterberg et al. 
(2006). The Cmax of the other age groups included in the present study are comparable with 
the Cmax obtained in the study of Osterberg et al. (2006). The desmopressin concentrations 
in the six-month-old age group are lower than the concentrations that are required to obtain 
antidiuretic effects. It is recommended that in future studies, a 240 µg oral lyophilisate 
should be administered instead of a 120 µg oral lyophilisate to the six-month-old piglets.  
No significant differences in PD parameters between desmopressin and control groups could 
be determined in the piglets, which confirms the results described by Ufer et al. (1995). 
Consequently, the piglet is not an appropriate model to study the PD of desmopressin in the 
paediatric population. However, it should be noted that the natural porcine ligand lysine 
vasopressin as well as the natural human ligand arginine vasopressin, bind to the porcine 
vasopressin V2 receptors (Ufer et al., 1995). Munsick et al. (1958) studied the potency of 
lysine vasopressin and arginine vasopressin as antidiuretic agents in piglets weighing 15 to 
30 kg and found that both agents are equally potent. Consequently, the piglet could be a 
potential model to study the PD of other synthetic analogues of the natural antidiuretic 
hormone vasopressin. However, it is recommended to perform proper ligand-binding studies 









The PK parameters of an oral lyophilisate of desmopressin were successfully determined in 
piglets aged eight days, four weeks, seven weeks and six months using nonlinear mixed 
effects modelling. A two-compartmental model with a dual input function best described the 
data, since two absorption peaks were observed in the plasma concentration-time curves. 
Age related differences could be observed in the current study. In human paediatric trials, a 
one-compartmental model with first-order absorption was fitted to the data and no double 
peaks were observed in the curves, likely due to the sparse sampling strategy applied in 
those studies. Therefore, it is recommended that additional studies in children, based on the 
sampling protocol in the current study, are performed to determine the PK parameters in 
children based on a full documentation of the plasma concentration-time profile. Such 
studies would enable to further validate if the pig is a reliable translational model to study 
the PK of desmopressin. No PD effects were observed, confirming the theory of Ufer et al. 
(1995) that desmopressin does not bind to the porcine vasopressin receptor. However, the 
natural hormone arginine vasopressin binds the porcine receptor, so the pig might be used 
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1. Paediatric drug research  
‘The children’s right to the highest attainable level of health enunciated by the Convention on 
the Rights of the Child cannot be realized if they are provided therapy based on evidence 
generated through studies carried out in adults’ (Bavdekar, 2013). 
Despite the existence of literature mentioning childhood illnesses in ancient Egypt, Greek 
and Roman century, the first official documentation about studies conducted in children was 
not prior to the 18th century. It was only in the 19th century, when paediatrics became a 
recognized specialty, that experiments in children became common practice (Bavdekar, 
2013). No strict guidelines about how to perform paediatric research were available until in 
1964 the World Medical Association issued a guideline about ethically conducting paediatric 
clinical trials (WMA, 1964). Today, both the FDA and EMA have warranted regulations to 
stimulate the industry to perform more paediatric drug research. Despite the increased 
regulatory efforts, still 50% of the drugs used in the paediatric population are prescribed off-
label (Kimland and Odlind, 2012). The well-worn phrase ‘children are not small adults’ is a 
common saying among paediatric care providers. It is widely accepted that the paediatric 
population cannot be considered as one age category, since many anatomical and 
physiological differences between paediatric age groups are observed (Soellner and 
Olejniczak, 2013). Despite the fact that there are inherent kinetic differences between 
children and adults, over the years, diagnostic and therapeutic guidelines for children are 
mainly just linearly extrapolated from trials conducted in adults (Kearns et al., 2003; 
Lehmann, 2010). The reluctance to study drugs in the paediatric population may occur for 
several reasons, namely the complexicity of clinical trials in children and the ethical concerns 
about these trials (Brasseur, 2011). However, recently it has been realized that off-label use 
of drugs may pose a greater risk than conducting paediatric clinical trials (Baldrick, 2010). In 
order to counteract the use of off-label drugs and further improve paediatric drug design, 
age-appropriate dosage schemes and formulations have to be developed. In this respect, the 
interest in juvenile animal models, which can provide additional information to support 
paediatric drug development, has grown (Silva-Lima et al., 2010). The usefulness of juvenile 
animal models to assess toxicological effects in children has already been demonstrated in 
the past, however, standardized juvenile animal models taking maturation and growth into 

















Figure 1. Overview of the concept and main results achieved in this doctoral thesis. ADME: Absorption, distribution, metabolism, excretion (the 




2. Paediatric animal models 
Performing clinical trials in children can be debatable both from an ethical and a societal 
point of view. Consequently, alternative populations (adults) and juvenile animal models are 
proposed to assess the safety of drugs, reduce the number of paediatric trials and to refine 
the study design of these trials. Before conducting juvenile animal studies, adult human and 
animal data need to be carefully reviewed to determine the PK, PD and safety properties of 
the test compounds. If there is insufficient information obtained from adult preclinical and 
clinical studies, conducting juvenile animal studies might be justified. A proper study design 
should be drafted taking into account the three R’s principle (reduction, refinement and 
replacement). It is essential to perform research about the feasibility of different species as 
juvenile animal models. The suitability of the conventional pig and its place among 
traditional animal models, i.e. dogs, rodents, non-human primates and minipigs, is discussed 
below.  
 
2.1 Is the conventional pig a suitable juvenile animal model? 
Conventional piglets might be potential juvenile animal models because of the striking 
anatomical and physiological resemblances between both species during the developmental 
stages of life (Gasthuys et al., 2016). However, the authors also concluded that more 
extensive research about the ontogeny of drug disposition has to be performed in order to 
evaluate if the piglet is really a suited animal model in paediatric drug design. Hence, the 
main focus of this doctoral thesis was to fill in some knowledge gaps about the 
developmental influences on the excretion of drugs. Figure 1 shows an overview of the 
concept and main results achieved in this doctoral thesis. The obtained results are a nice 
example proving that conducting animal trials is not always straightforward. For instance, 
the maturation of the GFR is comparable between both humans and pigs, rendering the 
conventional piglet a good animal model for studying the GFR in the paediatric population, 
and to evaluate the PK of renally excreted drugs which are mainly filtrated (see section 3.4 
General discussion). Moreover, the full PK study of desmopressin in growing piglets revealed 
new insights in the PK of a sublingual tablet, which might lead to adapted dosage protocols 




piglets however was not successful, demonstrating that the conventional pig is not suitable 
to evaluate the developmental effects on the PD parameters of desmopressin (see section 
4.2 General discussion). Consequently, conducting juvenile animal studies using conventional 
pigs are not always without risks, necessitating the need for a case-by-case approach and 
carefully designing of each study according to the PK, PD and toxicological properties of the 
drugs.  
 
2.2 Is the conventional pig a suitable alternative to traditional juvenile animal models? 
To answer this question it is important to keep in mind that paediatric drug research is 
notoriously difficult due to maturation of the different organ systems. Consequently, finding 
a single animal species that is appropriate for conducting all juvenile animal studies is 
impossible. The decision made about the feasibility of a certain animal model should be 
driven by scientific arguments. Yet the question is: ‘Is it also a valuable alternative to the 
traditional animal models?’ Up to now the use of conventional pigs by the pharmaceutical 
industry to perform preclinical paediatric studies is not common practice. Also the use of 
minipigs is limited, but as the advantages of this species become more widely known, the 
interest in them also grows (EMA, 2016). Since the weight gain of conventional pigs is much 
higher in comparison to traditional animal species, the interest of the industry to use 
conventional pigs as adolescent animal models is limited, since large quantities of drugs are 
required. The use of minipigs might then be preferred. However, this drawback does not 
hold true for younger animals, rendering the conventional pig more convenient as an animal 
model for the youngest age categories (neonate, infant and child). Maturation of the pig (14-
26 weeks) occurs in a much shorter period than other non-rodent species, i.e. dogs (20-28 
weeks) or monkeys (36-48 months), leading to reduced study duration (Buelke-Sam, 2003). 
When considering the practical part of the animal trials, conventional pigs are relatively easy 
to handle. For instance regarding blood sampling, a full PK study could already be conducted 
at the age of eight days, which is more difficult to achieve in rodents and even minipigs due 
to size restrictions. For the time being, there are also less public ethical concerns when 
working with piglets than with puppies or baby monkeys. Nevertheless, the animal welfare 




is the cost of this species regarding purchase and housing facilities, which is much lower in 
comparison with other non-rodent species, i.e. minipigs, dogs, monkeys. As primary non-
rodent species to perform paediatric preclinical studies, the use of the conventional pigs 
might however be questioned by the industry. The main reason is the fact that the selection 
of the type of animals being used is mostly dependent on the availability of adult animal 
data and the suitability as an adult animal model. Since the main disadvantage of 
conventional pigs is their large size at maturity, this species is less attractive for adult studies 
than for instance minipigs. But in studies where more than one species is required, the use 
of conventional pigs might be more appropriate, since only a limited number of adult 
animals could be included. The conventional pig might also be valuable to optimize several 
technical (i.e. microdialysis technique to measure the unbound tissue concentrations) and 
surgical procedures (i.e. stomach probe), which can afterwards be implemented and 
validated in other species, such as the minipig. When considering the paediatrician’s and the 
academic’s perspective on juvenile animal models, the conventional pig as an alternative 
model may be more interesting, since this perspective is less economically driven in 
comparison to the perspective of the industry. Indeed, the piglet may be a good alternative 
model to gain insights in the maturational processes occurring from birth till adulthood. 
Hence, the developmental effects on PK, PD and possible target organ toxicity of already 
existing drugs can be investigated, providing additional information for paediatricians to 
evaluate if these drugs are safe in the paediatric population. Moreover, the conventional pig 
can also be used to unravel pathophysiological differences between children and adults. 
Since the expression of some diseases can be different in children, different therapeutic 
approaches might be required.  
 
To further evaluate if and when the conventional pig is appropriate to use, a comprehensive 
literature search according to ILSI (2003) and Gasthuys et al. (2016) should be constructed. 
This literature review should comprise a comparative analysis of the ontogeny of the 
disposition of drugs between the different species linked to the “developmental milestones” 
of the different organ systems. Moreover, since the response to therapy in children might be 
altered, characterizing appropriate PD biomarkers might be of interest and should be 




3. Glomerular filtration rate 
The kidneys play a major role in the elimination of metabolic waste products, drugs and toxic 
substances. Renal excretion is thrived by the renal blood flow (RBF), glomerular filtration 
rate (GFR), tubular secretion and reabsorption (Kerl and Cook, 2005). Assessment of the GFR 
is still considered as the gold standard to determine the renal function in both humans and 
other mammal species. Accurate determination of the GFR is essential for preclinical PK, PD 
and safety studies in order to determine correct dosage strategies for drugs excreted by 
and/or acting on the kidney, monitoring potential nephrotoxicity of drugs.  
 
3.1 Measuring the glomerular filtration rate: is there an ideal method? 
GFR cannot be measured directly, but is calculated as clearance of an endogenous or 
exogenous marker (Schwartz and Furth, 2007). The ideal marker to measure the GFR is freely 
filtered by the glomerulus and not secreted, metabolized nor reabsorbed by the renal 
tubules. Next to the physicochemical properties of the marker, also its applicability in clinical 
practice of this marker needs to be considered. Each marker has its advantages and 
disadvantages. The gold standard both in adults and in children, namely inulin, fulfils the 
requirements about secretion, metabolization and reabsorption, but this technique is not 
routinely applicable. This is in contrast with creatinine, which is easily determined and 
considered as the gold standard in clinical practice, but the inter- and intra-patient 
variability, tubular secretion (proximal convoluted tubule by active transport) and analytical 
inaccuracies renders this technique less reliable. So the question remains: ‘are there any 
valuable alternative markers which fulfil all the criteria?’ Over the years, cystatin C has been 
proposed as an alternative GFR marker in clinical practice. The cystatin C concentrations are 
high in neonates (1.37 mg/L) and decrease during the first four months of life (0.98 mg/L), 
reflecting maturation of the kidney function (Kehr et al., 2017). The sensitivity of cystatin C 
to detect subtle GFR decreases in children is higher, which favours the use of cystatin C as a 
new marker (Finney et al., 2000). However to date, the clinical application of cystatin C is 
rather limited. One of the reasons is the high cost of the lab analysis in comparison to 
creatinine. Moreover, cystatin C can be found in urine when patients suffer from glomerular 




Other endogenous compounds, such as beta trace protein and β2-microglobulin have been 
proposed as valuable alternative GFR markers. Both markers are age and muscle mass 
independent (Delanghe, 2008). Beta trace protein and β2-microglobulin are promising 
alternatives to calculate the GFR of the paediatric population, but standardization and 
validation of these markers in clinical practice are still required. Iohexol is a reliable 
alternative to the gold standard inulin. Iohexol is a xenobiotic which does not require timed 
urine collections and only four sampling points are needed to accurately measure the GFR in 
children. Iohexol is also preferred to radioisotopes, since it is non-toxic and less plasma 
protein binding occurs. However, this technique might not be useful in clinical practice, since 
multiple blood samples over at least 5 h are required and analysis is quite expensive. 
Although iohexol can be a valuable alternative to inulin and radioisotopes in preclinical and 
clinical trials (Schwartz and Work, 2009).  
 
In this doctoral thesis, the GFR in growing piglets was determined using both creatinine 
clearance (Jaffe and enzymatic assay) and exo-iohexol clearance. These three techniques 
were chosen to be able to evaluate if exo-iohexol is a better marker in comparison with 
creatinine and to correlate the obtained results with the results obtained in humans. It was 
expected that significant differences between creatinine and exo-iohexol would appear, but 
the data demonstrated in this doctoral thesis show a good agreement between the three 
techniques. It is however important to notice that the creatinine clearance using Jaffe 
required additional steps in order to tackle the confounding parameters during the 
creatinine measurements. First, it was not possible to collect a 24 h urine sample from the 
piglets due to the size of the bags, whereby sparse sampling was applied. Moreover, it is not 
clear in this study whether or not the pigs emptied their bladder completely, possibly 
underestimating the true creatinine clearance. Consequently, the creatinine load was 
calculated to detect possible outliers. Urine was collected at three different time points: 
morning, afternoon and evening. When considering all the time points, less outliers were 
observed in the eight-day-old (5 out of 38) in comparison with the four- (6 out of 17) and 
seven- (10 out of 36) week-old piglets. The youngest piglets (eight days) urinated more 
frequently (approximately every two hours) in comparison with the older piglets 




empty their bladder completely when urinary creatinine concentrations were assessed or 
that they already urinated before the urine collection bags were adhered to their prepuce, 
resulting in more outliers in these age categories. However, despite the outliers, 
determination of the creatinine clearance could still be performed adequately, since most 
outliers were only observed at one time point for each piglet. In future studies it is 
recommended to collect urine during a longer period of time (at least three hours) and if 
possible 24 h. Second, it is known that the determination of plasma creatinine with Jaffe is 
not reliable when the total plasma protein content is lower than 75 g/L. Determination of 
the urinary protein concentration is not necessary, since urine contains almost no proteins 
(Delanghe, 2008). In all the age categories, except the six-month-old piglets, the total plasma 
protein concentration was below 75 g/L. Consequently, a correction factor had to be 
included to be able to calculate the true creatinine clearance. It is important to keep in mind 
that the total plasma protein concentration should be determined simultaneous with the 
plasma creatinine concentration. Third, creatinine is prone to secretion by the renal tubules. 
In humans, secretion of creatinine accounts for 10% (even more in patients suffering from 
chronic renal insufficiency) of the urinary creatinine concentration, leading to 
overestimation of the true GFR (Kehr et al., 2017). When creatinine is determined after 
administration of the H2-antagonist cimetidine (3 days, 20 mg/kg/day divided into two 
doses), a decline in creatinine secretion was observed, leading to more accurate GFR 
measurements (Hellerstein et al., 1998). Hansen et al. (1997) mentioned that creatinine is 
transported by the porcine renal tubules and that this transport is species dependent. For 
future studies, it may be important to assess the fraction of creatinine secreted by the renal 
tubules and to evaluate the effect of drugs that might alter creatinine secretion in growing 
piglets.  
 
Determination of iohexol is less sensitive to confounding factors in comparison with Jaffe 
and is a good alternative marker to assess the GFR. However, two remarks have to be 
considered when calculating the iohexol clearance. First, it is important to mention that 
iohexol exists as two stereoisomers, i.e. endo- and exo-iohexol. The in-house validated HPLC-
UV analysis is able to quantify separately the endo- and exo-iohexol isomer. Consequently, 




thesis, the most abundant isomer, namely exo-iohexol was chosen. Before calculating the 
exo-iohexol clearance it is important to assess the endo/exo ratio to be able to determine 
the correct administered exo-iohexol dose. Second, when administrating exogenous 
markers, proper PK modelling to determine the excretion of the marker should be 
performed. A two-compartmental model best describes the plasma concentration-time 
curve of most exogenous markers, whereas a one-compartmental model tends to 
overestimate the GFR (Peters, 2004; Van Rossum et al., 2005, Filler et al., 2014). Also in this 
doctoral thesis, a two-compartmental model with first order elimination best defines the 
plasma concentration-time curve of exo-iohexol in growing piglets, confirming the theory 
suggested by Filler et al. (2014).  
 
In this doctoral thesis, also plasma cystatin C was determined in growing piglets (eight days 
to seven weeks) (Laboratory of Clinical Chemistry, Ghent University Hospital, Ghent, 
Belgium). Remarkably, all concentrations were below the limit of detection. A possible 
explanation might be the technique is validated for humans but not yet for pigs. In the 
future, validation of porcine plasma should be performed to be able to draw any further 
conclusion on the usefulness of cystatin C as potential alternative marker to calculate the 
GFR.  
 
3.2 Estimating the glomerular filtration rate: is there an ideal equation?  
To date, determination of the true GFR is time-consuming, costly and labour-intensive. 
Therefore, many mathematical equations have been proposed to estimate the creatinine 
clearance based on readily available parameters, such as plasma creatinine concentration, 
BW, age, gender, ethnicity and body size. The most used equation in the paediatric 
population is the revised Schwartz equation (Schwartz et al., 2009): eGFR (mL/min 1.73 m²) = 
(k (0.45 for term infants during first year, 0.55 (♀)/0.75 (♂) for children) * height 
(cm))/(plasma creatinine concentration (mg/dL)). Since the equation is based on plasma 
creatinine concentrations, the GFR will be underestimated in muscular children and 




Rosenthal et al., 2007). When using equations based on the creatinine clearance, it is 
important to check which technique is being applied to determine the creatinine 
concentration, since different techniques can lead to different coefficients. Therefore, it 
might be interesting to standardize the creatinine assays and generate more universal GFR 
estimation equations, or laboratories could determine their own coefficients according to 
the techniques being used (Schwartz and Work, 2009). Moreover, the techniques being used 
should be reliable to predict the plasma creatinine concentrations in the paediatric 
population. These equations are mainly developed using patients suffering from chronic 
kidney diseases (< 60 mL/min/1.73m²) and/or patient with reduced kidney function. 
Consequently, the use of these equations is only justified in the studied population. If 
generalization of these equations is desirable, additional studies in other study populations 
are required (Stevens et al., 2006). 
 
Over the years alternative equations have been developed in the paediatric population using 
cystatin C as reference marker (Bokenkamp et al., 1998; Filler and Lepage, 2003; Hoek et al., 
2003). Adult plasma cystatin C concentrations are reached at the age of one year, enabling 
to use a single reference range of cystatin C from one year of age onwards (Finney et al., 
2000). Zachwieja et al. (2015) compared different cystatin C-based equations with the 
commonly used creatinine-based equations (Schwartz, MDRD, Cockcroft-Gault) in 353 
paediatric patients and concluded that each estimation method had its own advantages and 
limitations, not favouring one particular equation. These authors also emphasized the need 
for validated creatinine and cystatin C assays in order to be able to standardize the 
estimation equations. The same conclusions were drawn by Herget-Rosenthal et al. (2007), 
highlighting the need for improved and harmonized creatinine and cystatin C measuring 
techniques resulting in equations with less bias and more precision and accuracy. Despite 
the fact that cystatin C might be a promising alternative marker for the GFR estimation, the 
use of this marker in clinical practice is still limited due to the high cost of a single test in 
comparison with creatinine (Zachwieja et al., 2015).  
Up till this doctoral research, no equation to estimate the GFR in growing piglets was 




equation can be a useful tool for preclinical porcine studies as well as for the determination 
of correct dosage strategies for drugs that are renally excreted. The methods to develop the 
equations in this doctoral thesis (equation 1: eGFR = 1.879 * BW1.092/PCr
0.600 and equation 2: 
eGFR = 67.98 (mL/min) * (BSA/mean(BSA))1.45) were based on the Schwartz and the Leger 
equation, respectively. Both equations used exo-iohexol clearance as a reference method 
and were able to predict the GFR accurately. A good correlation between both equations (R² 
= 0.9943) was found equation (Figure 2). However, a validation study is further 
recommended, comparing both equations with the reference method using exo-iohexol in a 
larger group of piglets. Moreover, as in humans, these equations can only be used in the 
study population included during the experiments. Consequently, additional studies should 
be performed to be able to conclude if these equations can be applied to measure the GFR 
in all pigs. More breeds, more age categories (wider range: preterm and adult) and female 
pigs should be included to evaluate if one equation fits all or if it is necessary to add extra 
coefficients and constants to the equations. Furthermore, it might be interesting to also 
include different breeds of minipigs and to evaluate if these equations are also applicable for 
the minipig. Also, the possible variation in calibration of the assays among laboratories might 
lead to different coefficients, necessitating the need for standardized analytical protocols. As 
mentioned above (Section 2.1), during the experiments it was not possible to determine 
cystatin C in growing piglets. Consequently, development of a cystatin C-based equation in 
growing piglets can only be done when the analytical techniques are optimized for piglets.  
Figure 2. A positive correlation between eGFR equation 1 and eGFR equation 2 is seen in 
growing piglets aged eight days (n = 16), four weeks (n = 8), seven weeks (n = 16) and six 
months (n = 8). 
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3.3 Indexing glomerular filtration rate: is there an ideal method?  
Since the GFR represents the clearance of a substance by glomerular filtration, scaling of the 
GFR to a standard measure of body size should be performed to be able to compare GFR 
values among different populations. Different standard references could be used, e.g. body 
weight (BW), body surface area (BSA), kidney weight (KW), body length or extracellular fluid 
volume (ECFV). In human clinical practice, the GFR is traditionally normalized to a 
standardized BSA of 1.73 m², corresponding with an idealized adult BSA for an average 70 kg 
man (25-year-old) (McIntosh et al., 1928; Geddes et al., 2008). Ideally, the GFR should be 
scaled using KW, but data on KW are rarely available in clinical practice (Schwartz et al., 
2009). A linear correlation between BSA and KW has been observed in different animal 
species, e.g. dogs, rabbits, rats and humans (between 5 and 69 years of age) (Smith, 1951). 
This correlation was better than the correlation between KW and body length or BW, 
indicating that the BSA is more suitable to compare GFR values among populations. In 1916, 
the DuBois brothers proposed a height-weight equation derived from an experiment 
performed on 11 individuals, including one child: BSA (m²) = 0.007184 * weight (kg)0.425 * 
height (cm)0.725 (DuBois and DuBois, 1916). When this equation is applied to the paediatric 
population an underestimation of the BSA was observed (Haycock et al., 1987). Haycock et 
al. (1987) tried to improve this height-weight equation by including more children, but a 
single height-weight formula for all humans is difficult to establish, since the maturation of 
the body can be very different between individuals and there is a wide range of body shapes 
among the human population (Geddes et al., 2008). Despite the concerns being raised by 
several authors about the use of BSA to index GFR in the paediatric population, to date, 
indexing to BSA continues to being used in clinical practice. If the GFR is measured to 
evaluate the changes in kidney function within an individual, the type of normalization does 
not affect the clinical outcome, since the observed changes in GFR will be essentially the 
same (Geddes et al., 2008). However, when a single GFR measure is performed to guide 
clinical decisions, the type of normalization can affect the clinical outcome. Consequently, 
the question is: ‘is there a valid alternative, which is easily applicable in clinical practice?’ 
Several authors suggested the use of ECFV rather than BSA to normalize the GFR in the 
paediatric population (Peters et al., 1994; Peters et al., 2000; Bird et al., 2002). The rate 




administered GFR markers (inulin, DTPA, 51Cr-EDTA, iohexol) is a direct measure of GFR/ECFV 
(Brochner-Mortensen, 1980; Peters et al., 2000). Peters et al. (2000) regarded 12.5 L as the 
idealized adult ECFV for an average 70 kg man and demonstrated that the GFR/ECFV ratio 
tends to be similar in adults and young children. This in contrast with the GFR/BSA ratio, 
which tends to be smaller in young children (high BSA in relation to their weight). When 
comparing GFR/1.73 m² and GFR/12.5 L in the paediatric population, the GFR indexed for 
BSA is 20% lower than GFR indexed to ECFV, potentially leading to underestimating the GFR 
in children. Consequently, ECFV could be a valuable alternative to BSA in the paediatric 
population.  
 
In animals, the GFR is mostly indexed to BW, nonetheless this normalization was outdated in 
human clinical practice, because BW is mainly influenced by body fat content (Gleadhill et 
al., 1996; Bird et al., 2002). In this doctoral thesis, a comparison between three different 
methods (BW, BSA, and KW) to index the GFR in growing piglets was made to determine the 
most suitable indexation. Ideally, KW should be used to index the GFR in piglets. However, 
like in humans, it is not easy to determine KW in practice. Therefore alternatives, such as 
BSA and BW are proposed. When comparing maturation of the GFR indexed to BSA and KW, 
the increase in GFR was comparable. This is in contrast with GFR indexed to BW, were the 
increase in GFR was less pronounced. As in humans, a linear correlation (R² = 0.9962) 
between BSA and KW was also observed in pigs (Figure 3), possibly explaining the 










Figure 3. A positive correlation between mean kidney weight and mean body surface area is 
seen in growing piglets aged eight days (n = 16), four weeks (n = 8), seven weeks (n = 16) and 




The BSA in pigs can be determined using the equation of Meeh (BSA (dm²) = 9*BW (kg)2/3) 
and of Swindle (BSA (cm²) = 734*BW (kg)0.656) or the more accurate technique proposed in 
this doctoral thesis (CT-scan and 3D imaging) (Meeh, 1879; Swindle et al., 2012; Gasthuys et 
al., 2017). No significant differences (p < 0.05) were observed between the three methods. 
However, a small underestimation of the BSA was observed with both the Meeh (Δ = -3.82 
dm²) and the Swindle equation (Δ = -9.82 dm²) in comparison with 3D imaging. Different 
explanations can be found for this observation: (i) different breeds used, (ii) different age 
categories included, (iii) more/less sensitive techniques used. The Meeh and Swindle 
equations are easily to apply in practice, however, it would be interesting to refine these 
equations by including more breeds, more age categories and perform 3D imaging to 
determine the BSA. As in humans, also in pigs, the question can be raised whether or not it is 
more evident to scale on a volume-based whole-body variable (ECFV) rather than on an 
area-based whole-body variable (BSA). Additional studies should be performed to determine 
if ECFV is a valuable alternative to BSA and how the GFR/ECFV ratio changes during growth 
and maturation.  
 
3.4 Maturation of the glomerular filtration rate: is the pig an ideal model?  
Kleinman (1982) defined the three stages of GFR maturation: (i) equivalent rate of increase 
in GFR and kidney mass, (ii) greater rate of increase in GFR than kidney mass, followed by (iii) 
again equivalent rate of increase in GFR and kidney mass (Zoetis and Hurt, 2003). In humans, 
newborns have a low GFR at birth, which increases during the first eight weeks of life until it 
reaches adult values by one year of age (Schwartz et al., 2007). Comparable results were 
obtained in this doctoral thesis (Figure 4). The total GFR is an index of functioning renal 
mass, since the GFR is the product of filtration rate in each nephron (single nephron GFR) 
multiplied by the number of filtering nephrons in both kidneys (Filler et al., 2014). 
Consequently, maturation can be due to an increase in filtration rate or an increase in 
number of functioning nephrons or both. In humans, all nephrons are anatomically 
differentiated at 36 weeks of gestation, however only the juxtamedullary glomeruli are 
functional. Until 18 to 24 months of age, continuous recruitment of additional glomeruli 




was attributed to an increasing RBF and a higher capillary pressure (Spitzer and Edelmann, 
1971; Guignard et al., 1975; Friis, 1979). The increase in RBF is due to a decrease in renal 
vascular resistance and an increased cardiac output (Gruskin et al., 1970).  
 
 
Figure 4. Maturation of the glomerular filtration rate of conventional pigs (purple) and 
humans (pink) (Schwartz et al., 2007; Gasthuys et al., 2017). Results are presented as mean + 
SD for pig data.  
 
To appropriately define the added value of the pigs among the more traditional juvenile 
animal models (rodents, dog and non-human primates), it is necessary to evaluate the 
different comparative processes involved in the anatomical and the physiological maturation 
of the kidney. In rats, dogs and piglets, postnatal completion of nephrogenesis appears, 
whereas in mice, non-human primates and humans nephrogenesis is completed at birth 
(Frazier, 2017). The GFR is mature after 42 days, 28 to 32 days, 6 weeks, 8 weeks and 5 
months of age in rats, mice, dogs, piglets and non-human primates, respectively (Frazier, 
2017). When looking at piglets in specific, Friis (1979) demonstrated that despite a 
difference in anatomical maturation of the porcine kidney, the functional maturation of pigs 
and humans is comparable. These results were confirmed by this doctoral thesis (Figure 4). 
Therefore, appropriate comparative anatomical and functional maturation of the kidney 
function should be taken into account when comparing different species. Moreover, the 












































clearance? Huh et al. (2011) gave an overview of interspecies scaling and prediction of 
human renal clearance for both small- and macro-molecule drugs. These authors concluded 
that a single species, with preference to non-human primates > mouse > rat > dog, can be 
used to predict human clearance of macro-molecule drugs with an optimal allometric 
exponent of 0.80. Small-molecule drug clearance predictions using a single species, namely 
monkey, can be performed with an optimal allometric exponent of 0.65. The other species 
could be used as well, however, the predictions obtained with the other species were less 
accurate (higher average fold factor). No literature was found about the suitability of pigs 
and minipigs to predict human clearance. Moreover, no allometric exponent was established 
in these species. Additional studies should be performed to evaluate the estimation accuracy 







Despite the worldwide use of desmopressin to treat nocturnal enuresis in children, clinical 
studies in the paediatric population are still lacking. To date, most studies investigating the 
PK of desmopressin in this population applied a sparse sampling protocol on a limited 
number of patients (Osterberg et al., 2006 (n = 84); De Bruyne et al., 2016 (n = 23)). 
Moreover, the dosing schedules applied in the paediatric population were derived from 
studies performed in adults (Vande Walle et al., 2006). Informative animal models, such as 
the conventional piglet, can be used to perform full PK, PD and safety studies to provide 
additional information on sampling strategies, therapeutic ranges and drug toxicity for 
human paediatric clinical trials.  
 
4.1 PK of desmopressin: is the pig an ideal animal model? 
Before performing a PK/PD study of desmopressin, the effect of time of dosing (day or night) 
on the PK and PD parameter values needs to be considered, since desmopressin is used to 
treat nocturnal enuresis and contradictory most studies are performed during daytime. 
Rembratt et al. (2004) evaluated this effect in men aged 55 to 70 years and concluded that 
no clinically relevant differences were observed dependent on time of dosing. To the 
authors’ knowledge, no such studies exist in the paediatric population. Also in this doctoral 
thesis, the experiments were performed during daytime and the effect of day- versus night-
time was not considered. In the future, additional studies should be performed in both 
piglets and children to investigate whether desmopressin exhibits circadian variation. Also a 
possible gender effect on the PK of desmopressin should be determined in piglets to 
evaluate if the results obtained in this thesis can be correlated with the results obtained in 







Desmopressin is an oligopeptide and it is expected that most orally administered peptides 
are hydrolysed before being able to reach absorption sites in the gastro-intestinal tract 
(Skoog et al., 1997). The bioavailability following oral administration (0.1%) was lower in 
comparison to nasal administration (3-5%), leading to lower efficacy and duration of action 
of desmopressin (Fjellstad-Paulsen et al., 1993). This low bioavailability can be explained by 
the size (molecular weight > 1,000 Da) and the ionised arginine residue of the compound, 
restricting paracellular absorption of desmopressin (Lawton and Witty, 2013). Despite the 
lower bioavailability, the amount of desmopressin reaching the systemic circulation and 
subsequently reaching the vasopressin receptors is sufficient to attain adequate antidiuretic 
responses (Vande Walle et al., 2006). This can possibly be attributed to a high affinity of 
desmopressin to its receptor and high plasma stability of desmopressin (Lawton and Witty, 
2013). Since the bioavailability in growing piglets is not known, the apparent clearance and 
apparent volume of distributions were presented in the current study. The age-related 
differences observed in this study might be attributed to a significant difference in 
bioavailability. Since the bioavailability is very low in humans, which might also be the case 
in piglets, a small difference in bioavailability could potentially lead to a significant difference 
in clearance and volume of distribution. This should be confirmed by performing a cross-over 
study in growing piglets administered desmopressin both orally (sublingual tablet and 
conventional tablet) and intravenously.  
 
In both adults and children, a significant effect of food intake on the absorption of 
desmopressin was observed (Rittig et al., 1998; Norgaard, 1999; Michelet et al., 2016). A 
reduction and delay in absorption was observed when the patients were fed. In the current 
study, the effect of food was not evaluated. In each age category the following standardized 
protocol was applied: food was removed 2 h prior to desmopressin administration and food 
was given 1.5 h post-administration. This protocol was chosen since depriving food from the 
youngest age category longer than 4 h might cause hypoglycaemia. The effect of food intake 





In the present study, a two-compartmental pop-PK model with absorption described by a 
dual input function best fitted the data. Such a dual input function was required to describe 
the double peak phenomenon in the absorption phase of the plasma concentration-time 
curves. Despite research about desmopressin sublingual tablets being performed for more 
than 10 years, no such observation has been made before. It might be possible that this 
phenomenon can be attributed to pigs, however the lack of adequate sampling in the 
absorption phase can also be a possible explanation. Michelet et al. (2017, accepted) also 
found that the true plasma concentrations are possibly underestimated in their previously 
published PK/PD model in humans (Michelet et al., 2016). These underestimations are 
possibly linked to insufficient blood sampling during the absorption phase, potentially 
missing a larger or second peak in the plasma concentration-time curves. To further 
substantiate this hypothesis a well-designed PK study with multiple blood sampling during 
the absorption phase should be performed in the paediatric population. Currently, a 
paediatric clinical study is performed at Ghent University Hospital and adaptations of the 
sampling protocol according to the sampling points used in piglets in this doctoral thesis, and 
proposed by Michelet et al. (2017, submitted) were made. 
 
When developing new drugs for the paediatric population, carefully selecting or developing 
appropriate formulations for this population is essential to increase patient compliance. 
Over the years different desmopressin formulations have been developed of which the 
conventional and sublingual tablet are preferred (Lottmann et al., 2007). Bioequivalence 
studies between these formulations are rather scarce. In adult humans, a greater 
bioavailability for the sublingual tablet was demonstrated, i.e. a 60 µg sublingual tablet 
corresponded to a 100 µg conventional tablet (Vande Walle et al., 2006). These findings 
were also confirmed in the paediatric population by De Bruyne et al. (2014). Bioequivalence 
between a 120 µg sublingual tablet and a 200 µg conventional tablet was established. 
However, the results obtained by Michelet et al. (2016) suggested that a 150 µg rather than 
a 120 µg sublingual tablet corresponds better with a 200 µg conventional tablet in the 
paediatric population. This is possibly due to a reduced sublingual absorption in the 
paediatric population in comparison with adults. In this doctoral research, there was a 




the need for water and it is more practical to administer in pigs. However, in the future, 
bioequivalence studies comparing both formulations in growing piglets can be relevant to 
estimate bioequivalence in the paediatric population. Moreover, if in the future new 
vasopressin analogues and different formulations of these analogues (adult versus child) are 
going to be developed, piglets can also be useful models to predict the bioequivalence 
between these formulations in both the paediatric and adult population.  
 
In this doctoral thesis, a single dose of desmopressin was administered to evaluate the effect 
of growth and maturational changes on the PK parameter values of desmopressin. However, 
a dose-escalation scheme in growing piglets might also be interesting to find the most 
suitable doses for the different age categories, and eventually to extrapolate these results to 
the human paediatric population. Since no PD effects were observed in piglets, dosing 
regimens can only be constructed based on PK parameters. Next to the correct dosage 
regimen also the amount of drugs (large size or multiple dosing) administered should be 
carefully selected for the different formulations, since optimal dosages but large amounts of 
drugs might lead to a decrease in patient compliance, potentially leading to suboptimal 
dosing. Consequently, dosing regimens should be counterbalanced against the amount of 
drugs required to reach an optimal effect.  
 
4.2 PD of desmopressin: is the pig an ideal animal model?  
Two types of vasopressin can be found in animals. Humans secrete arginine vasopressin, 
whereas pigs secrete mainly lysine vasopressin and to a smaller extent arginine vasopressin 
(Braileanu et al., 2001). In pigs, the arginine in position eight of vasopressin is replaced by 
lysine. So the main question was: “is the pig suitable to study the effect of arginine 
vasopressin and its synthetic analogues or can it only be used to study the effect of lysine 
vasopressin?” Munsick et al. (1958) determined the antidiuretic potency of arginine and 
lysine vasopressin in pigs weighing 15 to 30 kg. They observed the antidiuretic responses 
(urinary volume and osmolality) to both hormones and concluded that lysine vasopressin 




receptor to compare it with the human receptor and to determine the ligand affinity of 
lysine vasopressin and arginine vasopressin. A good correlation between the porcine and 
human receptor was demonstrated with 90%, 80% and 62% identity for their 
transmembrane, C-terminal and N-terminal domains, respectively. The ligand affinity of 
lysine vasopressin in humans was much lower in comparison with arginine vasopressin. In 
pigs however, the ligand affinity of lysine and arginine vasopressin was comparable. These 
observations render the pig a suitable model to study the effects of arginine vasopressin and 
its analogues in growing piglets. Despite the good binding affinity of arginine vasopressin, 
Ufer et al. (1995) (in vitro) and this doctoral thesis (in vivo) demonstrated that the pig is not 
a suitable model to evaluate the PD of desmopressin. Since the lack of binding is attributed 
to sterical hindrance of a configuration specific for desmopressin, the pig might still be a 
valuable animal model for testing other synthetic analogues of both lysine and arginine 
vasopressin.  
 
On condition, the pig might be used for other vasopressin analogues, however, development 
of an appropriate protocol to determine the PD parameters of these compounds is essential. 
Major PD parameters studied in this doctoral thesis and in paediatric clinical trials are 
osmolality, urinary volume and sodium concentration. The osmolality and urinary volume 
were included to assess the antidiuretic effects, whereas the sodium concentration was 
determined to evaluate if hyponatremia occurred, potentially causing severe side effects. 
The current study protocol was assessed in association with Ghent University Hospital to 
align the protocols used in both nonclinical and clinical studies. Some suggestions to further 
optimize the current study design in the future can be formulated. It is important to notice 
that the current study was only performed in male piglets, since to the authors’ knowledge, 
no technique exists to collect urine in female piglets according to the protocol applied in the 
male piglets (timed whole voids). Therefore, it is essential to continue the search for urine 
collection techniques suitable for female piglets to be able to evaluate gender differences in 
antidiuretic response to vasopressin analogues. Moreover, it might be interesting to 
standardize the fluid intake according to the milk consumption required by the eight-day-old 
piglets. De Guchtenaere et al. (2009) evaluated the effect of concomitant fluid and 




during the night) and a fluid loaded group (15 mL/kg, twice a night). Restriction of fluid one 
hour prior to desmopressin administration was suggested by the authors in order to 
maximize urine concentration capacity. Also the effect of food intake has to be considered. 
Rittig et al. (1998) evaluated the effect of food on the antidiuretic activity of desmopressin in 
adults and found no significant differences between fasted and fed patients. In the future, 
when studying other vasopressin analogues in piglets, the effect of fluid and food intake 
should be taken into account when drafting the study protocol. To determine optimal dosing 
schedules, evaluating when antidiuretic responses are required to treat nocturnal enuresis is 
essential. Norgaard et al. (1989) demonstrated that most children suffering from nocturnal 
enuresis have an enuretic event during the first hours of the night. Consequently, it might be 
sufficient to only have an antidiuretic response during this period, which can be achieved 
with lower doses (Vande Walle et al., 2006). A piglet model might be interesting to evaluate 
the dose required to achieve sufficient antidiuretic responses without under- (suboptimal 





5. Future Perspectives 
‘Take small steps every day and eventually you will get there’ 
To date, the use of conventional piglets as potential paediatric animal models is not yet 
established in the pharmaceutical industry. Main reasons are the lack of information on the 
ontogeny of the different organ systems and ADME processes, the lack of studies validating 
the conventional piglet as potential animal model and some practical reasons with respect 
to the amount of drug available in early discovery phase. To further establish the usefulness 
of the conventional piglets as potential juvenile animal models to perform PK, PD and safety 
studies, additional and more extensive studies should be performed. 
First, the technical aspects of the piglet model as such should be further developed and 
characterized. This doctoral thesis only focused on the development of blood and urine 
collection techniques in growing piglets. Blood collection in both male and female piglets 
and urine collection in male piglets was performed without any technical complications, but 
an urine collection technique in female piglets is still lacking. Consequently, new techniques, 
e.g. other collection bags, Foley catheters, cystocentesis, could be tested and evaluated in 
female piglets. Also the suitability to use pigs for other drug formulations/routes of 
administration frequently used in the paediatric population and multiple dosing should be 
assessed. Furthermore, there is a need for advanced techniques to evaluate different 
parameters (e.g. blood pressure, tissue distribution, organ blood flow) when performing PK, 
PD and safety studies. Some techniques have never been tested before in pigs in general or 
more specific in growing piglets. Therefore, additional studies are required to develop and 
optimize these techniques. Moreover, additional age categories could be included (preterm). 
Second, maturation of the different factors influencing the ADME processes should be 
explored and compared with humans in the different age categories (neonate, infant, child 
and adolescent). Many physiological factors will influence the rate and the extent of 
absorption of drugs, such as solute carrier/ABC transporters and enzymes functions. 
Moreover, the concomitant administration of drugs and food or milk can also influence the 
absorption of drugs. Today, little is known about the maturation of those factors in growing 
piglets. Consequently, experiments could be performed to characterize the gastro-intestinal 




of drugs is influenced by protein binding (capacity and binding affinity) and physicochemical 
characteristics of the drug (pKa, lipid solubility, molecular weight) on the one hand, and body 
composition on the other hand. The contribution to the extent of distribution by plasma and 
tissue protein binding and the free fraction in tissues should be evaluated for the tested 
drugs. The key organs involved in metabolization of drugs are liver, intestine and kidney. 
CYP450 biotransformation pathways are of major importance in drug metabolization and 
still little is known about the maturation in pigs. Therefore, it is important to characterize the 
maturation of intestinal, hepatic and renal CYP450 enzymes in piglets. Biliary and renal 
excretion are the predominant routes of excretion of drugs. The GFR is a major drug 
excretion pathway and the maturation was described in this doctoral thesis. Besides GFR, 
maturation of active tubular drug secretion and reabsorption should be determined as well 
since these are quantitatively major processes for some drugs, e.g. beta-lactam antibiotics. 
Third, the studies that were performed in this doctoral thesis and proposed above are all 
performed in healthy piglets. In preclinical animal studies, it is not always easy to mimic the 
exact ‘illness or condition’ the child is suffering from. Therefore, it would be useful to 
develop juvenile porcine models taking the disease state of the child into account. One 
example is the development of a sepsis model, which can be useful to predict the PK of 
antibiotics in critically ill children suffering from sepsis, leading to appropriate antibiotic 
treatment and reducing the mortality rate in this population.  
Last, validation of the conventional piglet model should be done by performing PK, PD and 
safety studies in growing piglets and comparing the results with the results obtained in 
clinical studies performed in the paediatric population. It is important that most drug classes 
and even biologicals will be used for validation of the pig model. Therefore, literature search 
should be performed and hospitals around the world should be contacted for the search of 
potential drug candidates. No contraindications for the use of piglets for a certain drug 
should be found in literature and enough paediatric data should be available to be able to 
make a comparison between humans and pigs. Some model drug classes include 
antimicrobials, NSAIDs and ACE-inhibitors. After literature search, proper PK, PD and safety 




Following preclinical animal studies, the obtained data are usually analysed by conventional 
compartmental PK modelling approaches. These are data-driven approaches in which the 
model structure is defined by the data and is therefore empirical. This requires 
comprehensive preclinical animal studies, since rich sampling strategies are needed. In 
contrast, physiologically based pharmacokinetic or PBPK modelling could be used to 
simulate the plasma concentration-time profile, by integrating the physicochemical 
properties of the compound with the physiology of the species. This mechanistic approach 
aims to describe the PK of drugs within the body in relation to blood flows, tissue volumes, 
routes of administration, biotransformation and excretion pathways, and interactions with 
the tissue or organ. In the future, a pig PBPK model accounting for the actual physiology, 
anatomy and biochemistry encountered in the pigs’ body, including maturational changes, 
should be developed. This model can be used to predict the PK parameters of drugs in 
piglets as a preclinical animal model.  
This doctoral research was conducted as partner of the SAFE-PEDRUG consortium, which 
aims to improve the availability of correctly labelled, safe and effective drugs in the 
paediatric population. The consortium is a collaboration between different institutes, 
including Ghent University Hospital, Ghent University Faculties of Veterinary Medicine and 
of Pharmaceutical Sciences, VUB and Catholic University of Leuven. Moreover, a cooperation 
between these institutes, the pharmaceutical industry and regulatory authorities was 
established. In the future, these collaborations should be extended. Moreover, more 
stakeholders should be added to the consortium to further identify the knowledge gaps in 
paediatric drug development and to further expand the consortium with experts in their 
fields. A collaboration between the different stakeholders should eventually lead to the 
development of a paediatric expert unit and paediatric clinical trial unit, comparable to the 
adult D.R.U.G.-unit (Drug Research Unit Ghent) in Ghent University Hospital, where 
preclinical and clinical trials could be performed. Furthermore, this consortium should advice 
the authorities on what are the minimal requirements for paediatric studies to reach optimal 






In conclusion, this doctoral thesis demonstrated the usefulness of growing conventional 
piglets to study drugs excreted by the kidney. The suitability of this animal model was 
proven by evaluating the maturation of the kidney function expressed as GFR, and 
performing a full PK/PD study of the model compound desmopressin. However, this doctoral 
thesis also demonstrated that the conventional pig might be inappropriate to study the PD 
of desmopressin. To further evaluate the appropriateness and added value of the 
conventional pig among the traditional animal models, a lot of extensive research has to be 
done about the ontogeny of other ADME processes in growing piglets. Moreover, a 
comparative analysis of the ontogeny of the disposition of drugs between humans and pigs 






Baldrick P. Juvenile animal testing in drug development – is it useful? Reg Tox Pharm 2010; 
57:291-299. 
Bavdekar SB. Pediatric clinical trials. Perspect Clin Res 2013; 4(1):89-99. 
Bird N, Henderson B, Lui D, et al. Indexing glomerular filtration rate to suit children. J Nucl 
Med 2003; 44:1037-1043. 
Bokenkamp A, Domanetzki M, Zinck R, et al. Cystatin C – a new marker of glomerular 
filtration rate in children independent of age and height. Pediatrics 1998; 101(5):875-
881. 
Braileanu GT, Simasko SM, Hu J, et al. Effects of arginine- and lysine-vasopressin on 
phospholipase C activity, intracellular calcium concentration and prostaglandin 
F2alpha secretion in pig endometrial cells. Reproduction 2001; 121(4):605-612. 
Brasseur D. Paediatric research and the regulation "better medicines for the children in 
Europe". Eur J Clin Pharmacol 2011; 67:S1-S3. 
Brochner-Mortensen J. A simple single injection method for the determination of the 
extracellular fluid volume. Scand K Clin Lab Invest 1980; 40:567-573. 
Buelke-Sam J. Comparative schedules of development in rats and humans: implications for 
developmental neurotoxicity testing. Presented at the 2003 Annual Meeting of the 
Society of Toxicology, Salt Lake City. 
De Bruyne P, De Guchtenaere A, Van Herzeele C, et al. Pharmacokinetics of desmopressin 
administered as tablet and oral lyophilisate formulation in children with 
monosymptomatic nocturnal enuresis. Eur J Pediatr 2014; 173:223-228. 
De Guchtenaere A, Raes A, Vande Walle C, et al. Evidence of partial anti-enuretic response 
related to poor pharmacodynamic effects of desmopressin nasal spray. J Urol 2009; 
181(1):302-309. 
Delanghe JR. How to establish glomerular filtration rate in children. Scand J Clin Lab Invest 
Suppl 2008; 241:46-51. 
DuBois D, DuBois E. A formula to estimate the approximate surface area if height and weight 
be known. Arch Intern Med 1916; 17:863-871. 
EMA. Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals 
for paediatric indications. EMEA/CHMP/SWP/169214/2005. 2008. 
EMA. 10 year Report to the European Commission: General report on the experience 
acquired as a result of the application of the Paediatric Regulation. 2016. 
FDA. Guidance for industry: non-clinical safety evaluation of pediatric drug products. 2006. 
Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin 
C formula? Pediatr Nephrol 2003; 18(10):981-985. 
Filler G, Yasin A, Medeiros M. Methods of assessing renal function. Pediatr Nephrol 2014; 
29:183-192. 
Finney H, Newman D, Thakkar H, et al. Reference ranges for plasma cystatin C and creatinine 
measurements in premature infants, neonates, and older children. Arch Dis Childh 
2000; 82:71-75. 
Fjellstad-Paulsen A, Hogland P, Lundin S, et al. Pharmacokinetics of 1-deamino-8-D-arginine 
vasopressin after various routes of administration in healthy volunteers. Clin 
Endocrinol 1993; 38:177-182. 
Frazier KS. Species differences in renal development and associated developmental 




Friis C. Postnatal development of renal function in piglets – glomerular filtration rate, 
clearance of PAH and PAH extraction. Biol Neonate 1979; 35(3-4):180-187. 
Gasthuys E, Vandecasteele T, De Bruyne P, et al. The potential use of piglets as human 
pediatric surrogate for preclinical pharmacokinetic and pharmacodynamic drug 
testing. Curr Pharm Des 2016; 22:1-17. 
Gasthuys E, Millecam J, Sys S, et al. Assessing the postnatal maturation of the glomerular 
filtration rate in piglets as potential juvenile animal models by measuring and 
estimating the glomerular filtration rate. Front Pharmacol 2017; 8(431):1-7. 
Geddes CC, Woo YM, Brady S. Glomerular filtration rate – what is the rationale and 
justification of normalizing for body surface area? Nephrol Dial Transplant 2008; 
23:4-6. 
Gleadhill A. Quantitative assessment of renal function in domestic animals: measurement of 
glomerular filtration rate by the plasma clearance of technetium-
diethylenetriaminepentacetic acid (dissertation). London, University of London 1996. 
Gorbulev V, Büchner H, Akhundova A, et al. Molecular cloining and functional 
characterization of V2 (8-lysine) vasopressin and oxytocin receptors from a pig kidney 
cell line. Eur J Biochem 1993; 215:1-7. 
Gruskin AB, Edelmann CM, Yuan S. Maturational changes in renal blood flow in piglets. 
Pediatr Res 1970; 4(1): 7-13. 
Guignard JP, Torrado MD, Da Cunha O, et al. Glomerular filtration rate in the first three 
weeks of life. J Pediat 1975; 87(2):268-272.  
Hansen CP, Bie P, Stadil F. Assessment of renal function by 51Cr-EDTA and endogenous 
creatinine clearances in the pig. Acta Physiol Scand 1997; 161:253-260. 
Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: 
a height and weight formula validated in infants, children and adults. J Pediatr 1987; 
93:62-66. 
Hellerstein S, Berenbom M, Alon US, et al. Creatinine clearance following cimetidine for 
estimation of glomerular filtration rate. Pediatr Nephrol 1998; 12:49-54. 
Herget-Rosenthal S, Bökenkamp A, Hofmann W. How to estimate GFR - serum creatinine, 
serum cystatin C or equations? Clin Biochem 2007; 40:153-161. 
Hoberman AM, Lewis EM. Non-clinical drug testing: principles, requirements and practices. 
New Jersey: John Wiley & Sons 2012. 
Hoek F, Kemperman F, Krediet R. A comparison between cystatin C, plasma creatinine and 
the Cockcroft and Gault formula for the estimation of glomerular filtration rate. 
Nephrol Dial Transplant 2003; 18(10):2024-2031. 
Huh Y, Smith DE, Feng MR. Interspecies scaling and prediction of human clearance: 
comparison of small- and macro-molecule drugs. Xenobiotica 2011; 41(11):972-987. 
ILSI. Principles and practices for direct dosing of pre-weaning mammals in toxicity testing 
and research. In Zoetis, Tracey, Walls, Isabel, A report of the ILSI risk science institute 
expert working group. ILSI Press 2003. 
Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - Drug 
disposition, action, and therapy in infants and children. New Engl J Med 2003; 
349(12):1157-1167. 
Kearns GL. Beyond biomarkers: an opportunity to address the ‘pharmacodynamic gap’ in 
pediatric drug development. Biomarkers Med 2010; 4(6):783-786. 
Kehr KK, Schnaper HW, Greenbaum LA. Clinical pediatric nephrology. New York: CRC press: 




Kerl M, Cook C. Glomerular filtration rate and renal scintigraphy. Clin Tech Small Anim Pract 
2005; 20(1):31-38. 
Kimland E, Odlind V. Off-Label drug use in pediatric patients. Clin Pharmacol Ther 2012; 
91:796-801. 
Klassen TP, Hartling LH, Craig C, et al. Children are not just small adults: the urgent need for 
high-quality trial evidence in children. PLoS Med 2008; 5(8):e172 
Kleinman LT. Developmental renal physiology. Physiologist 1982; 25:104-110. 
Lawton G, Witty DR. Progress in medicinal chemistry. The Netherlands: Elsevier 2013. 
Lehmann B. Arzeneimittel für Kinder. Z Phytother 2010; 31:9-12. 
Lottmann H, Froeling F, Alloussi S, et al. A randomized comparison of oral desmopressin 
lyophilisate (MELT) and tablet formulations in children and adolescents with primary 
nocturnal enuresis. Int J Clin Pract 2007; 61(9):1454-1460. 
Meeh K. Oberflächenmessungen des menschlichen körpers. Ztschl Biol 1879; 15:425-458. 
McIntosh JF, Moller E, Van Slyke DD. Studies of urea excretion: III. The influence of body size 
on urea output. J Clin Invest 1928; 6:467-483. 
Michelet R, Dossche L, De Bruyne P, et al. Effects of food and pharmaceutical formulation on 
desmopressin pharmacokinetics in children. Clin Pharmacokinet 2016; 55:1159-1170. 
Michelet R, Dossche L, van Herzeele C, et al. Claiming desmopressin therapeutic equivalence 
in children requires pediatric data: a population PKPD analysis. (2017, accepted Eur J 
Clin Pharm). 
Munsick RA, Wilbur H, Sawyer HB. The antidiuretic potency of arginine and lysine 
vasopressins in the pig with observations on porcine renal function. Endocrinology 
1958; 63(5):688–693. 
Norgaard JP, Hansen JH, Nielsen JB, et al. Nocturnal studies in enuretics. A polygraphic study 
of sleep-EEG and bladder activity. Scand J Urol Nephrol Suppl 1989; 125:73-78. 
Norgaard JP. A clinical and pharmacological model for explaining response to desmopressin. 
Scand J Urol Nephrol 1999; 202:53-55. 
Odeberg JM, Callréus T, Lundin S, et al. A pharmacokinetic and pharmacodynamic study of 
desmopressin: evaluating sex differences and the effect of pre-treatment with 
piroxicam, and further validation of an indirect response model. J Pharm Pharmacol 
2004; 56(11):1389-1398. 
Osterberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administered 
as an oral lyophilisate dosage form in children with primary nocturnal enuresis and 
healthy adults. J Clin Pharmacol 2006; 46:1204-1211. 
Peters AM, Gordon I, Sixt R. Normalization of glomerular filtration rate in children: body 
surface area, body weight or extracellular fluid volume? J Nucl Med 1994; 35(3):438-
444. 
Peters AM, Henderson BL, Liu D. Indexed glomerular filtration rate as function of age and 
body size. Clin Sci (Lond) 2000; 98(4):439-444. 
Peters AM. The kinetic basis of glomerular filtration rate measurement and new concepts of 
indexation to body size. Eur J Nucl Med Mol Imaging 2004; 31:137-149. 
Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and 
pharmacodynamics of desmopressin administered orally versus intravenously at 





Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and 
antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin 
Endocrinol 1998; 48:235-241. 
Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic 
kidney disease. Pediatr Nephrol 2007; 22:1839-1848. 
Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate the GFR in children 
with CKD. J Am Soc Neprhol 2009; 20:629-637. 
Schwartz and Work. Measurement and estimation of GFR in children and adolescents. Clin J 
Am Soc Nephrol 2009; 4:1832-1843. 
Silva-Lima B. Due Theilade-Thomsen M, Carleer J, et al. Juvenile animal studies for the 
development of paediatric medicines: a description and conclusions from a European 
medicines agency workshop on juvenile animal testing for non-clinical assessors. 
Birth Defects Res B Dev Reprod Toxicol 2010; 89:467-473. 
Skoog SJ, Stokes A, Turner KL. Oral desmopressin: a randomized double-blind placebo 
controlled study of effectiveness in children with primary nocturnal enuresis. J Urol 
1997; 158:1035-1040. 
Smith H. The kidney: structure and function in health and disease. New York: Oxford 
University Press 1951. 
Soellner L, Olejniczak K. The need for juvenile animal studies – a critical review. Reg Tox 
Pharm 2013; 65:87-99. 
Spitzer A, Edelmann CM. Maturational changes in pressure gradients for glomerular 
filtration. Am J Physiol 1971; 221:1431-1435. 
Stevens L, Coresh J, Greene T, et al. Assessing kidney function - measured and estimated 
glomerular filtration rate. N Eng J Med 2006; 354:2473-2483. 
Swindle M, Makin A, Herron A, et al. Swine as models in biomedical research and toxicology 
testing. Vet Pathol 2012; 49(2):344-356. 
Ufer E, Postina R, Gorbulev V, et al. An extracellular residue determines the agonist 
specificity of V2 vasopressin receptors. FEBS letters 1995; 362:19-23. 
Vande Walle J, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of 
desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. 
BJU Int 2006; 97:603-609. 
van Rossum LK, Cransberg K, de Rijke YB, et al. Determination of inulin clearance by single 
injection or infusion in children. Pediatr Nephrol 2005; 20:777–781.  
WMA. Code of ethics of the world medical association: declaration of Helsinki. Helsinki, 
Finland: BMJ 1964; Vol 2, p. 177. 
Zachwieja K, Korohoda P, Kwinta-Rybicka J, et al. Which equation should and which equation 
should not be employed in calculating eGFR in children. Adv Med Sci 2015; 60(1):31-
40. 
Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. 





























The General Introduction of this doctoral thesis first described a general overview of 
paediatric drug development, with focus on paediatric animal models. Since the general aim 
of this doctoral thesis was to develop a juvenile porcine animal model, a comparative 
literature review about the absorption and disposition of drugs in both humans and pigs was 
performed. The main focus was on the renal excretion of drugs, more specifically on the 
ontogeny of the glomerular filtration rate (GFR), which is a major drug excretion pathway. 
Furthermore, the model drug used in this doctoral research, desmopressin, was introduced 
with respect to its pharmacokinetic (PK), pharmacodynamic (PD), and safety profile and 
therapeutic use in paediatrics.  
The General Aim of this doctoral thesis was to determine if conventional pigs are potential 
biomedical animal models to perform preclinical paediatric studies. The anatomical and 
physiological similarities between adult pigs and humans are striking, rendering the adult pig 
a suitable preclinical animal model for PK, PD and safety studies in adult humans. The adult 
pig is a valuable alternative to rodents, rabbits, dogs, minipigs and non-human primates. 
However, to date, the suitability of growing conventional piglets as a preclinical model for 
the paediatric population still needs to be evaluated. 
To evaluate if the pig is a suitable animal model, first, suitable sampling techniques to 
repetitively collect blood and urine in growing piglets aged eight days, four weeks and eight 
weeks needed to be optimized and validated. Chapter I evaluated several blood collection 
techniques in growing piglets (♀/♂) and non-invasive urine collection in male growing 
piglets. Both catheterization of the jugular vein with a double lumen catheter (age eight 
days, four weeks) as well as direct venepuncture of the jugular vein with a Venoject® system 
(age four weeks, eight weeks) were evaluated and these techniques were well tolerated. 
Catheterization of the jugular vein was preferred since this is a more ethical method of 
collecting multiple blood samples in growing piglets. Moreover, this technique makes it 
possible to administer drugs intravenously. A non-invasive urine collection technique in male 
piglets was developed using urine collection bags. This technique cannot be used in female 
piglets, since it was not possible to attach the urine pouches to the perineum of the pigs, 




Since the main focus of this doctoral thesis is on drug excretion, it is important to determine 
the maturation of the GFR. On the one hand, it is essential to evaluate which technique is 
the most accurate and applicable in practice to determine the GFR. On the other hand, it is 
useful to develop an equation, comparable to the equation described by Schwartz et al. 
(2009), to be able to estimate the GFR with only one blood sample. In Chapter II, two 
different approaches were used to determine the ontogeny of the GFR. On the one hand, 
the maturation of the GFR was determined using two different markers, namely creatinine 
(Jaffe and enzymatic assay) and exo-iohexol (compartmental PK) (Chapter II.i). On the other 
hand, the maturation of the GFR of piglets was described based on “non-linear mixed effects 
modelling (NLME)” of exo-iohexol plasma concentration-time profiles (population PK or 
popPK) (Chapter II.ii). A single bolus of iohexol (64.7 mg/kg BW) was administered 
intravenously to piglets aged eight days (n = 16), four weeks (n = 8), seven weeks (n = 16) 
and six months (n = 8). Blood and urine were subsequently sampled at different time points. 
The endogenous creatinine concentrations were determined in blood and urine using Jaffe 
and enzymatic assays. An in-house developed and validated HPLC-UV method was used to 
determine the exo-iohexol plasma concentrations. The clearance of both markers was 
calculated and the results were normalized to body weight, body surface area and kidney 
weight. No significant differences were observed between the different techniques. More 
specifically, the clearance of both creatinine (Jaffe, enzymatic) and exo-iohexol were 
comparable, as well as the clearance obtained with compartmental or population PK 
analysis. Furthermore, the GFR values obtained in the current studies were comparable to 
humans (neonate: pig: 42 mL/min/m², human: 39 mL/min/1.73 m²; infant: pig: 65 
mL/min/m², human: 58 mL/min/1.73 m²; child: pig: 99 mL/min/m², human: 103 
mL/min/1.73 m²; adolescent: pig: 121 mL/min/m², human: 127 mL/min/1.73 m²). It can be 
concluded that the pig is a convenient juvenile animal model for studying the GFR in the 
paediatric subpopulation, and for evaluating the PK of renally excreted drugs that are mainly 
filtrated. To facilitate the assessment of the GFR in growing piglets in subsequent studies, 
two equations were elaborated to estimate the GFR. The first equation is based on plasma 
creatinine concentrations (PCr) and body weight (BW) of conventional piglets: eGFR (mL/min) 
= 1.879 x BW1.092/PCr
0.600. The second equation (population PK) is based on exo-iohexol 
clearance and body surface area (BSA) of piglets: exo-iohexol clearance (mL/min) = 67.98 x 




To evaluate the pig as a potential model, a PK/PD study with the vasopressin analogue 
desmopressin was performed (Chapter III). An oral lyophilisate (120 µg) was administered to 
32 male piglets aged eight days, four weeks, seven weeks and six months (n = 8 for each age 
category). Eight additional piglets aged eight days (control group) were included to compare 
the PD parameters (urinary volume, osmolality and sodium concentration) between control 
and desmopressin groups. Blood and urine samples were collected at different time points 
and plasma desmopressin concentrations were determined using a radio-immunoassay. 
Population PK analysis was performed to derive the values of the PK parameters of 
desmopressin. Desmopressin plasma concentration-time curves best fitted a two-
compartmental model, with dual, sequential first-order absorption, and first-order 
elimination. Body weight was the only significant covariate on clearance and on volume of 
distribution of the central compartment. In human paediatric trials, no double peak was 
observed in the absorption phase of the plasma-concentration time curves, possibly due to 
the sparse sampling strategy applied in the paediatric studies. Therefore, it is recommended 
to perform additional paediatric trials, based on the sampling protocol applied in the pig 
study. No significant differences in PD results between the control and desmopressin-
treated groups were observed, most probably due to steric hindrance of the D-arginine 
group in position eight of desmopressin and the tyrosine group of the porcine vasopressin 2 
receptor.  
In the General Discussion, paediatric drug development in general and juvenile animal 
models in specific were addressed. A comparison between the conventional pig and 
traditional animal models, i.e. rodents, dogs, minipigs and non-human primates, was made. 
The suitability of the conventional pig as a potential juvenile animal model was evaluated 
using the results obtained in this doctoral thesis.  
In Conclusion, this doctoral thesis demonstrates the usefulness of growing conventional 
piglets to study renally excreted drugs. To establish the added value of the conventional pig 
among the more traditional animal models, extensive research has to be performed to 



























In de Algemene Inleiding van dit doctoraatsonderzoek werd eerst een algemeen overzicht 
gegeven van het pediatrisch geneesmiddelenonderzoek, met focus op pediatrische 
preklinische diermodellen. Aangezien de algemene doelstelling van dit doctoraat het 
ontwikkelen van een juveniel varkensmodel was, werd er vervolgens een vergelijkend 
literatuuroverzicht gegeven van de absorptie en dispositie van geneesmiddelen bij varken en 
mens. Het deel van de dispositie dat specifiek onderzocht werd in dit doctoraat is de renale 
excretie van geneesmiddelen, met focus op de ontogenie van de glomerulaire 
filtratiesnelheid (GFR). Tot slot werd een overzicht gegeven van het voorbeeld geneesmiddel 
bestudeerd in deze thesis, namelijk desmopressine, voor wat betreft het farmacokinetisch 
(PK), farmacodynamisch (PD) en veiligheidsprofiel, evenals het therapeutisch gebruik ervan 
in de pediatrie.  
De Algemene Doelstelling van dit doctoraatsonderzoek was om na te gaan of het 
conventionele varken een potentieel diermodel kan zijn voor preklinisch pediatrisch 
geneesmiddelenonderzoek. Aangezien varkens uitgesproken anatomische en fysiologische 
gelijkenissen vertonen met de mens, werd vroeger reeds aangetoond dat het adult 
varkensmodel geschikt is voor PK, PD en veiligheidsstudies in volwassenen. Echter, tot op 
heden is nog niet onderzocht of het conventioneel varken ook een geschikt pediatrisch 
diermodel is.  
Om dit doel te kunnen bereiken werd er eerst gezocht naar geschikte methoden voor 
repetitieve urine en bloedcollectie bij biggen van de geïncludeerde leeftijden (acht dagen, 
vier weken en acht weken). Hoofdstuk I beschrijft diverse bloedcollectie technieken bij 
groeiende biggen (♀/♂) en urine collectie bij mannelijke biggen. Zowel katheterisatie van de 
halsvene met behulp van een dubbel lumen katheter (leeftijd acht dagen, vier weken) als 
direct aanprikken van de halsvene met behulp van een Venoject® systeem (leeftijd vier 
weken, acht weken) werden getest met gunstig resultaat. Katheterisatie van de halsvene 
kreeg de voorkeur op direct aanprikken, aangezien het meer ethisch verantwoord is om deze 
techniek te gebruiken en via deze techniek ook intraveneus producten kunnen toegediend 
worden. Er werd bovendien een niet-invasieve techniek voor urine collectie m.b.v. zakjes 
ontwikkeld om urine te collecteren bij mannelijke biggen, waardoor het mogelijk is om vlot 
urine te collecteren. Het was echter niet mogelijk om deze techniek ook toe te passen bij 




Aangezien er in dit doctoraat gefocust werd op de renale excretie van geneesmiddelen, was 
het van belang dat de maturatie van de GFR in kaart gebracht werd. Enerzijds was het 
belangrijk om na te gaan welke techniek het meest accuraat en toepasbaar is om de GFR te 
bepalen. Anderzijds was het ook nuttig om een formule te ontwikkelen analoog aan de 
formule van Schwartz et al. (2009), om via één bloedstaal de GFR te kunnen voorspellen. In 
Hoofdstuk II werd de bepaling van de GFR op twee manieren benaderd. Enerzijds werd de 
maturatie van de GFR bestudeerd met behulp van twee verschillende merkers, namelijk 
creatinine (Jaffe en enzymatische methode) en exo-iohexol (compartimentele PK) 
(Hoofdstuk II-i). Anderzijds werd de ontwikkeling van de GFR bepaald gebruik makend van 
“non-lineair mixed effects modelling (NLME)” van de exo-iohexol plasmaconcentratie-
tijdscurves (populatie PK of popPK) (Hoofdstuk II.ii). Een éénmalige intraveneuze bolus van 
iohexol (64.7 mg/kg LG) werd toegediend aan biggen van acht dagen (n = 16), vier weken (n 
= 8), zeven weken (n = 16) en zes maand (n = 8). Vervolgens werd er op verschillende 
tijdstippen na de toediening bloed en urine gecollecteerd, gebruik makend van de 
technieken ontwikkeld in Hoofdstuk I. De endogene creatinine concentraties werden 
bepaald in bloed en urine met behulp van zowel Jaffe als enzymatische methoden. Exo-
iohexol concentraties werden in plasma bepaald via een in-huis ontwikkelde en gevalideerde 
HPLC-UV methode. De klaring voor beide merkers werd berekend en normalisatie van de 
bekomen resultaten werd uitgevoerd aan de hand van lichaamsgewicht, 
lichaamsoppervlakte en niergewicht. Uit deze studie is gebleken dat er geen significante 
verschillen waren tussen de verschillende technieken. Zowel creatinine (Jaffe, enzymatisch) 
als exo-iohexol gaven gelijkaardige resultaten. Ook de resultaten bekomen door zowel 
compartimentele als populatie PK analyse waren vergelijkbaar. Wanneer de resultaten 
gecorreleerd werden met de resultaten bekomen in de mens, kan besloten worden dat de 
ontwikkeling van de GFR gelijkaardig verloopt bij de mens en het conventionele varken 
(neonaat: varken: 42 mL/min/m², mens: 39 mL/min/1.73 m²; zuigeling: varken: 65 
mL/min/m², mens: 58 mL/min/1.73 m²; kind: varken: 99 mL/min/m², mens: 103 
mL/min/1.73 m²; puber: varken: 121 mL/min/m², mens: 127 mL/min/1.73 m²). Daardoor is 
het varken een geschikt pediatrisch diermodel om de GFR in de pediatrische populatie, en de 
PK van renaal geklaarde geneesmiddelen die hoofdzakelijk gefiltreerd worden, te 
bestuderen. Twee vergelijkingen werden opgesteld om de GFR te schatten in biggen. De 




lichaamsgewicht (LG) van biggen: eGFR (mL/min) = 1.879 x LG1.092/PCr
0.600. De tweede 
vergelijking (populatie PK) is gebaseerd op de exo-iohexol klaring en lichaamsoppervlakte 
(BSA) van biggen: exo-iohexol klaring (mL/min) = 67.98 x (BSA/gemiddelde(BSA))1.45. Er werd 
een goede correlatie tussen beide vergelijkingen vastgesteld (R² = 0.9943). 
Als laatste onderdeel van dit doctoraat werd het varkensmodel geëvalueerd door een PK/PD 
studie uit te voeren met het vasopressine analoog desmopressine (Hoofdstuk III). Een 
sublinguaal lyofilisaat (120 µg) van desmopressine werd toegediend aan 32 mannelijke 
biggen van acht dagen, vier weken, zeven weken en zes maand (telkens 8 dieren per 
leeftijd). Er werden acht bijkomende biggen (controle groep, leeftijd: 8 dagen) geïncludeerd 
om de PD parameters (urinair volume, osmolaliteit en natrium concentratie) van de 
desmopressine groep te kunnen vergelijken met de controle groep. Bloed en urine stalen 
werden gecollecteerd op verschillende tijdstippen na de toediening en desmopressine 
plasmaconcentraties werden bepaald met behulp van een radio-immunoassay. Vervolgens 
werden de populatie PK parameters bepaald door middel van NLME. De 
plasmaconcentratie-tijdscurves van desmopressine vertoonden een twee-compartimentele 
PK, met tweevoudige, sequentiële eerste-orde absorptie, en eerste-orde eliminatie. 
Lichaamsgewicht was de enige significante covariaat voor klaring en distributievolume van 
het centrale compartiment. In humane pediatrische studies werd er echter geen dubbele 
piek in de absorptiefase van de plasmaconcentratie-tijdscurves geobserveerd. Dit is 
waarschijnlijk te wijten aan het feit dat er in de absorptiefase slechts enkele bloedstalen 
genomen werden, waardoor de dubbele piek mogelijks gemist werd. Het is dus aan te raden 
dat er additionele studies uitgevoerd worden in kinderen gebaseerd op het bloedafname 
protocol gebruikt in de varkensstudie. Er werden geen verschillen in PD resultaten 
waargenomen tussen de controle en de behandelde groep. De verklaring hiervoor is 
hoogstwaarschijnlijk sterische hinder tussen de D-arginine groep in positie acht van 
desmopressine en de tyrosine groep van de vasopressine 2 receptor in varkens.  
In de Algemene Discussie van dit doctoraat werd de pediatrische geneesmiddelen-
ontwikkeling in het algemeen, en meer specifiek de juveniele diermodellen bediscussieerd. 
Er werd een vergelijking gemaakt tussen het conventionele varken en traditionele 




geschiktheid van het conventioneel varken als een potentieel juveniel diermodel werd 
geëvalueerd aan de hand van de resultaten bekomen in dit doctoraat.  
Als Conclusie kunnen we stellen dat het nut van conventionele biggen aangetoond werd 
voor het bestuderen van geneesmiddelen die renaal geklaard worden. Om de toegevoegde 
waarde van het conventionele varken ten opzicht van andere traditionele diermodellen te 
bepalen, is bijkomend onderzoek nodig betreffende de ontogenie van andere ADME 
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